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Zusammenfassung 
 
Das Ziel dieser Arbeit bestand in der Herstellung eines Mausmodels, mit dessen Hilfe die 
Funktion von Neuregulin-1 (NRG1) im adulten Nervensystem untersucht werden kann. 
NRG1 ist ein Wachstumsfaktor mit einer 'epidermal growth factor like' Domäne, der als 
Ligand für Tyrosinkinase-Rezeptoren der ErbB-Familie wirkt. Durch alternative RNA-
Prozessierung enstehen mindestens 15 NRG1-Isoformen, welche in die Typen I, II und III 
unterteilt werden. Bisher wurde NRG1 primär als Wachstumsfaktor betrachtet, der eine 
wichtige Rolle bei der Entwicklung des Nervensystems spielt. Neuere Beobachtungen weisen 
jedoch darauf hin, dass auch im erwachsenen Tier ein kontinuierlicher Bedarf an NRG1 
besteht. Der frühe Tod der NRG1-Mausmutanten hat allerdings Untersuchungen zur Funktion 
von NRG1 im postnatalen und adulten Nervensystem erschwert. 
Im Rahmen dieser Arbeit wurde das System zur tetrazyklinabhängigen Genregulation (Tet-
System) eingesetzt, um eine regulierbare adulte Überexpression von NRG1-Isoformen zu 
erreichen. NRG1 wird von nahezu allen cholinergen Neuronen exprimiert. Um die Expression 
des tetrazyklinabhängigen Transaktivators tTA2S in allen cholinergen Zellen zu 
gewährleisten, wurden daher regulatorische Elemente des Cholin-Azetyltransferase Gens 
gewählt. Für eine möglichst präzise Expressionskontrolle wurde ein etwa 200 kb großes 
‚bacterial artificial chromosome’ (BAC) verwendet, welches das gesamte ChAT-Gen und 
flankierende Bereiche umfasst. Durch homologe Rekombination in Bakterien wurde die 
tTA2S-cDNA in das ChAT-Gen eingebracht und das resultierende ChAT-tTA2S BAC-
Konstrukt zur Herstellung transgener Mäuse verwendet. Die Charakterisierung ChAT-tTA2S 
transgener Mäuse erfolgte durch in situ-Hybridisierung und Verpaarung mit Reporterlinien, 
die ein tTA-induzierbares β-Galaktosidase-Gen tragen. Es wurden zwei transgene ChAT-
tTA2S Linien identifiziert, die eine cholinerg-spezifische tTA-Aktivität aufweisen. Weiterhin 
wurden Mauslinien hergestellt, die eine tTA-abhängige Expression von NRG1-Isoformen 
ermöglichen sollten. Diese Mauslinien wurden durch Verpaarung mit der α-CamMKII-tTA 
Mauslinie charakterisiert, die tTA in Prinzipalneuronen des Vorderhirns exprimiert. Es konnte 
eine Mauslinie identifiziert werden, die sich durch eine stringente, doxyzyklinabhängige 
Expression von NRG1 Typ I-mRNA auszeichnet.  
Mit Hilfe ChAT-tTA:NRG1 Typ I doppelt-transgener Mäusen wird es erstmals möglich sein, 
die Auswirkungen einer erhöhten NRG1 Typ I-Expression auf die Funktion von Synapsen 
und die Myelinisierung im adulten Nervensystem zu untersuchen. Darüber hinaus stellen 
ChAT-tTA transgene Mäuse ein wertvolles Werkzeug dar, mit dessen Hilfe die Funktion von 
Genen  in cholinergen Neuronen untersucht werden kann.  
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I. Summary 
 
The goal of this thesis was to create a mouse model permitting the analysis of neuregulin-1 
(NRG1) function in the adult nervous system. NRG1 is a polypeptide growth factor, which 
contains an ‘epidermal growth factor like’ (EGFL) domain and serves as a ligand for the erbB 
receptor tyrosine kinase family. Alternative splicing of the NRG1 gene gives rise to at least 
15 NRG1 isoforms, which can be grouped into type I, II and III variants. NRG1 has been 
traditionally viewed as a growth factor important for development. However, recent studies 
have suggested a continuous requirement for NRG1 signaling in the mature animal. Thus far, 
the study of NRG1 function in vivo has been hampered by the early embryonic or perinatal 
death of complete and isoform-specific null mutants.  
To overcome the limitations of the available mouse mutants, the tetracycline regulated gene 
expression system (Tet-System) was utilized in this thesis. NRG1 is expressed by virtually all 
cholinergic neurons, therefore the choline acetyltransferase (ChAT) gene was selected to 
direct the expression of the tetracycline-dependent transactivator (tTA2S) to cholinergic 
neurons. In order to increase the likelihood that all required regulatory elements were present, 
a bacterial artificial chromosome (BAC), roughly 200kb in size, containing the ChAT gene 
and flanking sequences was used. Homologous recombination in bacteria was used to insert 
the tTA2S cDNA into the ChAT gene. The resulting ChAT-tTA2S BAC construct was used 
for the generation of transgenic animals by oocyte injection. The ChAT-tTA2S transgenic 
mice were subsequently characterized by in situ hybridization and by mating them to reporter 
mice carrying a tTA-inducible β-galactosidase gene. In two independent transgenic founder 
lines, a faithful cholinergic expression was observed. In addition, mouse lines for the tTA-
inducible expression of NRG1 isoforms were generated. Their functionality was assessed by 
mating them to the α-CaMKII-tTA mice, in which tTA expression is directed to principal 
neurons of the forebrain. One mouse line was identified that showed a tight doxycyline-
dependent regulation of transgene-derived NRG1 type I mRNA expression.  
Through the use of ChATtTA:NRG1 type I doubly transgenic animals, it is now possible to 
examine the effects of increased NRG1 type I expression on synaptic function and 
myelination in the mature nervous system. Moreover, the ChATtTA transgenic mouse lines 
that have been generated are universal tools to regulate the expression of any transgene of 
interest in cholinergic cells. 
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II. Introduction  
 
Cell-cell interactions regulate fundamental processes during embryogenesis, organ 
morphogenesis and nervous system formation. In the developing nervous system, neuron-glia 
interactions regulate many processes that are required for proper nervous system function. 
Glial cells provide attractive or repulsive guidance cues for axons en route to their target area, 
which are needed for the formation of a proper neuronal circuitry in the central nervous 
system. In addition, both, neurons and glial cells, are dependent on reciprocal trophic support 
from each other: While, for example, electrical activity in neurons evokes the activity-
dependent release of adenosine, which is a potent neuron-glia transmitter, glial cells provide 
trophic support to neurons through the production of factors that induce sodium channel 
clustering, through myelination and through the sectretion of neurotrophins (Wilkins et al., 
2001; Dai et al., 2003). Synaptogenesis in the central nervous system is another example that 
is, at least in part, dependent on neuron-glia interaction. Here, glial cells serve two functions, 
on the one hand they are required for homeostasis and on the other hand they have a profound 
influence on activity-dependent remodeling processes of the synapses and synapse number 
(Ullian et al., 2004). 
Neuregulin-1 (NRG1), a polypeptide growth factor expressed by neurons, is one example of a 
signaling molecule that provides trophic support to glial cells. NRG1 signaling through erbB 
receptor tyrosine kinases has been shown to be important in regulating several aspects of glial 
cell biology. Schwann cells and oligodendrocytes, the myelinating glia of the peripheral and 
central nervous system, are depending on NRG1 signaling for proliferation, survival and 
myelination (Falls, 2003; Michailov et al., 2004).  
 
1. The Neuregulin-1-erbB signaling network 
 
NRG1 is a polypeptide growth factor of the epidermal growth factor family and belongs to a 
family of 4 members of which it is the best characterized (Busfield et al., 1997; Carraway et 
al., 1997; Higashiyama et al., 1997; Zhang et al., 1997; Harari et al., 1999). NRG1 is known 
to play critical roles in the developing heart, mammary gland and nervous system. NRG1 was 
identified as the biological activities known as heregulin/neu differentiation factor (NDF) for 
its apparent ability to bind to and activate the HER2/neu oncogene and as glial growth factor 
(GGF) for its ability to promote Schwann cell proliferation (Peles et al., 1992) (Raff et al., 
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1978; Brockes et al., 1980). It was also identified as the acetylcholine receptor-inducing 
activity (ARIA), as it increased the expression of acetylcholine receptors when added to 
muscle cells grown in vitro (Jessell et al., 1979; Corfas et al., 1993; Falls et al., 1993). It was 
later discovered that heregulin/NDF, GGF and ARIA are all splice variants of the same gene, 
which was subsequently called “neuregulin” combining the “neu” and “heregulin” 
nomenclature (Marchionni et al., 1993). Although the NRG1 isoforms have been traditionally 
viewed as molecules important for neural development, recent studies suggested that there is 
a continuing requirement for NRG1 signaling in mature animals (Sandrock et al., 1997). 
 
1.1. Structure of Neuregulin-1 
 
Common to all NRGs is an epidermal growth factor-like (EGF-like) domain of 50-60 amino 
acids in length, which is characterized by two sets of anti-parallel β-pleated sheets held 
together by 3 pairs of disulfide-bonded cysteine residues (see Fig.1).  
 
 
Figure 1: Sequence alignment of the EGF-like domains of NRG1–4. 
Shaded in black are conserved amino acid residues in the EGF-like domains of NRG1 – 4. Asterisks denote 
conserved cysteine residues that form disulfide bonds within the EGF-like domain as indicated by brackets. 
Pairwise sequence alignment of the NRG1 EGF-like domain with the EGF-like domains of NRG2, NRG3 and 
NRG4 reveals amino acid homologies of 47%, 31% and 33% respectively. 
 
The study of NRG1 has been complicated by the identification of more than 15 cDNA 
variants that arise by alternative splicing and the use of 3 alternative promoters (reviewed in 
(Lemke, 1996; Rosen et al., 1996; Falls, 2003). On the genomic level this complex splicing 
pattern is reflected by the number of exons in the NRG1 gene. NRG1 spans ~800kb on 
chromosome 8qA3 in the mouse genome and has 23 identified exons (see Fig.2) (Stefansson 
et al., 2002). The recent identification of 6 novel exons within the human NRG1 gene, for 
which there are syntenic regions in the murine NRG1 gene, suggests that the regulation of 
NRG1 might be even more complex (Steinthorsdottir et al., 2004). However, it is unclear 
whether the novel exons are expressed in the mouse, or whether their expression is restricted 
to humans. 
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(adapted from Falls, 2003 and Steinthorsdottir et al., 2004) 
Figure 2: Genomic organization and splicing of the murine NRG1 gene. 
(A) Genomic organization of the murine NRG1 gene. Exons are represented by rectangles and are not drawn to 
scale. The colors used in (A) match the exons in the splicing scheme in (B). The 6 recently identified novel 
exons are indicated below the cartoon. The core at risk region for schizophrenia, which was identified in a 
genetic linkage study in an Icelandic population surrounds the genomic region of exons encoding types II and IV 
(Stefansson et al., 2002). 
(B) Dashed lines indicate possible splicing events. Type-specific exons are shown on the left with type I 
referring to splice variants NDF, HRG and ARIA, type II to glial growth factor (GGF) and type III to 
SMDF/CRD-NRG1. The type III exon has a second transmembrane (TM) domain, which is indicated by the box 
within the type III-specific exon. The hydrophobic region in the type II-specific exon does not function as a TM 
domain, but is thought to be an uncleaved signal sequence. Type II and type III isoforms lack the ‘glyco’ exons; 
in NRG1 α2 and β2 isoforms the EGFα and EGFβ domain is directly spliced into the TM-encoding exon 
following the α or β exon. NRG1β3 splice variants contain an in-frame stop codon (indicated by ‘*’) 5’ to the 
TM domain so that these isoforms are secreted. All TM-domain containing NRG1 isoforms contain the exons 
c1, c2 and c3; TM domain-containing NRG1β isoforms are always spliced to the a-tail, whereas NRG1α 
isoforms are not confined to the a-tail (Ben-Baruch and Yarden, 1994). The novel NRG1 isoforms, as described 
by Steinthorsdottir (Steinthorsdottir et al., 2004), were omitted from the scheme, since little is known about their 
expression and underlying splicing in mouse. It should be noted that not all splice variants depicted in this 
scheme have been observed in vivo. 
 
In mice, alternative splicing gives rise to three major isoforms, types I, II and III that differ in 
their N-termini and contain either an immunglobulin-like (Ig-like) domain (types I, II) or a 
cysteine-rich domain (‘CRD’, type III), which is also referred to as "sensory and motor 
neuron-derived factor" (SMDF) (see Fig.2) (Ho et al., 1995). 
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The Ig-containing isoforms can be further subdivided into type I and type II, which differ not 
only by the type II-specific exon, but also by the presence of a glycosylation-rich segment 
(type I, “glyco”, see Fig. 2). The type III splice variants are the predominantly expressed 
isoforms in the nervous system and they are characterized by an apolar region within the CRD 
domain, which serves as an uncleaved, internal membrane insertion signal (Ho et al., 1995; 
Meyer et al., 1997). Splicing in the C-terminal part of the EGF-like domain yields "α" and 
"β" isoforms, which display different affinities for the ErbB receptors (Pinkas-Kramarski et 
al., 1998; Jones et al., 1999). The "α" splice variants exert their biological function outside 
the nervous system where they are required for lobuloalveolar development of the mouse 
mammary gland (Li et al., 2002), whereas the "β" isoforms are predominantly expressed in 
the nervous system. 
The NRG1 gene encodes isoforms which are secreted (β3 isoforms) or that contain a 
transmembrane domain (α2, β  1, β2 and β4 isoforms). Isoforms with a transmembrane 
domain can be proteolytically processed to yield soluble forms (Burgess et al., 1995; Loeb et 
al., 1998; Shirakabe et al., 2001). The proteolysis appears to be mediated by different 
proteases and involves distinct regulatory mechanisms. Proteolytic processing of NRG1 can 
be induced by neuronal electric activity and interaction of NRG1 with its receptors. A PKC-
controlled mechanism seems to be underlying the proteolytic cleavage upon electrical 
stimulation of NRG1 expressing neurons, whereas NRG1 receptor interaction induces γ-
secretase-mediated intramembrane cleavage (Bao et al., 2003; Ozaki et al., 2004). 
Extracellular proteolytic processing of β-isoforms is mediated by β-meltrin and does not 
appear to be regulated by electric activity or NRG1-receptor interaction (Shirakabe et al., 
2001). 
 Upon proteolytic processing of type III-β1 isoforms at their stalk region the new C-terminus 
becomes membrane associated through a poorly understood mechanism (Wang et al., 2000; 
Cabedo et al., 2002). Type III isoforms were shown to dimerize in the plasma membrane 
following proteolytic processing accompanied by a redistribution into lipid rafts. The 
redistribution of type III fragments into lipid rafts is inhibited by O-glycosylation of the 
protein, which also interferes with the dimerization process (Cabedo et al., 2004). In addition, 
type I and type II isoforms can remain associated with the cell surface or the extracellular 
matrix (ECM) as the Ig-like domains bind heparin through interactions with N-sulfates, 2-O-
sulfates and 6-O-sulfates of the heparan-sulfate proteoglycans of the ECM (Loeb et al., 1999; 
Pankonin et al., 2005). 
Introduction 
 
6 
The cytoplasmic tail of NRG1-β1a (‘a-tail’ or intracellular domain, ‘ICD’) that is released by 
γ-secretase, was shown to translocate into the nucleus of spiral ganglion neurons in vitro, 
where it serves as a transcription factor increasing the expression of anti-apoptotic genes (Bao 
et al., 2003). Recent studies found that increased synaptic activity in the mouse cochlea leads 
to increased nuclear localization of the NRG1 ICD (Bao et al., 2004). In the nucleus the 
NRG1 ICD interacts with the zinc-finger transcription factor Eos. This NRG1-ICD-Eos 
complex binds to the promoter of PSD-95 and stimulates its transcription (Bao et al., 2004). 
These findings provide evidence for an activity-dependent modulation of synaptic plasticity 
by NRG1. The C-terminus of the NRG1 cyoplasmic a-tail is furthermore characterized by a 
class II PDZ consensus binding motif, but thus far no PDZ domain-containing protein has 
been reported to interact with the a-tail. 
 
1.2. Neuregulin-1 expression in the nervous system 
 
NRG1 expression has been studied by in situ hybridization as well as by knock-in approaches 
of β-galactosidase into the NRG1 gene in mice (Chen et al., 1994; Corfas et al., 1995; Meyer 
et al., 1997). NRG1 expression is first detected in the mesoderm of mouse embryos at 
E7.5/E8 in the ectoplacental cone and rhombomeres 2, 4 as based on lacZ expression in 
nrg1∆EGF-lacZ mutant embryos, in which the EGF-like domain was replaced by the lacZ gene 
(Meyer et al., 1997). By E8.5 NRG1 expression can be detected in the brachial arch cartilage, 
the developing heart, the dorsal neural tube and rhombomere 6 next to rhombomeres 2 and 4. 
Isoform-specific expression analysis by ISH has revealed that NRG1 type I and type III are 
both expressed during the formation of cranial ganglia. NRG1 type I can be detected around 
E10 in trigeminal, glossopharyngeal and vagal ganglia; at E18 some DRG neurons are found 
to express NRG1 type I (Meyer et al., 1997).  
NRG1 type III is the predominantly expressed isoform in the CNS and type III transcripts can 
be detected in cranial ganglia, DRGs and developing spinal cord between E10-E18. NRG1 
type III expression persists in the adult animal, where it is expressed by motor neurons, in the 
cortex, the medial septal area and at high level in the facial nuclei and the habenulae (Chen et 
al., 1994; Meyer et al., 1997). NRG1 type II transcripts are found in the notochord at E10 as 
well as in spinal cord and DRGs by E12 – E18. NRG1 type II also appears to be expressed at 
lower levels in muscle between E12 – E18 (Meyer et al., 1997). Taken together, the 
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experimental data suggest that NRG1 is expressed by virtually all cholinergic neurons in the 
CNS including the spinal cord. 
1.3. Cholinergic neurons in the CNS and structural organization of the 
ChAT gene 
 
Immunohistochemical and ISH studies on rodent brains have revealed that cholinergic 
neurons in the CNS are aggregated in 8 major groups: the medial septal nucleus, vertical 
nucleus of the diagonal band of Broca, the horizontal limb of the diagonal band of Broca, the 
nucleus basalis of the substantia innominata (Meynert), the pedunculopontine nucleus, the 
laterodorsal tegmental nucleus, the medial habenulae and the parabigeminal nucleus. In 
addition to the 8 major groups, cholinergic neurons are also found in the striatum and as 
motor neurons in the anterior horn of the spinal cord (Oda, 1999). The earliest time point at 
which cholinergic neurons have been described in the mouse forebrain is E13.5. At this time 
mitotic ChAT positive cells can be found near the ventricular lumen of the germinal zone of 
the olfactory, lateral and third ventricles (Schambra et al., 1989). The generation of 
cholinergic neurons peaks between E14 and E16 and ChAT positive neurons can be found in 
various areas of the developing brain, from which they migrate to their target areas. 
ChAT is the key enzyme for the synthesis of acetylcholine from choline and acetyl-CoA and 
the most specific marker for cholinergic neurons in both CNS and PNS. The murine ChAT 
gene is located on the long arm of chromosome 14 and possesses 15 exons (Ishii et al., 1990). 
Analysis of the resulting mRNAs revealed that exons R, N and M, which are located on the 5’ 
end of the gene, are non-coding, alternatively spliced exons (see: results, Fig. 1). Alternative 
splicing results in the generation of 7 different mRNAs in the mouse. 
An important and unusual structural feature of the ChAT gene is the presence of the intron-
less vesicular acetylcholine transporter (VAChT) gene within the first intron of the ChAT 
gene, located between exons R and N. Both genes appear to be co-regulated, which would 
provide a reason for this unusual arrangement (Berrard et al., 1995; Berse and Blusztajn, 
1995; Misawa et al., 1995). 
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1.4. Neuregulin receptors 
 
The neuregulins bind to and activate members of the ErbB receptor-tyrosine kinase family. 
Four ErbB receptors have been identified: EGFR (ErbB1/HER1), ErbB2 (neu/HER2), ErbB3 
(HER3) and ErbB4 (HER4), with the "HER" nomenclature referring to "human epidermal 
growth factor receptor". The ErbBs are large integral membrane glycoproteins with a 
molecular weight ranging from 170-185kDa. They consist of four extracellular domains (I-
IV), a single transmembrane domain and an intracellular tyrosine kinase domain. The 
extracellular region of erbBs is heavily glycosylated, which can contribute to up to 20% of the 
molecular weight (Lax et al., 1990). Domains I (L1) and III (L2) mediate ligand binding 
whereas the cysteine-rich domains II (S1) and IV (S2) are involved in receptor dimerization 
(Burgess et al., 2003). The cytoplasmic tail of erbBs is also characterized by the presence of 
8-18 tyrosine residues, which are sites of autophosphorylation (Carraway and Cantley, 1994).  
Most of the structural analyses for ligand-receptor interaction studies for the erbB RTK 
family were performed on EGFR – EGF or TGF-α complexes. It was shown that the EGFR 
undergoes a conformational change upon ligand binding by the L1 and L2 domains. The 
conformational change leads to the binding of a second ligand to the EGFR dimer. The 
primary dimerization mediator between the two EGFR molecules is a β-hairpin loop 
(dimerization loop), which protrudes from the S1 domain (Burgess et al., 2003). 
ErbB2 is an unusual receptor in that it has no known ligand, but it increases ligand-binding 
affinity when recruited into a receptor heterodimer. Its crystal structure revealed that domains 
L1 and L2 show a strong interaction, mimicking a ligand-bound state. The consequence of 
this interaction is a constitutively extended conformation of the dimerization loop, making 
erbB2 a promiscuous dimerization partner. It also explains the inherent inability of erbB2 to 
bind EGF-like ligands (Citri et al., 2003). ErbB3 is also an atypical receptor in that it 
possesses little or no tyrosine kinase catalytic activity (Guy et al., 1994). This deficit appears 
to be the result of the lack of conservation of critical amino acids residues, which are believed 
to be essential in the kinase active site. Despite this lack of catalytic activity, ErbB3 can be 
phosphorylated in trans by a catalytically active ErbB dimerization partner. ErbB4 is similar 
in its overall structure to EGFR and is capable of forming functional homodimers as well as 
heterodimers with ErbB2 and ErbB3. There are 2 regions within ErbB4 at which alternative 
splicing occurs, one located in the stalk region, the other one in the C-terminal domain, which 
potentially can result in 4 alternative splice variants. The C-terminal splice variants are 
Introduction 
 
9 
characterized by the presence (CYT-1) or absence (CYT-2) of a PI3K binding site (Carpenter, 
2003). The C-terminus ending in –TVV further harbors a PDZ binding motif mediating the 
interaction of ErbB4 with PSD-95 at neuronal synapses (Garcia et al., 2000; Huang et al., 
2000).  
ErbB4 is also proteolytically processed by TNFα-converting enzyme (TACE), which sheds 
its ectodomain and subsequently by γ-secretase, which releases the cytoplasmic tail from the 
membrane. The cytoplasmic tail was shown to translocate into the nucleus of the erbB4 
expressing cell. Although the cytoplasmic tail was shown to act as a transcriptional activator 
in cultured oligodendrocytes increasing the expression of myelin basic protein (MBP), its 
biological function is poorly understood (Lai and Feng, 2004). 
Upon ligand binding the tyrosine residues on the cytoplasmic tails of the ErbB receptor 
dimers are phosphorylated through phosphorylation in trans. Different EGF-like domain-
containing ligands have been shown to exhibited distinct patterns of receptor 
autophosphorylation. The specific subset of tyrosines that are phosphorylated is thought to 
determine the signaling pathways that are induced, as the 5-8 amino acids surrounding the 
phosphotyrosine residue confer the specificity of SH2 and phosphotyrosine binding (PTB) 
domain binding (Marmor et al., 2004). The 3 best characterized signaling pathways induced 
by ErbB signaling are the Ras-MAPK, PI3K-Akt and the phospholipase-Cγ (PLCγ)-PKC 
pathways (reviewed in (Yarden and Sliwkowski, 2001; Marmor et al., 2004). All activated 
ErbBs feed into the Ras-MAPK pathway, either directly through SH-2 domain-mediated 
recruitment of Grb-2, or indirectly through PTB domain-mediated binding of Shc (Marmor et 
al., 2004). 
 
1.5. Neuregulin-1 function 
 
NRG1 has been studied for over 25 years as the biological activities known as the 
acetylcholine receptor (AChR) inducing activity (or “ARIA”; reviewed in Fischbach and 
Rosen, 1997; Buonanno and Fischbach, 2001). Next to its in vitro function as ARIA, several 
studies suggest that NRG1β can serve an ARIA-like role at neuronal synapses. The addition 
of recombinant NRG1β to cultured cerebellar granule cells stimulates the expression of 
NMDA-receptor subunit NR2C as well as the expression of GABAAβ2 subunits (Ozaki et al., 
1997; Rieff et al., 1999). In a related finding recombinant NRG1β was able to induce the 
expression of α7-nAChR in cultured hippocampal neurons (Liu et al., 2001). NRG1 type III 
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appears to possess similar inductive properties: Its application in vitro to cultured chick 
sympathetic neurons increases the expression of α3, α5, α7 and β4 nAChR subunits (Yang et 
al., 1998). In vivo NRG1 type III is expressed by preganglionic visceral motor neurons that 
innervate these sympathetic neurons. 
The presence of ARIA in vivo however, is less clear. NRG1-Ig heterozygous mice, lacking 
one functional copy of the Ig domain encoding exon, display roughly a 50% reduction in 
AChR number at the NMJ and are myasthenic, suggestive of an ARIA function of the Ig-
containing isoforms (Sandrock et al., 1997). However, neither NRG1 type I nor type II are 
required for the expression of AChRs embryonically (Yang et al., 2001). Therefore, based 
upon current evidence, the early appearance of AChRs at the developing NMJ is a NRG1-
independent event, but AChR number in the mature Ig-NRG1 heterozygous animal is 
suggestive of an ARIA-like function. The Ig-domain containing forms have recently been 
identified as being essential for muscle spindle development, revealing a role for NRG1 
signaling in the differentiation of proprioceptors (Hippenmeyer et al., 2002). These findings 
are supported by recent in vitro data demonstrating that the addition of NRG1 to cultured 
primary human myotubes induces the expression of not only AChRs, but also of the muscle 
spindle-specific transcription factors Egr1-3 and myosin heavy chains (Jacobson et al., 2004). 
In vivo function of NRG1 has also been addressed genetically: Homozygous NRG1 mouse 
mutants die during embryogenesis at E10.5 due to a heart defect (Meyer and Birchmeier, 
1995). Histological data reveal that structures within the developing heart, known as 
trabeculae fail to form. This phenotype is shared by mice that are deficient in either ErbB2 or 
ErbB4 indicating that both receptors are required to transduce NRG1 signals (Gassmann et 
al., 1995; Lee et al., 1995). In the developing heart, NRG1 is expressed in endocardial cells 
and the receptors, ErbB2 and ErbB4 are expressed by the adjacent myocardial cells. Genetic 
rescue of the cardiac phenotype of ErbB2 null mutants provided further insight into ErbB2 
function in the peripheral nervous system (Morris et al., 1999). Rescued animals survive until 
birth, but show a severe loss of motor and sensory neurons. Schwann cells along peripheral 
nerves are missing, although Schwann cell precursors are present in DRGs indicating that 
their ability to migrate may be impaired.  
Mice lacking the type I and type II isoforms (NRG1 Ig-specific knockout) die of the same 
cardiac defect as NRG1 complete null mutant animals as well as ErbB2 and ErbB4 null 
mutant animals (Kramer et al., 1996). This indicates that the Ig-domain containing NRG1 
isoforms are required for proper heart development and that the ErbB2/4 heterodimer 
transduces the signal in the opposing myocardium. The importance of Ig-NRG1 signaling for 
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cardiovascular function throughout life is underscored by recent findings that NRG1-Ig+/- 
animals display an increased sensitivity towards the chemotherapeutic doxorubicin in 
comparison to wild type animals. NRG1 heterozygous animals develop a dilated 
cardiomyopathy and have an increased mortality rate upon doxorubicin treatment (Liu et al., 
2005).  
In contrast to NRG1 type I and type III null mutants, homozygous NRG1 type II-specific 
knockouts are viable and fertile and show a developmental phenotype in the cerebellum of 
incomplete penetrance. (Alistair N. Garratt, MDC Berlin, personal communication; 
unpublished).  
Multiple linkage studies have identified specific haplotypes within the genomic region 
surrounding the NRG1 type II exon as risk factors for schizophrenia in Icelandic and Scottish 
populations (Stefansson et al., 2002; Stefansson et al., 2003). Interestingly, the 
polymorphisms found, were non-coding and the mechanism by which they contribute to 
schizophrenia are not understood. It has been suggested that the polymorphisms alter 
regulatory elements required for normal expression levels of NRG1 type II. Behavioral 
analysis of NRG1 Ig+/- mice revealed that mutant animals exhibit behavioral aspects that are 
related to schizophrenia-like behaviors: Administration of the atypical antipsychotic drug 
clozapine suppresses open field and running wheel activity and it impairs latent inhibition 
(Stefansson et al., 2002; Rimer et al., 2005).  
It is thought that aberrant NMDA receptor (NMDAR) function is one of the causes in the 
pathophysiology of schizophrenia (Tsai and Coyle, 2002). A potential link between NRG1 
signaling and NMDAR function has been provided through a recent finding that demonstrates 
a reduction of whole-cell NMDAR currents in acutely dissociated and cultured prefrontal 
pyramidal neurons (Gu et al., 2005). The findings suggest that a reduction in NRG1 signaling 
may reduce NMDAR-mediated activity. The use of pharmacological inhibitors has identified 
PLC/IP3 and Ras/MEK/ERK signaling pathways as potential mediators of the NRG1-induced 
down-regulation of NMDAR currents. It is thought that activation of both signaling pathways 
by NRG1 leads to an actin-dependent internalization of the NMDAR NR1 subunit. 
It has also been reported that hippocampi of schizophrenics display increased levels of 
GABAA receptors (Benes and Berretta, 2001). A potential involvement of NRG1 signaling in 
the reported pathological changes is supported by the finding that the application of NRG1 to 
hippocampal slices decreases the expression of GABAA receptor subunits. Therefore, a 
dysregulation of NRG1 signaling could contribute to the observed increase of GABAA 
receptors (Okada and Corfas, 2004). Another link between NRG1 and schizophrenia is 
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provided by its ability to induce the expression of α7-nAChRs subunits and by the finding 
that in schizophrenics the frontal cortex appears to express lower levels of α7-nAChRs (Yang 
et al., 1998; Guan et al., 1999; Liu et al., 2001). This suggests that a deficit in NRG1 signaling 
could account for the observed downregulation of α7-nAChRs in schizophrenics.  
Alterations in interneuronal function through aberrant cell placement and migration during 
development has been proposed to be another likely cause underlying the pathophysiology of 
schizophrenia (Benes and Berretta, 2001). Recent findings implicate NRG1 type I and type III 
in interneuronal migration during development: NRG1 type I was identified as a long-range 
attractant for embryonal GABAergic interneurons migrating from the medial ganglionic 
eminence (MGE) to the developing cortex (Flames et al., 2004). In the same study NRG1 
type III was identified as a ‘permissive substrate’ for the migrating cells, suggesting that it 
promoted their migration out of the MGE. In related studies by Anton et al. (2004), which 
examined the consequences of the loss of ErbB4 in the adult brain, the NRG1 type III isoform 
was also identified as a permissive substrate for migrating interneuron precursors from the 
subventricular zone (SVZ) to the olfactory bulb. Phenotypically, the ErbB4 deficient mice 
were characterized by defects in the final placement of olfactory interneurons (Anton et al., 
2004). Despite the fact that the existence of a rostral migratory stream in humans is less clear, 
it is interesting to note that schizophrenics also suffer from olfactory deficits (Moberg et al., 
1999). These findings provide causal links as to how alterations in NRG1 signaling can 
contribute to changes in neural connectivity and neurotransmission, strengthening a role of 
NRG1 in the pathophysiology of schizophrenia. It has also been proposed that alterations in 
NRG1-erbB signaling are the underlying cause for the myelin defects that are found in 
schizophrenics (Corfas et al., 2004). 
NRG1 type III is the predominantly expressed NRG1 isoform expressed at the time of 
synaptogenesis of somatic and visceral motor neurons (Meyer et al., 1997; Yang et al., 1998). 
It continues to be expressed postnatally in spinal motor neurons and in the brain. NRG1 type 
III deficient animals survive until birth and die as a result of neuromuscular defects resulting 
in an inability to breathe. Schwann cells are initially present along embryonic peripheral 
nerves, but die during later stages of embryogenesis, which leads to nerve degeneration 
(Wolpowitz et al., 2000).  
The DRGs of null mutant animals are characterized by a marked loss of sensory neurons, as 
indicated by a 60% reduction in Islet1+ cells. Sensory neurons are initially present, but 
degenerate between E14.5 and E18.5. Nerve-muscle synapses begin to form in type III mutant 
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animals, but the nerve-muscle interactions are not sustained as peripheral axons fragment, 
retract and degenerate (Wolpowitz et al., 2000).  
1.6. NRG1 as a regulator of myelin sheath thickness 
 
At the time this thesis was started, the signals that determine myelin sheath thickness were 
poorly understood. It was well established, however, that axon diameter and myelin sheath 
thickness are strongly correlated and that small caliber axons in the PNS (<0.8µm) are usually 
not myelinated (Friede, 1972; Friede and Bischhausen, 1982; Smith et al., 1982). Recent 
studies have provided evidence that Schwann cells read signals on axonal surfaces that can be 
uncoupled from axonal diameter (Elder et al., 2001). Evidence for a direct involvement of 
NRG1-erbB signaling in myelination was obtained through the analysis of conditional erbB2 
mutants in which erbB2 function was ablated at a time point where Schwann cells express the 
transcription factor Krox-20 (Garratt et al., 2000). Krox-20 is expressed in Schwann cells as 
they make the transition from a Schwann cell precursor to an immature Schwann cell. The 
resulting erbB2 mutant animals exhibited considerably thinner myelin sheaths, a finding that 
was interpreted to suggest that erbB2 function was required for the formation of myelin 
sheaths of normal thickness. 
Analysis of NRG1 heterozygous mice revealed that these animals are characterized by thinner 
myelin sheaths, suggestive of NRG1 as being the axonal signal regulating myelin sheath 
thickness (Michailov et al., 2004). The production of transgenic mice, which overexpress 
NRG1 type III under transcriptional control of the Thy1.2 promoter revealed that the myelin 
sheath thickness of neurons expressing the transgene was significantly increased. This is an 
intriguing finding as it suggests that NRG1 type III is one of the factors that determine myelin 
sheath thickness. Subsequent analyses also revealed the presence of ectopically myelinated 
small caliber fibers (<0.8µm), indicating that NRG1 expression that exceeds a certain 
threshold level induces ectopic myelination (Dr. M.H. Schwab, unpublished observations). 
In addition to NRG1, other factors are known to influence myelination. Brain-derived 
neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and the modulation of NRG1 signaling 
by integrins were all shown to affect myelination (Colognato et al., 2002; Cosgaya et al., 
2002; Tolwani et al., 2004).  
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1.7. Neuregulin-2, -3 and -4 
 
NRG2 is similar in its overall structure to the Ig-like domain containing forms of NRG1 types 
I, II and shares an overall 35% amino acid sequence identity when compared to NRG1 type I 
β1a. Within the EGF-like domain NRG1 and NRG2 share a 50% sequence identity (Carraway 
et al., 1997). The murine NRG2 gene is smaller than the NRG1 gene, covering ~178kb on 
chromosome 18qB2 and contains 12 exons (Yamada et al., 2000). There are at least 9 
different splice variants for NRG2 with "α" and "β" splice variants C-terminal to the EGF-
like domain, in analogy to NRG1. Unlike for NRG1, the "α" and "β" domains are not 
mutually exclusive and can be spliced into the same transcript (Yamada et al., 2000). Despite 
the sequence similarity to NRG1 type I, NRG2 does not promote Schwann cell proliferation 
and does not possess a significant ARIA-like function (Rimer et al., 2004 and C. Lai, 
unpublished results). 
An additional region of high sequence homology surrounds the transmembrane-domains of 
NRG1 and NRG2 (see Fig. 3), suggesting that NRG2 may be proteolytically processed in a 
fashion similar to that of NRG1. The cytoplasmic tail of NRG2 also harbors a nuclear 
localization signal, but it is unknown whether the cytoplasmic tail acts as a transcription 
factor, as has been suggested for the NRG1 cytoplasmic a-tail.  
 
 
Figure 3: Sequence alignment of the transmembrane domains of NRG1 and NRG2.  
Displayed are the amino acid sequences of the highly conserved transmembrane domains of NRG1 and NRG2 
including parts of their stalk region and juxtamembrane region. Underlined in red is the nuclear localization 
signal (NLS) sequence, which was shown to target the cytoplasmic tail of NRG1 to the nucleus of spiral 
ganglion neurons in culture (Bao et al., 2003). The putative NLS of NRG2 was shown to target EGFP–NRG2 
cytoplasmic tail fusion proteins to the nuclei of transfected COS1 and primary hippocampal neurons in culture 
(personal unpublished observations). The numbering refers to amino acid positions within the published 
sequences for NRG1 type I and NRG2 (NCBI accession#: AAT68241, ENSEMBL accession#: 
ENSMUSP00000044380). Boxed in grey are the predicted transmembrane (TM) domains of both proteins. 
 
NRG3 shares little sequence similarity outside the EGF-like domain with NRG1 and NRG2, 
lacking an obvious Ig-like domain. Instead NRG3 contains a unique alanine/glycine rich 
segment at the N-terminus (Zhang et al., 1997). In situ and Northern blot analysis have shown 
that NRG3 is predominantly expressed in the nervous system and in the testis.  
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NRG4, the most recently identfied member of the neuregulin family is distinct from the other 
NRGs. Its extracellular region consists of only the EGF-like domain and the cytoplasmic tail 
is mere 33 amino acids in length, making it the shortest NRG known. It also differs from the 
other NRGs in that it is detected at very low levels in the nervous system, but has been 
observed in human pancreas and brown adipose tissue in mouse (Harari et al., 1999) (M.H. 
Schwab, personal communication).  
 
1.8. Transgenic approaches to study gene function in vivo 
 
Several methodologies have been developed to study gene function in vivo: Generation of 
transgenic animals through pronuclear injection (Gordon et al., 1980; Palmiter et al., 1982; 
McKnight et al., 1983) and targeted gene ablation in embryonic stem (ES) cells either by a 
loss-of-function mutation (‘knock-out’) or by the insertion of a reporter gene into the genetic 
locus of interest (‘knock-in’) or by conditional ablation of gene function in a specific cell type 
(Doetschman et al., 1987; Thomas and Capecchi, 1987; Gu et al., 1994; Wang et al., 1996). 
In contrast to knock-in approaches, the promoters used in transgene constructs often do not 
provide the same pattern of expression seen for the endogenous promoter, but instead give 
rise to varying expression profiles. This variation in expression may be attributed to cis-acting 
regulatory elements that surround the site of transgene integration into the genome (Caroni, 
1997). Thus, multiple founders have to be analyzed to identify an animal with the desired 
transgene expression profile. 
 
1.8.1. Modification of BACs by homologous recombination in bacteria 
 
The use of larger genomic DNA fragments for the generation of transgenes increases the 
likelihood that the regulatory elements required for proper expression are contained within the 
transgene construct. Large genomic fragments have become available through the generation 
of bacterial artificial chromosomes (BACs) (Shizuya et al., 1992) and subsequently BAC-
based libraries (Shizuya et al., 1992; Kim et al., 1996; Osoegawa and de Jong, 2004; 
Osoegawa et al., 2004). As a result of their large size, BACs cannot be readily manipulated by 
restriction-ligation based methodologies and have thus required the development of different 
techniques for their modification. The precise insertion of DNA fragments into BACs is now 
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possible through the use of homologous recombination systems devised in bacteria (Yang et 
al., 1997; Zhang et al., 1998; Yu et al., 2000) 
The first recombination that was successfully used for the modification of BACs by 
homologous recombination in bacteria and the subsequent generation of transgenic mice, was 
introduced by Dr. N. Heintz in 1997 (Yang et al., 1997). The system utilizes recA-mediated 
homologous recombination in a recombination deficient bacterial strain. The recE/recT-based 
homologous recombination system as described by Stewart and co-workers uses transient 
expression of recombinogenic proteins in a recombination-deficient bacterial strain (Zhang et 
al., 1998). The recombination functions are contained on a plasmid, which encodes a 
truncated single strand binding protein, a 5’-3’ exonuclease and an inhibitor of the bacterial 
recBCD helicase/DNAse complex. 
Stewart and co-workers were able to demonstrate that the systems worked very efficiently 
with homology arms as short as 50-70bp, which permitted the addition of homology arms to 
targeting constructs by PCR without the need for multiple cloning steps. Furthermore, the 
recombinogenic factors are encoded on one plasmid and can thus be easily transferred into 
most BAC hosts. However, the system suffers from the fact that constitutive expression of 
recBCD inhibitor is toxic to E.coli, thereby reducing the efficacy of the homologous 
recombination event. Furthermore, transient transfection of plasmids generally leads to a 
‘leaky’ expression of plasmid-encoded proteins, which results in a higher background of 
unwanted recombination events. 
Yu and colleagues improved the recombination system by using a defective λ-prophage to 
stringently control the expression of Red recombinogentic factors exo, beta and gam (Yu et 
al., 2000). The proteins are functionally analogous to the Rac-encoded recET system: exo is a 
5’-3’ exonuclease that generates 3’ ssDNA overhangs, which are then bound by the ssDNA-
binding protein beta forming proteonucleic filaments that initiate strand invasion. Both 
proteins are functionally assisted by gam, which inhibits the bacterial recBCD 
helicase/DNAse complex. The recombination functions were placed under transcriptional 
control of the temperature-sensitive λ-repressor cI857, which is tightly bound to its operator 
sequenc es at 32°C thereby prohibiting transcription. Shifting the cells to 42°C for 15-18 
minutes inactivates the repressor and leads to the coordinate expression of the exo, beta and 
gam genes at very high levels from the λ-pL promoter. 
In addition to exo, beta and gam the defective prophage was engineered to encode either Cre 
or eFlp recombinases, whose transcription was placed under the control of the pBAD 
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promoter (Lee et al., 2001). These prophages were then used to generate 2 bacterial strains, 
EL250 and EL350 harboring the inducible eFlp and Cre recombinases, respectively. In this 
manner, ‘floxed’ or ‘flped’ selectable markers can be removed from modified BACs through 
the addition of L-(+)-arabinose to the growth medium (Fig.4). This system works efficiently 
with short homology arms of 50-70bp in length making it a very reliable and convenient 
method to modify BACs. A major disadvantage of the λ-prophage-based strategy is, however, 
the fact that the BACs have to be transferred to the corresponding bacterial strains by 
electroporation making it less flexible in use. 
 
 
Figure 4: Schematical representation of the λ-prophage-based Red recombination system. 
(A) At 32°C the temperature-sensitive λ-repressor cI857 is tightly bound to its repressor thereby prohibiting 
transcription of exo, beta and gam from the λ-pL promoter. At 42°C the repressor becomes unstable and allows 
the coordinate expression of exo, beta and gam. The prophage also harbors a site specific recombinase (shown 
here is Cre recombinase), which is under transcriptional control of the L-(+)-arabinose-inducible PBAD promoter. 
(B) Shown is a recombination event of rtTA2S-M2 into exon 4 of the choline acetyltransferase gene. A, B denote 
homology arms, which were added to the targeting construct by PCR. Addition of L-(+)-arabinose to the growth 
medium will induce Cre expression form the PBAD promoter, which will result in the excision of the floxed 
kanamycin resistance, leaving one loxP site behind (not shown). 
 
1.8.1.1. Inducible transgenes 
 
A number of systems have been devised to achieve the inducible and reversible expression of 
transgenes in vitro an in vivo. One of the first examples of a system permitting inducible gene 
regulation was the metallothionein-1 promoter, which was responsive to heavy-metals 
(Chalifour et al., 1990). The use of this system was very limited, however, since the 
administration of heavy-metals has severe side effects, particularly at higher doses, which are 
needed for the maximal induction of transgene expression. Another inducible system was 
engineered by Evans and colleagues utilizing a modified ecdysone – ecdysone-receptor based 
switch (No et al., 1996). Here, the ecdysone receptor was N-terminally fused to the VP16 
trans-activation domain of the herpes simplex virus (VpEcR) and when co-expressed with the 
retinoic X receptor (RXR), ecdysone/muristerone induced the heterodimerization of VpEcR 
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and RXR. This heterodimer is then able to bind to ecdysone response elements in a target 
promoter with high affinity to stimulate transcription.  
Recently, Dr. Heidi Scrable and colleagues have adapted the E.coli lac operon for controlled 
gene expression in the mouse (Cronin et al., 2001). The system is a binary system requiring 2 
lines of mice: One that ubiquitously expresses a synthetic lac repressor, synlacI, and a second 
line that harbors a tissue- or cell type-specific promoter into which operator sequences were 
inserted surrounding the transcriptional start of the gene to be expressed. In this case a 4.1kb 
promoter fragment of the tyrosinase gene was used. The bacterial origin of lacI required a 
codon optimization of its cDNA for the use in eukaryotic cells or transgenic mice. Almost all 
CpG islands had to be mutagenized to avoid transcriptional silencing of lacI by methylation 
through mammalian DNA methyltransferases. Additionally, a cryptic splice donor-acceptor 
site was removed that gave rise to aberrantly spliced lacI mRNA (Scrable and Stambrook, 
1997).Transgene induction is achieved through IPTG, which can simply be added to the 
drinking water of the mice. IPTG does not have any toxic effects at concentrations required 
for transgene induction (0.1 – 1mM), which makes the system suitable for transgenic work. 
However, the system has not been widely used due to several factors. First, the system was 
published recently and additional mouse lines need to be generated to better validate the 
technology in other tissues and through the use of promoters other than the tyrosinase 
promoter. Second, the need to insert operator sequences surrounding the transcriptional start 
site of the transgene can have adverse effects on transgene expression by altering the 
secondary structure of the resulting mRNA. 
 
1.8.2. Tetracycline-regulated gene expression 
 
The most widely used system for inducible gene expression in the mouse is the tetracycline-
regulated gene expression system (tet system). The system was invented by Gossen and 
Bujard and is based on the tetracycline resistance of E.coli encoded on transposon Tn10 
(Gossen and Bujard, 1992). Tetracycline (Tc) resistance in E.coli is conferred by the export of 
tetracycline-magnesium complexes [Tc·Mg]+ by the membrane-embedded proton-[Tc·Mg]+ 
antiporter tetA. The expression of tetA is under tight transcriptional control of the tetracycline 
repressor tetR. Both genes, tetA and tetR, are transcribed in opposite directions from two 
palindromic operator sites tetO1,2 (Hillen and Berens, 1994). In the absence of [Tc·Mg]+ 
complexes, tetR is tightly bound to the operator sites inhibiting the expression of tetA and its 
own. The association constant for the binding of tetR to its operator sequences is very high 
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(Ka ~ 1011 M-1). This tight regulation of tetA is vital for bacteria, since its uncontrolled 
expression results in an unspecific cation influx into the cell, reducing its membrane potential, 
which can be lethal. [Tc·Mg]+ binds to the 30S subunit of ribosomes with Ka~106M-1 thereby 
inhibiting protein synthesis. The affinity of tetR to [Tc·Mg]+ is ~109M-1 and binding of 
[Tc·Mg]+ reduces its binding constant for tetO by a factor of ~109 making it a sensitive switch 
controlling the expression of tetA at tetracycyline concentrations that are 1000-fold lower 
than the affinity of tetracycline to the 30S ribosomal subunit. 
 
1.8.2.1. Components of the tet-system 
 
In order to provide tight transcriptional control in eukaryotic cells Gossen and Bujard 
converted the prokaryotic tetR into a eukaryotic transcriptional activator by fusing it to the 
negatively charged C-terminal domain of HSV-VP16 (Gossen and Bujard, 1992). The 
resulting tetracycline-controlled transactivator, tTA, binds to its operator sequences within the 
tetracycline-inducible promoter Ptet with high affinity and thereby strongly stimulates 
transcription.The tetracycline-inducible promoter itself is comprised of the human 
cytomegalovirus minimal promoter, spanning the region of –53 to +75 relative to its 
transcriptional start and heptamerized tetO sequences inserted 5’ to it. 
Transcriptional regulation of Ptet-controlled genes by tTA is achieved with tetracycline or one 
of its derivatives, doxycycline, anhydrodoxycycliene, minocycline or 4-epidoxycycline. 
Binding of one of the effectors reduces the affinity of tTA to its operator sequences by a 
factor of ~109, which represses transcription from Ptet to undetectable levels. In luciferase 
assays tTA was shown to lead to a 105-fold reporter gene activation when bound to Ptet, which 
was reduced to background levels at tetracycline concentrations of 100ng/ml (Gossen and 
Bujard, 1992). 
The continuous requirement for tetracycline in order to repress the transcription of Ptet-
controlled genes by tTA has potential disadvantages. Using tTA, the kinetics by which a 
target gene can be switched from “OFF” to “ON” is slowed by the clearance of residual 
tetracycline that is stored in lipid-rich tissues or membranes. This is particularly important in 
transgenic animals where larger amounts of tetracycline or its more lipophilic analog 
doxycycline can be stored in adipose tissue or bone, which can lead to a significant delay in 
the activation or re-activation of tTA-mediated transcription. Bujard and colleagues therefore 
screened tetR mutants to identify variants that possessed the opposite DNA-binding properties 
that would enable the tetracycline/doxycycline-mediated activation of transcription. One 
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mutant was identified that was characterized by 4 amino acid substitutions (E71K, D95N, 
L101S and G102D) and that exhibited the desired DNA binding properties. When this variant 
was fused to the C-terminal transactivation domain of VP16, the reverse tetracycline-
controlled transactivator, or “rtTA” was produced (Gossen et al., 1995). 
The initial version of rtTA was characterized by a residual affinity to Ptet in the absence of 
doxycycline and it also displayed a lower sensitivity to doxycycline than tTA. These 
properties still made tTA the transactivator of choice, despite the favorable pharmacokinetics 
of rtTA. Urlinger and co-workers therefore subjected rtTA to repeated cycles of mutagenesis 
in S. cerevisae to obtain rtTA mutants with a lower residual affinity to Ptet as well as an 
increased sensitivity to doxycycline (Urlinger et al., 2000). The mutagenesis screen yielded 
two new rtTA mutants, rtTA2S-S2 and rtTA2S-M2, both of which have no residual affinity for 
Ptet increasing the induction range from 103 to 105 orders of magnitude. The sensitivity to 
doxycycline was also increased about 10-fold in the case of rtTA2S-M2.  
The use of the viral transactivation domain of VP16 can lead to a ‘squelching’ of cellular 
factors (Gill and Ptashne, 1988). It was later also discovered that high levels of VP16 protein 
can induces changes in chromatin structure (Tumbar et al., 1999). Furthermore, the viral 
VP16 moiety is potentially able to provoke an immune response, which would have 
deleterious consequences for the transgenic animal. Therefore, the viral VP16 transactivation 
domain of tTA and rtTA was replaced by 3 minimal transactivation domains of the “F” type, 
which have the same transactivation potential as VP16, but lack the ability to ‘squelch’ 
cellular factors (Baron et al., 1997).  
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1.9. Aims of this thesis 
 
The analysis of NRG1 gene function in the mouse is limited by the early embryonic death of 
NRG1 null mutant animals. Isoform-specific ablation of NRG1 gene function led to an 
improved understanding, as NRG1 type I/II mutant animals die, like the complete null 
mutant, in utero at E10.5, indicating that either or both of these forms is required for cardiac 
development. NRG1 type III mutant animals, however, proved to be more informative, as at 
least some animals lacking this isoform survive until birth. The loss of this isoform is 
correlated with a near total loss of Schwann cells and while neuromuscular synapses initially 
formed, they could not be maintained. The analysis of NRG1 heterozygous animals provided 
additional insight into NRG1 gene function in the mature nervous system, where NRG1 
continues to be expressed. Findings by Sandrock and co-workers suggested that the Ig-NRG1 
isoforms help to regulate acetylcholine receptor (AChR) number at the neuromuscular 
junction (NMJ), as heterozygous animals show a ~40% reduction in receptor number 
(Sandrock et al., 1997). Together, these genetic studies have revealed that different NRG1 
isoforms serve distinct biological roles with NRG1 type I/II isoforms appearing to serve in the 
role of “ARIA” and NRG1 type III forms serving as glial growth factor. 
The observations of Sandrock et al. lead to the hypothesis that the level of expression of 
NRG1 in mature animals may help to regulate AChR at the NMJ throughout the life of the 
animal. In order to test this hypothesis, it was reasoned that an inducible overexpression of the 
type I/II isoforms of NRG1, should lead to detectable increases in AChR number at the NMJ. 
Furthermore, the reversibility of these changes could be assessed by halting the increased 
expression of NRG1 and returning the system to the normal level of expression. In order to 
test this hypothesis, an animal model had to be generated that would permit the inducible 
expression of distinct NRG1 isoforms. The binary tet system was selected, requiring the 
production of 2 distinct types of mice. The first set of mice, described in Aim 1, permits the 
expression of the tetracycline-dependent transactivator (rtTA or tTA) allowing for an 
inducible gene expression in cells that normally express NRG1. The second type of mice, 
described in Aim 2, would permit the expression of distinct NRG1 isoforms under 
transcriptional control of tTA or rtTA in a doxycycline-dependent fashion.  
Although the initial motivation was based on studying the “ARIA”-like role of the type I/II 
isoforms, the analysis of NRG1+/- mice also revealed a reduction in the thickness of the 
peripheral myelin sheath, suggesting that the NRG1 type III isoform may serve as a regulator 
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of sheath thickness. Indeed, recently published findings by Michailov and co-workers, which 
were initiated after this thesis was started, have demonstrated that the constitutive 
overexpression of NRG1 type III does lead to increases in sheath thickness (Michailov et al., 
2004). In view of these findings, the proposed inducible NRG1 mouse model should permit 
determining if NRG1 type III can regulate myelin sheath thickness throughout the life of the 
animal or if its actions are confined to specific developmental periods. 
Thus, the availability of an animal model permitting the inducible expression of NRG1 should 
permit testing the hypothesis that distinct isoforms of NRG1 can exert their effects either on 
muscle cells at the NMJ to regulate AChR number or on myelinating glia to influence myelin 
sheath thickness throughout the life of the animal.  
 
1.9.1. Aim 1: Generation of a transgenic mouse model permitting regulated gene 
expression in cholinergic neurons 
 
Although the ideal promoter to regulate NRG1 expression is the NRG1 promoter itself, the 
available evidence at the inception of this project suggested the existence of 3 distinct 
promoters (one for each of types I, II and III), complicating the selection of the most suitable 
promoter. Based on the observation that NRG1 is known to be expressed in virtually all 
cholinergic neurons as well as in a subset of non-cholinergic cells, a mouse model permitting 
expression of NRG1 in cholinergic cells was elected (Chen et al., 1994; Corfas et al., 1995; 
Meyer et al., 1997). This would limit expression to cells that, in general, already expressed 
this factor. This approach seemed reasonable as it had been reported that a promoter fragment 
from the choline acetyltransferase gene had been used to direct the expression of a lacZ 
reporter gene to cholinergic neurons in the mouse (Naciff et al., 1999). Unfortunately, the 
promoter fragment was lacking functionally important regulatory sequences, which resulted 
in low expression levels of the transgene as well as in incomplete and ectopic expression. 
Despite these problems, their findings suggested that the approach was feasible, however 
there was a need to identify a promoter containing the regulatory elements conferring faithful 
expression in all cholinergic cells. The use of a bacterial artificial chromosome harboring the 
ChAT gene was therefore thought to provide a means to achieve cholinergic expression of 
rtTA2S-M2. 
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1.9.2. Aim 2: Generation of transgenic animals permitting the doxycycline-
regulated expression of distinct NRG1 isoforms. 
 
In order to generate a mouse model permitting regulated NRG1 expression in cholinergic 
cells, transgenic mouse lines have to be generated that express distinct NRG1 isoforms under 
transcriptional control of the tTA/rtTA-responsive Ptet promoter. 
For the generation of rtTA2S-M2-inducible NRG1 expression constructs, full-length murine 
NRG1 type I and type III clones have to be assembled and placed under control of Ptet. The 
expression constructs will then be used to generate transgenic animals through pronuclear 
injection and subsequently be analyzed for their inducibility and expression pattern of the 
transgene by mating them to the well characterized α−CaMKIItTA mouse line (Mayford et 
al., 1996). 
PtetNRG1 transgenics will then be used to assess the consequences of NRG1 overexpression 
during various developmental time points: NRG1 type I overexpressing animals may be 
evaluated for structural alterations of neuromuscular synapses while NRG1 type III 
overexpressing animals should be suitable for the analysis of alterations of myelin 
ultrastructure and changes in Schwann cell number. 
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III. Results 
 
The role of NRG1 in the mature nervous system is very limited as most experimental 
approaches to its function are based on loss-of-function experiments, which are hampered by 
the early embryonic or perinatal death of NRG1 null mutant animals (Meyer and Birchmeier, 
1995; Wolpowitz et al., 2000). The goal of this thesis was therefore to generate a mouse 
model that would allow for the regulated overexpression of NRG1 during various time points 
in development as well as in the mature animal. A BAC-based approach was chosen to target 
rtTA2S-M2 and subsequently tTA2S expression to cholinergic neurons, as NRG1 appears to 
be expressed in virtually all cholinergic neurons (Chen et al., 1994; Corfas et al., 1995; Meyer 
et al., 1997). In addition, full-length NRG1 cDNA clones encoding NRG1 type I and type III 
were assembled and used for the generation of rtTA2S-M2/tTA2S-responsive transgenic 
mouse lines.  
 
1.1. Characterization of pBelo11 ChAT-BAC 
 
As proposed in aim 1 of the thesis, a BAC that would potentially confer cholinergic 
expression of rtTA2S-M2 was identified through a custom pBeloBAC11 library screen at 
Incyte Genomics. For the screen ChAT promoter-specific primers were used as indicated in 
Fig. 1. The identified BAC clone contained a 135kb 129/SvJ-dervied genomic DNA fragment 
of the ChAT gene. Restriction mapping and subsequent BAC end sequencing revealed that 
the BAC contained ~96kb of sequence 5’ to the ATG of the ChAT gene and ended 2kb 3’ to 
coding exon 12, missing the last 3 coding exons of the gene (Fig.1). As shown in Fig.1 the 
first intron of the CHAT gene contains the intron-less vesicular acetylcholine transporter 
(VAChT) gene. 
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Figure 1: Organization of pBelo11 ChAT BAC. 
Structural organization of pBelo11 ChAT-BAC as determined by restriction mapping, Southern blotting and 
BAC end sequencing. Exons are indicated by blue boxes and are not drawn to scale. Exons R, N and M represent 
untranslated, alternatively spliced exons of the ChAT gene. The intron-less VAChT gene is located within the 
first intron of the ChAT gene. Arrows represent the primers, which were used to screen the BAC library. The 
genomic fragment contained in pBelo11 is flanked by 2 NotI restriction sites, which were used to release the 
insert from the pBelo11 vector. Indicated by a red triangle is a loxP site within the pBelo11 backbone, the yellow 
rectangle represents a cosN site. 
 
1.2. Generation of pBelo11 ChAT rtTA2S-M2 
 
For the modification of pBelo11 ChAT BAC using homologous recombination in bacteria, 
the first step was to inactivate the loxP site in the pBelo11 vector backbone, as its presence 
would interfere with subsequent manipulation. The loxP site was replaced by a β-lactamase 
resistance cassette through homologous recombination. Subsequently, the VAChT gene was 
inactivated by targeting it with a construct that introduced two in-frame stop codons 3’ to the 
4th codon. This construct also contained a FRT-flanked kanamycin cassette, which served as a 
selectable marker for the recombination event.  
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Figure 2: (A) Final pBelo11 ChAT rtTA2S-M2 BAC after three rounds of homologous recombination. 
Shown is the genomic insert without the modified pBelo11 backbone vector. Shown are the sites of integration 
of the targeting constructs to inactivate the VAChT gene as well as for the insertion of rtTA2S-M2 into the start 
codon of the ChAT gene. Indicated below the scheme is the location of the 800bp ChAt promoter probe, which 
was used for Southern blotting.  
(B) Restriction digest and Southern blot of unmodified and final pBelo ChAT rtTA2S-M2 BAC. “W” 
denotes the wild type and “R” the final, recombined ChAT rtTA2S-M2 BAC. The upper panel shows the 
restriction digest of one unmodified BAC and two clones after the homologous recombination events. The 
restriction digests were resolved by PFGE, blotted and probed with a ChAT promoter-specific and rtTA2S-M2-
specific probes. The enzymes that were used for the restriction digests are indicated. 
 
The resistance cassette was removed by L-arabinose-induced eFlpe recombinase expression 
in the bacterial strain EL250. In a third homologous recombination step rtTA2S-M2 was 
inserted into the start codon of the ChAT gene. The targeting construct used contained a 
floxed kanamycin cassette 3’ to the rtTA2S-M2 ORF, which was excised upon PCR 
verification of the homologous recombination event. The integrity of the final pBelo11 
ChAT-rtTA2S-M2 BAC was verified by Southern blotting with a ChAT promoter-specific 
and a rtTA2S-M2-specific probe (Fig.2). The rtTA2S-M2 ORF was PCR amplified in 
independent reactions and PCR products were sequenced following the homologous 
recombination event prior to pronuclear injection. 
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1.3. Generation of pBelo11 ChAT rtTA2S-M2 BAC transgenics 
 
For the generation of ChAT rtTA2S-M2 BAC transgenics, the genomic insert was released 
from the pBelo backbone by a NotI restriction digest and resolved by PFGE. The 135kb 
fragment was cut from the gel and electro-eluted, followed by repeated steps of dialysis 
against injection buffer.  
Pronuclear injection of the 135kb fragment into C57Bl6 oocytes resulted in very few pups, 
none of which harbored the transgene. Linearization of the BAC with λ-terminase at the cosN 
site within the vector backbone to circumvent electro-elution did not result in sufficient 
amounts of linearized, full length BAC DNA for pronuclear injection. Therefore, circular, 
maxi-prep grade BAC DNA was used for pronuclear injections at a concentration of 0.6ng/µl. 
Additionally, the injection buffer was modified and the polyamines spermine and spermidine 
were omitted from the buffer, as they appeared to be toxic to the oocytes in control 
experiments. 
Multiple rounds of injection resulted in 106 pups, 13 of which had integrated the transgene 
into their genome. 11 animals were able to transmit the transgene to the F1 generation. This 
corresponded to an efficiency of transgenesis of 10.4%, compared to ~20% for smaller, 
conventionally-sized transgene constructs. 
 
1.4. Analysis of ChAT rtTA2S-M2 BAC transgenics 
 
The resulting founder animals were mated to GFPG3 reporter mice to assess the functionality 
and the expression pattern of the integrated ChAT rtTA2S-M2 transgene (Fig. 3) (Krestel et 
al., 2001). The use of circular BAC DNA for the generation of transgenic animals was 
expected to give rise to founder animals with varying expression patterns for rtTA caused by 
circular permutation, increasing the number of founder animals to be screened. 
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Figure 3: Characterization of ChAT rtTA2S-M2 BAC transgenic animals. 
ChAT rtTA2S-M2 BAC transgenic animals were mated to GFPG3 reporter mice. GFPG3 reporter mice harbor a 
bi-directional tTA/rtTA responsive transegene construct that allows the simultaneous expression of eGFP and 
β-galactosidase from the bidirectional promoter Ptet-bi (Krestel et al., 2001).  ChAT rtTA2S-
M2:GFPG3 doubly transgenic offspring was fed DOX food (6mg dox/g food) to induce the expression 
of the GFPG3 reporter transgene. 
 
ChAT rtTA2S-M2:GFPG3 doubly transgenic offspring were fed DOX food for 10 days to 
induce the rtTA-dependent expression of the GFPG3 transgene, after which they were 
sacrificed and β-galactosidase expression was assessed by X-Gal staining. 
None of the lines examined showed significant levels of lacZ expression, even after 
doxycycline administration in both food and drinking water for 2 weeks. In order to analyze 
whether the absence of detectable lacZ activity was caused by the lack of rtTA2S-M2 
expression, a subset of the ChAT rtTA2S-M2 mouse lines was further analyzed for rtTA 
expression by RT-PCR (Fig. 4, Table 1). 
 
 
Figure 4: RT-PCR analysis of two ChAT rtTA2S-M2 BAC transgenic lines. 
(A) Displayed are the organization and primer locations for the endogenous ChAT locus and the BAC-derived 
ChAT rtTA2S-M2 locus. The asterisks denote the two in-frame stop codons that were introduced into the 
VAChT ORF. The filled triangles represent a residual FRT site (for VAChT) and a loxP site (for ChAT). Exons 
are not drawn to scale. (B) RT-PCR analysis of cDNA prepared from spinal cord (s.c.) and brain of transgenic 
mouse lines #64, #106 and wild type (wt) control using primers that amplify endogenous ChAT and a fusion 
product of the ChAT M-exon and rtTA2S-M2. Both lines were generated using circular BAC DNA and random 
breakage during chromosomal integration (circular permutation) might account for the absence of rtTA 
expression in the brain of line#106. 
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MOUSE LINE BRAIN SPINAL CORD LIVER 
ChATrtTA#18 + + N.D. 
ChATrtTA#27 + N.D. - 
ChATrtTA#51 + - - 
ChATrtTA#64 + + - 
ChATrtTA#77 - - - 
ChATrtTA#106 - + - 
Table 1: RT-PCR analysis of rtTA expression in 6 ChAT rtTA2S-M2 mouse lines. 
Based on the detectable rtTA expression in both brain and spinal cord, lines#18 and #64 were further examined 
by in situ hybridization. N.D.:rtTA expression was not determined. Liver cDNA was used as a negative control. 
 
Two mouse lines ChATrtTA#18 and #64 were further examined by in situ hybridization, as 
both lines showed rtTA expression in brain and spinal cord. 
A comparison of the rtTA and endogenous ChAT mRNA expression are shown in Fig. 5. It 
appears that neither line exhibited the pattern observed for ChAT, as evidenced by the ectopic 
expression of rtTA detected in the cortex of line#18 and the absence of rtTA expression in the 
septum and striatum in line#64. The RT-PCR product from the brain cDNA of line#64 
appears to be due to a weak and ectopic expression of rtTA in the hippocampus of that line 
(not shown). 
 
 
Figure 5: Analysis of ChAT and rtTA2S-M2 expression by in situ hybridization. 
Shown are in situ hybridizations of cross sections in the medial septal area of the brain and the spinal cord for 
ChAT and for rtTA for 2 mouse lines, #18 and #64. In comparison to the endogenous ChAT mRNA, 
ectopic rtTA transcripts can be detected at low levels in the cortex of line#18. Low levels of rtTA are 
also found in motor neurons of the spinal cord. rtTA expression is absent from the brain section of 
line#64, the expression of rtTA in the spinal cord does not appear to be restricted to motor neurons.  
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The failure to observe β-galactosidase activity, despite the expression of rtTA led to concerns 
that the blood brain barrier (BBB) may have prevented doxycycline from entering the brain in 
sufficient amounts to activate transcription from Ptet-bi by rtTA2S-M2. In support of this 
concept, measurements conducted by Dr. S. Berger in the laboratory of Prof. H. Bujard 
indicated that the oral administration of doxycycline at a dose of 2mg DOX/g food resulted in 
an effective concentration in the brain of 0.5ng/ml. Based on dose-response measurements 
from that laboratory, the transcriptional activation achieved by rtTA2S-M2 at this 
concentration of doxycycline was <1% of its maximal transactivation potential (Berger, 
2003).  
In light of these findings, a slice culture experiment was set up to circumvent the BBB and to 
determine whether the rtTA2S-M2 expressed in line#18 was able to induce reporter gene 
transcription. For this purpose P5 ChATrtTA2S-M2 BAC:GFPG3 and GFPG3 transgenic 
animals from line#18 were sacrificed and brain slices were kept in culture for 3 days in the 
presence or absence of doxycycline as indicated in Fig. 6, followed by fixation and X-Gal 
staining. None of the slices derived from the doubly transgenic animal in the presence of 
DOX at a concentration of 1µg/ml showed detectable β-galactosidase activity, suggesting the 
absence of functional rtTA protein. Sequencing of PCR amplified rtTA2S-M2 transcripts from 
this mouse line did not reveal any mutations. 
 
 Surprisingly, sequencing of independent RT-PCR reactions that amplified the splicing 
product of the ChAT N-exon and rtTA revealed no mutation in the transcript. 
 
 
Figure 6: LacZ-stained slice cultures of doubly and singly transgenic animals from a ChAT rtTA2S-
M2#18 x GFPG3 litter. 
Brain slices from P5 animals were kept in culture for 3 DIV with or without doxycycline as indicated, fixed with 
4%PFA and lacZ stained ON. Slices shown in (1,2) are derived from a doubly transgenic animal, the slice in (3) 
was taken from a GFPG3 singly transgenic animal. “+DOX” indicates the addition of 1µg/ml doxycycline to the 
culture medium. 
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1.5. Alternative approach to cholinergic expression of tTA 
 
The analysis of the ChATrtTA2S-M2 BAC transgenic mouse lines indicated that despite the 
presence of ~89kb of putative promoter sequence 5’ to the R-exon of the ChAT gene, 
important regulatory elements important for proper cholinergic expression of rtTA2S-M2 
were not contained on the pBelo11ChAT BAC. Based on the genomic organization of the 
BAC, it appeared likely that the missing regulatory elements were located 3’ of the gene. A 
similar problem was also subsequently observed by Dr. N Heintz during the generation of a 
ChAT-EGFP BAC transgenic mouse line for the GENSAT database (Gong et al., 2003). 
Meanwhile, through advances in the assembly and annotation of the public murine genomic 
databases (such as ENSEMBL), the location of BAC clones in the genome became readily 
available. A new BAC that contained the complete ChAT gene and roughly equal amounts of 
genomic 5’ and 3’ flanking sequence was identified through the “cytoview” application 
implemented in the ENSEMBL database. The structural organization of the new BAC, RP24-
70D4, is depicted in Fig. 7. 
 
 
Figure 7: Structural organization of the RP24-70D4 BAC. 
The 199kb RP24-70D4 BAC contains all coding and non-coding exons of the ChAT gene, which span 58.9kb in 
the genome. It is furthermore characterized by ~58kb of promoter 5’ to the R-exon and ~82kb 3’ flanking 
sequence to the last exon of the ChAT gene. An important feature of the pTARBAC1 BAC backbone is the 
recognition site for the homing endonuclease PI-SceI, which was used for linearization of the final BAC. Exons 
are indicated by rectangles, which are not drawn to scale.  
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In addition, as the BBB prevented the levels of doxycycline required for the transcriptional 
activation of Ptet-bi by rtTA2S-M2 from entering the brain, a humanized, second generation 
tTA, htTA, was chosen to achieve doxycycline-dependent gene expression in cholinergic 
neurons. htTA does not require doxycycline for transcriptional activation of Ptet, thus full 
transcriptional activation can be achieved in the absence of doxycycline. Due to a roughly 10-
fold greater sensitivity of htTA to doxycycline, repression of transgene expression to low 
levels was thought to be possible, despite the presence of the BBB.  
 
1.6. Generation of RP24-70D4 ChATtTApA (‘ChATtTApA’) 
 
For the generation of ChATtTApA, the same recombination scheme was used as for the 
generation of pBelo11 ChAT rtTA2S-M2 (see Fig. 8). However, a different selection marker 
were used for the generation of the homologous recombination fragements: For the insertion 
of tTA into the start codon of the ChAT gene, the tTA cDNA was first cloned into 
pFRTzeo5’MCSpA (see: appendix, plasmid maps), which also contained a polyadenylation 
signal, as this was not contained in the htTA cDNA.  
The resulting construct, pFRTzeo5’MCSpA-htTA was used as a PCR-template to add the 
55bp homology arms to the targeting construct. The PCR product was subcloned into pGemT, 
sequenced and used for homologous recombination in bacterial strain EL250 harboring the 
RP24-70D4∆VAChAT∆neo BAC.  
The recombination event, the subsequent excision of FRT-flanked zeocin resistance and the 
presence of both 5’ and 3’ BAC ends were PCR verified as shown in Fig. 8. The final BAC 
was linearized with PI-SceI and column purified over Sepharose ClL-4B. Based on the results 
of the PFG-analysis of the collected fractions after column purification of the linearized BAC, 
fraction#10 was chosen for pronuclear injection.  
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Figure 8: Analysis and linearization of the final ChATtTApA BAC. 
(A) Structure of the final ChATtTApA BAC. Primers that were used to verify the integrity of the BAC are 
indicated. (B) Results of the PCR verification of the BAC integrity. 1: primers#5/#8 (5’ ChAT/tTA), 2:  
primers#7/#8 (tTA), 3: primers#6/#7 (3’ ChAT/tTA as, post Flp expression), 4: primers#1/#2 (5’ BAC end), 5: 
primers#3/#4 (3’ BAC end), 6: primers #6/#7 (tTA FRTzeo clone, prior to Flp expression). (C) PFGE analysis 
of the wt RP24-70D4, ∆VAChT∆neo and the final, RP24-70D4:∆VAChT∆neo:tTApA:∆zeo, BAC. The 
enzymes used for restriction analysis are indicated above the corresponding lanes, “S”: SalI, “C”:ClaI, “C/S”: 
ClaI/SalI. (C) Shown is a PFG of different fractions of the PI-SceI-linearized final RP24-70D4 BAC after 
column purification for pronuclear injection. Based on OD260 300ng of DNA were loaded for each lane. As a 
standard the indicated amounts of linearized λ-DNA were loaded. Fraction #10 was used for pronuclear 
injection.  
 
This fraction appeared to have the best ratio of full length BAC to sheared BAC DNA, which 
arises as a contamination during linearization and subsequent handling. 
 
1.7. Generation of RP24-70D4 ChATtTApA BAC transgenics  
 
Injection of the linearized BAC DNA from fraction#10 into CByB6F1 oocytes resulted in the 
birth of 66 pups 9 of which had stably integrated the transgene into their genome. One 
founder did not transmit the BAC transgene to the F1 generation and was therefore sacrificed. 
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The remaining 8 animals were mated to GFPG3 mice in the absence of doxycycline to permit 
reporter gene expression.  
During the analysis of the founders generated using linearized BAC DNA, circular BAC 
DNAs were also used for the production of a second set of transgenic mice. Three rounds of 
injections yielded a total of 40 pups. Of these, 6 animals that were found to be tTA positive 
using PCR were mated to GFPG3 mice to assess their tTA expression pattern. 
 
1.8. Analysis of ChATtTApA BAC transgenics generated with linear 
BAC DNA 
 
ChATtTApA:GFPG3 doubly transgenic animals from each of the 8 founder lines were 
perfused with 4% PFA, brains and spinal cords were removed and sectioned on a vibratome. 
Coronal brain sections containing the medial septal area and the habenulae, brain regions 
known to contain a large number of cholinergic neurons, as well as coronal sections of the 
spinal cord were subjected to X-Gal histochemistry. Unexpectedly, 7 of the 8 lines examined 
did not show any detectable lacZ activity. Of the 7 lines two were analyzed further by RT-
PCR. Both lines showed tTA expression in brain and spinal cord. One of the lines was then 
chosen for a more detailed analysis by in situ hybridization to determine the spatial 
distribution of tTA transcripts (Fig. 9). 
 
 
Figure 9: tTA-specific RT-PCR and in situ hybridization for line ChATtTApA#9. 
Shown on the left are  tTA-specific and  ChAT-specific RT-PCRs demonstrating that tTA is expressed in both 
brain and spinal cord. Liver cDNA was used as a negative control. Shown on the right are in situ hybridizations 
with a tTA-specific probe. Strong hybridization signals for tTA were detectable in the medial septal nucleus, the 
striatum (middle panel), as well as in the lateral habenular nuclei and amygdaloid structures (right panel), areas 
known to contain cholinergic neurons. tTA expression was not seen in the cortex or hippocampus.  
 
It was determined that despite the absence of detectable lacZ expression, tTA was being 
faithfully expressed in a cholinergic cells. The reasons for an apparently cholinergic, but non-
functional tTA expression were not additionally pursued. 
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1.9. Analysis of the ChATtTApA#44 BAC transgenic line 
 
A preliminary X-Gal histochemical analysis of line ChATtTApA#44 suggested cholinergic 
expression of tTA as judged by the location of lacZ-positive cells in the brain as well as by 
lacZ positive cells in the spinal cord and sciatic nerve (Fig. 10A). Administration of 
doxycycline for 10 days in both food and drinking water was used to achieve maximal 
repression of the transcriptional transactivation by tTA (Fig. 10B). Following this initial 
characterization, in situ hybridization was used to compare the expression pattern of ChAT 
and tTA, revealing prominent expression of tTA in apparent cholinergic structures in the 
brain and spinal cord (Fig. 11).  
 
 
Figure 10: Doxycycline-dependent histo-chemical detection of lacZ-activity in ChATtTApA#44:GFPG3 
doubly transgenic animals. (A) A coronal cross section through the medial septal area of a doubly transgenic 
animal is shown in the left panel. Shown on the right is the medial septal area in a sagittal plane of section of a 
doubly transgenic littermate. Inset: Higher magnification of the boxed area. (B) The medial septal area of a 
doubly transgenic animal after 10 days of doxycycline administration in both food and drinking water. (C) LacZ-
stained spinal cords (left) and sciatic nerves (right) of doubly transgenic animals that were fed doxycycline for 
10 days in both drinking water and food (lower panel, “+dox”) or were fed regular food (“-dox”). 
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Figure 11: Comparative in situ hybridization for a ChATtTApA#44 transgenic animal using ChAT- and 
tTA-specific probes. Panels (A-C’) show cross sections through brain areas known to contain characteristic 
cholinergic structures: (A, A’) medial septal area and striatum, (B, B’) Habenular nuclei, caudal striatum, (C, 
C’) facial nuclei. (D, D’) Panels show motor nuclei in the spinal cord. Scale bars: 500µm. 
 
In the next step ChAT and transgene-derived EGFP co-localization were assessed by 
immuno-histochemistry to address faithful cholinergic expression (Fig. 12). 
Based on the co-localization of ChAT and transgene-derived EGFP founder line 
ChATtTApA#44 appeared to exhibit a cholinergic expression pattern of tTA in the forebrain 
and the spinal cord. 
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Figure 12: Immuno-histochemical co-localization of ChAT and EGFP in line ChATtTApA#44. 
Shown are 45µm vibratome sections of cholinergic neurons in different brain areas and motor neurons in the 
spinal cord stained with α-ChAT (in green) and α-EGFP antibodies (in red). The merged images show a high 
degree of co-localization of both signals. Scale bars: striatum, pedunculopontine tegmental nucleus, lateral 
habenular nucleus: 50µm, spinal cord: 20µm. It should be noted that the images taken for the habenular nucleus 
were acquired with a confocal microscope and have thus a different spatial resolution than the other images in 
the composite. Differences in the localization of the EGFP and ChAT signals are due to different fluorescent 
intensities of tyramide and AlexaFluor568, which are not apparent by conventional microscopy.  
 
 
Results 
 
 38
1.10. Detection of β-galactosidase-positive Bergmann glia in 
ChATtTApA#44 transgenics 
 
Histo-chemical processing of sagittal brain sections revealed the presence of lacZ-positive 
cells in the cerebellum appear to be Bergmann glia based on location and morphology (Dr. F. 
Kirchhoff, MPI f. Exp. Med., personal communication) (Fig. 13). The transgene expression in 
Bergmann glia was initially thought to be ectopic, however α-ChAT immunohistochemical 
analyses have revealed that a subset of these cells are ChAT positive. In addition, the 
expression of lacZ in those cells was repressed upon doxycycline administration (Fig. 13C). 
 
 
Figure 13: Detection of lacZ-positive Bergmann glia in ChATtTApA#44:GFPG3 doubly transgenic 
animals. (A) X-Gal-stained sagittal section of a cerebellum from a doubly transgenic animal. (B) LacZ-positive 
cells can also be seen in a coronal plane of section in a doubly transgenic littermate. (C) Doubly transgenic 
animal after 10 days of doxycycline administration in the food. (D, E, F) Immuno-histochemical detection of 
ChAT and EGFP in Bergamann glia in the cerebellum of a doubly transgenic mouse. 
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1.11. Analysis of ChATtTApA BAC transgenics generated with circular 
BAC DNA 
 
The use of circular BAC DNA for the generation of transgenic animals was believed to result 
in a higher percentage of animals displaying either a failure in expression or ectopic 
expression of tTA as a result of the random breakage of the circular DNA prior to integration. 
This would have led to a permutation of genomic sequences relative to the linear map 
depicted in Fig. 7. Of the 6 founders analyzed 2 displayed ectopic or partial cholinergic 
expression of tTA. One animal however, ChATtTApA#73, appeared to exhibit faithful 
expression in cholinergic cells.  
 
 
Figure 14: Coronal sections of the brain and spinal cord of a ChATtTApA#73:GFPG3 doubly transgenic 
animal after histo-chemical lacZ detection. Depicted are the medial septal area (A), the striatum (B), the 
lateral habenular nuclei and their projections into the dorsal thalamus (C) and the spinal cord (D). 
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Figure 15: Autoradiographic in situ hybridization images of a ChATtTApA#73 transgenic animal. Shown 
are the hybridization signals of a 33P-labeled tTA-specific probe after a 72h exposure. (A) Hybridization signals 
can be seen in the medial septum and the striatum, (B) the habenular nuclei and the basal nucleus of Meynert and 
(C) the facial nuclei. Shown in panel (D) are tTA-positive motor neurons in the spinal cord. 
 
This mouse line was then further evaluated by in situ hybridization as shown in Fig. 15. 
Based on the number and location of tTA-positive neurons, which resembles the pattern 
observed for line#44, these results suggest that line#73 also expresses tTA in a cholinergic 
fashion.  
 
Upon comparison of the number of tTA-positive versus lacZ-positive neurons, significant 
disparities in cell number were observed (compare Fig.10A, 11A’). This apparent difference 
was found in both mouse lines and it was initially assumed that technical reasons could 
account for the observed differences, as it was possible that the radioactive signals were more 
readily detected than the X-Gal stain due to a better tissue penetrance. Subsequent analysis 
(see Fig. 19 and discussion), indicated that the problem is most likely caused by the lacZ 
reporter gene. 
 
1.12. Determination of BAC copy numbers in mouse lines 
ChATtTApA#44 and #73 
 
Both linear and circular BAC DNA forms were successfully used for the generation of mouse 
lines with cholinergic expression of tTA. In order to determine whether tTA expression levels 
correlated with transgene number, BAC vopy number for each line was determined by 
Southern blotting (Fig. 16). 
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The Southern blots shown in Fig.  16 demonstrate that wild type and BAC-derived 
ChATtTApA locus can be distinguished by restriction digests, due to the presence of tTA in 
the BAC, which results in a size shift of roughly 1kb. A MacBas5000 phosphoimager was 
used to quantify the signal ratios between wild type and transgene-derived bands. 
The signal ratios revealed that mouse line ChATtTApA#44 harbors 3 copies of the BAC in its 
genome, while line #73 carries 5 BAC transgene copies. It should be noted that in one 
restriction digest for ChATtTApA#73 using the restriction enzymes SacII, EcoRV only half 
of the DNA was cut to a fragment of the expected size.  
A potential reason for this incomplete cleavage was a single nucleotide polymorphism (SNP) 
leading to a loss of the SacII site in half of the DNA sample. In order to clarify the situation, a 
500bp genomic DNA fragment surrounding the SacII restriction site in question was 
amplified by PCR and digested with SacII. In the event of an underlying SNP, only half of the 
DNA should be cut and thus result in 3 fragments: uncut, and 2 smaller fragments. However, 
no difference was found in the restriction digest pattern for wt and ChATtTApA#73-derived 
fragments, indicating that the underlying cause was likely not a SNP, but may instead be 
attributed to differences in the methylation of one of the two CpG dinucleotides within the 
SacII restriction site 5’-CCGCGG.  
Results 
 
 42
 
 
Figure 16: Southern blot scheme and blots of mouse lines ChATtTApA#44 and #73. Shown in (A) is 
organization of the wt ChAT locus surrounding the ChAT start codon. The resulting restriction fragment sizes 
are indicated below the cartoon. (B) Structural organization of the recombined ChAT-tTApA locus, along with 
the resulting restriction fragment sizes below the cartoon. The location of the ChAT promoter probe is indicated 
in both cartoons. (C) ChAT and tTA-specific Southern blots of wt, ChATtTApA#44 and ChATtTApA#73 
genomic DNA, which was cut as indicated above each lane. The lower band in the ChAT-specific Southern blot 
corresponds to the wt ChAT locus, while the upper bands, which are shifted by 1kb, correspond to the BAC-
derived ChATtTApA locus. Restriction sites that were used for the analysis are: RI: EcoRI, BH1: BamH1, B: 
BspE1, RV: EcoRV, N: NdeI, SII: SacII. 
 
1.13. Whole-mount histo-chemical detection of lacZ in 
ChATtTApA:GFPG3 doubly transgenic embryos 
 
The embryonic expression of tTA in each of the ChATtTApA lines was assessed. Previous 
studies have indicated that during development cholinergic neurons can be first detected using 
α-ChAT antibodies at E12.5 in the upper thoracic spinal cord (Phelps et al., 1991). Studies by 
Schambra et al. have demonstrated that the majority of cholinergic neurons emerge between 
E14-E16 in the mouse forebrain (Schambra et al., 1989). In view of these observations, tTA 
expression was assessed between E14 – E16 in ChATtTApA:GFPG3 doubly transgenic 
embryos. Later time points were not chosen for evaluation, as the clearing process of the 
embryos for whole mount lacZ histo-chemistry is inefficient and prohibits a detailed analysis. 
Timed-pregnant females from matings that would result in doubly transgenic offspring were 
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sacrificed at the desired gestation day. For genotyping purposes a small piece of tail was 
removed and the remainder of each embryos was subjected to whole mount lacZ histo-
chemistry, the results of which are shown in Fig. 17. 
 
 
 
Figure 17: Whole mount lacZ-stained ChATtTApA#73:GFPG3 embryos. 
Embryos depicted in panels A-C were fixed at E14, embryos in D, E at E15. The embryos shown in (C) and (E) 
are GFPG3 singly transgenic control embryos. 
(A) Dorsal, (B) lateral view of a tTA:GFPG3 doubly transgenic embryo at gestation day 14 after lacZ detection 
and clearing of the embryo. The structures visible are (1) olfactory nerves converging on olfactory lobe of brain, 
(2) germinal zone of lateral ventricle, (3) extrinsic tongue muscle [m. genioglossus], (4) Ggl. oticum 
(pterygopalatinum), (5) Ggl. trigeminale, (6) Ggl. cervicothoracicum, (7) superior cervical ganglion, (8) 
Intumescencia cervicalis, (9) Nervus vagus, (10) Truncus sympathicus, (11) Plexus hypogastricus, (12) Plexus 
sacralis, (13) parts of the umbilical cord, (14) developing enteric nervous system. Shown in (D) is a lacZ-stained 
E15 embryo. Some of the lacZ-positive structures as seen in (A), (B) are still visible, although the staining is 
much weaker and appears incomplete. Scale bar: 0.5mm 
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Figure 18: Whole mount lacZ-stained and cleared ChATtTApA#44 E15.5 embryos. 
(A) A lacZ-stained and cleared ChATtTApA#44:GFPG3 doubly transgenic E15.5 embryo. Despite the less 
efficient clearing of the embryo at E15.5, an increased number of cholinergic neurons is visible in comparison to 
the E14 embryo shown in fig.17. Most notably are the migrating cholinergic neurons in the cortex and lateral 
ventricle as well as the intercostals motor neurons. (B) GFPG3 singly transgenic control embryo. Scale bar: 
1mm. 
 
The later developmental time point of the embryos shown in Fig. 18 does not allow for a 
complete clearing of the embryonic tissue, but cholinergic neurons are still visible.  
The incomplete lacZ stain as seen in Fig.  17D may indicate potential functional limitations of 
the lacZ reporter transgene that was used to generate the GFPG3 mouse line. This finding 
does not appear to be restricted to mouse line ChATtTApA#73, but it is also apparent in line 
ChATtTApA#44. In this line, lacZ expression appears to be incomplete in the adult animal 
and prominent cholinergic structures are characterized by a small number of lacZ-expressing 
cells, although tTA is expressed by virtually all cholinergic neurons (see Fig. 10 and 11A’). 
 
1.14. Analysis of β-galactosidase expression in ChATtTApA#73:GFPG3 
transgenic animals 
 
The difference in the number between tTA-positive neurons seen by in situ hybridization and 
by lacZ histo-chemistry prompted the question whether this lack of β-galactosidase activity 
was due to improperly expressed tTA or caused by the lacZ gene in the GFPG3 reporter.  
In situ hybridization with tTA- and lacZ- specific probes was used to assess the expression of 
each of the two transgenes in a ChATtTApA#73:GFPG3 doubly transgenic animal (Fig. 19). 
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Figure 19: Autoradiographic in situ hybridization images for tTA- and lacZ specific probes on coronal 
brain and spinal cord sections of a ChATtTApA#73:GFPG3 doubly transgenic animal. (A) Adjacent 
coronal brain sections are shown that were hybridized with a tTA- and lacZ-specific probe. Cholinergic 
expression can be seen in interneurons of the striatum and the cholinergic neurons of the beginning medial 
septum. LacZ-expressing cells are sparsely distributed and are absent from the medial septal area. (B) Displayed 
are adjacent sections of the spinal cord. Whereas tTA is expressed by motor neurons, no lacZ transcripts can be 
detected. 
 
The results of the in situ hybridization suggest that the lack of lacZ-positive cholinergic 
neurons is not due to an improperly expressed tTA, since tTA transcripts can be readily 
detected and they appear to be expressed in a cholinergic fashion. The possibility that the tTA 
gene was not functional as a result of mutation did not appear to be the case, as lacZ-positive 
cells were detected, although their number appeared to be decreasing with each succeeding 
mouse generation.  
The finding that lacZ was subject to a ‘silencing’ effect in cholinergic neurons was 
unexpected and of great importance for the generated tTA-inducible NRG1 transgenic lines. 
The parental plasmid for the construction of the NRG1 expressing lines was the same 
construct used to generate the GFPG3 reporter line and thus lacZ silencing could potentially 
influence or repress the expression of the NRG1 transgene in those lines. 
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2. Generation of Ptet-bi NRG1 transgenic animals 
 
For the tTA-regulated overexpression of NRG1 isoforms in cholinergic neurons NRG1 
cDNAs encoding the β1a variants of the type I, type II and type III isoforms were generated 
by standard molecular cloning techniques. The NRG1 expression constructs were 
subsequently tested in tissue culture prior to cloning the transgene constructs. 
 
2.1. Molecular cloning of NRG1 isoforms 
 
A full-length murine NRG1 type III β1a cDNA clone (‘GGF#9’) was used as the source 
plasmid for the transmembrane domain and cytoplasmic tail regions to produce full-length 
clones for NRG1 types I, II and III. The full-length NRG1 type III clone was amplified by 
PCR to add SalI restriction sites to its 5’ and 3’ end and sequenced. A unique SacI restriction 
site that was located 5’ to the transmembrane domain in conjunction with the 3’ SalI 
restriction site of the modified NRG1 type III cDNA were subsequently used to assemble 
NRG1 type I and type II β1a cDNAs. NRG1 type I and type II cDNA fragments encoding the 
extracellular parts of the corresponding proteins up to the SacI restriction site, were PCR 
amplified from brain cDNA libraries and EST clones. The resulting clones were sequenced 
and subcloned into CMV promoter containing expression plasmids.  
The nucleotide sequences of NRG1 type I and type III, along with their conceptual 
translations were also deposited in the NCBI database (accession numbers: AY648976, 
AY648975). 
 
2.2. Expression of NRG1 cDNAs in cultured cell lines. 
 
The generated NRG1 types I, II and III β1a expression constructs were transfected into cos7 
fibroblasts and PC12 cells to test whether the assembled cDNAs could be expressed and 
detected in cell lysates with a NRG1β1a-specific antibody (Fig. 20).  
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Figure 20: Examination of NRG1 cDNA expression in heterologous cells.  
(A) Depicted are the domains of the NRG1β proteins encoded by the assembled cDNAs. ‘EGFP-a-tail’ denotes 
an expression construct that was used as a positive control for the sc-348 antibody that was used to detected 
recombinant NRG1 protein in cell lysates. The red bar indicates the epitope recognized by the sc-348 antibody, 
the arrow head indicates the MMP cleavage site within the stalk region of NRG1. (B) Western blots from PC12- 
and cos7-derived cell lysates probed with the NRG1β-a-tail-specific sc-348 antibody. Roman numerals indicate 
NRG1 type I-III, m: mock transfected sample, e-a-tail: eGFP-a-tail fusion. Protein sizes are indicated. Arrows 
mark the bands of interest. The expected (calculated) protein sizes are: NRG1 type I: 71kD, type II: 90kD, type 
III: 77kD, EGFP-a-tail: 69.5kD and a-tail (post MMP cleavage) ~44kD.  
 
Western blotting indicated that all isoforms were expressed in non-neuronal and neuronal-like 
cell lines. Interestingly, processing differs between cos7 and PC12 cells; cos7 cells appear to 
favor a cleavage of the full-length NRG1 isoforms, indicated by the presence of the 44kD a-
tail specific band. In PC12 cells, however, most of the NRG1 protein appears to be full length 
and uncleaved, since only little a-tail fragment can be detected.  
 
2.3. Generation of Ptet-bi NRG1 transgenics. 
 
NRG1 type I and type III cDNAs were subcloned into pGFPlacZ, which carries a bi-
directional tTA/rtTA-responsive promoter, Ptet-bi, that enables the expression of lacZ and 
EGFP from the same promoter in opposite directions (Baron et al., 1995). The cDNA 
fragment encoding EGFP was released form pGFPlacZ through a NotI digest and the NRG1 
type I or type III cDNA were inserted into this site. The resulting transgene constructs, 
pNRG1typeI-lacZ (‘IgBetaBi’) and pNRG1typeIII-lacZ (‘SMDFBi’), were linearized with 
AseI, gel purified and used for pronuclear injection at a concentration of 6ng/µl. 
The pronuclear injections of the pNRG1typeI-lacZ (‘IgbetaBi’) construct resulted in the birth 
of 46 pups, 9 of which had stably integrated the transgene into their genome and were able to 
transmit it to the F1 generation. The pronuclear injection of pNRG1typeIII-lacZ resulted in 
the birth of 64 pups of which 8 were founders. 
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2.4. Analysis of pNRG1typeI-lacZ (‘IgBetaBi’) transgenic animals 
 
Conventionally-sized transgenes are often subject to positional effects that are caused by 
neighboring regulatory elements in the genome. These elements may influence the expression 
pattern of the transgene and can lead to ectopic expression or to the silencing of the transgene. 
Inducible transgenes are prone to be influenced by positional integration effects through 
transactivation by a nearby enhancer. It is therefore important to establish that the expression 
of pNRG1-lacZ transgenes is not affected by positional effects, which can lead to abberant 
transgene expression. The α-CaMKII-tTA line is the best characterized and most widely used 
tTA-expressing mouse line and it was therefore chosen for the characterization of 
pNRG1typeI-lacZ founder animals. Doubly transgenic mice were used to assess the ability of 
doxycycline to induce or repress lacZ reporter gene expression. Animals that displayed a α-
CaMKII-tTA-like expression of lacZ were further analyzed by RT-PCR for a doxycycline-
dependent expression of transgene-derived NRG1 type I mRNA.  
Out of the 9 founder animals analyzed, 1 line was characterized by a α-CaMKII-tTA-like 
expression pattern of β-galactosidase as well as by a reversible doxycycline-dependent 
expression of the pNRG1typeI-lacZ transgene (Fig. 21). 
As evidenced by RT-PCR a weak transgene expression can be detected in IgbetaBi#24:α-
CaMKIItTA doubly transgenic animals after a week of doxycycline administration. A likely 
reason is the BBB, which prevents sufficient amounts of doxycycline form entering the brain 
that are needed for a complete repression of transgene expression. Based on RT-PCR and X-
Gal stains it is apparent that after a week of doxycycline withdrawal transgene expression is 
not fully re-induced.  
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Figure 21: Characterization of IgbetaBi#24:α-CaMKII-tTA transgenics. (A) Mating scheme for the 
generation of α-CaMKII-tTA:IgbetaBi#24 doubly transgenic animals. (B) Depicted are coronal brain sections 
from 2 mice on (+Dox) and off (-Dox) doxycycline for an initial assessment of transcriptional repression of 
transgene expression through doxycycline administration (C) Shown is a time course for the re-induction of 
transgene expression after doxycycline administration for 7 days and doxycycline withdrawal for 7 days. The 
mice were sacrificed subsequently sacrificed and lacZ expression was assessed by X-Gal staining. (D) RT-PCR 
analysis of transgene expression in singly and doubly transgenic animals, which were fed DOX food as 
indicated. “tTA*#24”: α-CaMKII-tTA:IgbetaBi#24 doubly transgenic animal. “wt”: wild type, “-RT”: no 
reverse transcriptase added to RT-PCR. The wild type control cDNA used was generated independently with 
less total RNA and overall PCR product yields are lower. “tg typeI”: transgene-derived NRG1 type I transcripts. 
“type I”: total NRG1 type I transcripts. All lacZ-stains were allowed to proceed for 90 minutes at 37°C, after 
which the reaction was stopped.  
 
2.5. Analysis of pNRG1typeIII-lacZ (‘SMDFBi’) transgenic animals 
 
The SMDFBi founder mice were mated to GFPG3 animals and lacZ expression was assessed 
as done for IgbetaBi founders. Of the 8 founder animals analyzed one animal, SMDFBi#26, 
displayed a α-CaMKII-tTA-like expression of lacZ (Fig. 22A), however the administration of 
6mg dox/g food for 9 days was not able to substantially repress transgene expression (Fig. 
22A). To address the question whether this line is functional in cholinergic neurons despite 
the poor repression of transgene expression, SMDFBi#26 animals were mated to 
ChATtTApA#44 mice. Doubly transgenic SMDFBi#26:ChATtTApA#44 animals were 
sacrificed and transgene expression was assessed by X-Gal staining. LacZ-positive cells were 
found in cholinergic structures in the brain (Fig. 22B, C), but they were absent from the spinal 
cord. Silencing effects of lacZ expression, which were also seen in the GFPG3 line, were also 
observed in SMDFBi#26:ChATtTApA#44 doubly transgenic animals as shown in Fig. 22D. 
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In comparison to Fig. 22B, only few, randomly distributed lacZ-positive cells can be found in 
the medial septal area. 
It should be noted that continuous dox administration throughout embryogenesis lead to a full 
repression of transgene expression in SMDFBi#26:ChATtTApA doubly transgenic animals 
(not shown).  
 
 
Figure 22: Histo-chemical analysis of lacZ expression in mouse line SMDFBi#26. (A) LacZ expression in 
coronal brain sections of SMDFBi#26:α-CaMKII-tTA doubly transgenic animals. The brain sections are derived 
from animals that were fed dox (6mg dox/g food) as indicated. Dox administration for 9 days did not result in a 
complete repression of transgene expression as evidenced by the residual lacZ activity. (B) Shown is the lacZ 
expression in a ChATtTApA#44:SMDFBi#26 doubly transgenic animal in the medial septum (left) and the 
lateral habenular nuclei along with their projections into the dorsal thalamus. (C) LacZ expression in a 
ChATtTApA#44:SMDFBi#26 doubly transgenic animal in the posterior limb of the interstitial nucleus and 
substantia innominata. Shown in the inset is a higher magnification of the boxed area. (D) Medial septal area of a 
doubly transgenic animal in which lacZ expression was silenced. Only few cells are lacZ-positive, which are 
randomly distributed within the medial septal area. 
 
RT-PCRs for the detection of transgene-specific NRG1 type III transcripts in 
ChATtTApA#44:SMDFBi#26 doubly transgenic animals failed to detect transgene-derived 
transcripts. This could be attributed to a very low effective mRNA copy number in the 
sample, which may be in part due to the limited number of cholinergic neurons in the sagittal 
brain section utilized. 
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IV. Discussion 
 
The primary goal of this thesis was to test the hypothesis that the polypeptide factor, 
Neuregulin-1 (NRG1), is required throughout the life of the animal in the peripheral nervous 
system in order to perform at least 2 functions, first, to regulate acetylcholine receptor 
(AChR) expression at the neuromuscular junction and second, to maintain the myelin sheath. 
In order to test this hypothesis, it was reasoned that if one were able to increase the expression 
of distinct NRG1 isoforms in adult animals, one should be able to determine if there were 
detectable changes in either AChR number or the thickness of the myelin sheath. Therefore, 
we elected to produce a mouse model that would permit the regulated expression of distinct 
NRG1 isoforms in cells known to normally express this factor. As the NRG1 gene was 
believed to have at least 3 distinct promoter elements, none of which had been characterized, 
a different promoter was utilized that would restrict expression to cholinergic cells. This 
selection was based on the observation that virtually all cholinergic neurons appeared to 
express NRG1 (Chen et al., 1994; Corfas et al., 1995; Meyer et al., 1997). In order to obtain 
regulated expression, we elected to use the tetracycline-regulated transcriptional transactivator 
system (Gossen and Bujard, 1992). Thus the overall strategy required the production of 2 
types of transgenic mice, one type expressing the transactivator in cholinergic cells and the 
other type expressing distinct NRG1 isoforms under the control of a tetracycyline 
transactivator-regulated promoter. When these two types of transgenic mice are mated 
together, the doubly transgenic offspring were anticipated to inducibly express NRG1 
isoforms in a doxycycline-dependent fashion in cholinergic neurons. 
 
Although these studies are still ongoing, significant progress has been made toward 
accomplishing these goals. In the sections that follow, the progress that has been made on the 
construction and characterization will be summarized and the efforts on the construction of 
the NRG1-expressing lines will be evaluated. In general, the cholinergic lines of mice appear 
to be functioning at least by the criterion that the transactivators are being expressed in 
cholinergic cells and not in other cell types. However, when mated to the NRG1-expressing 
lines, or other reporter lines, reporter gene expression is not detected in all cholinergic 
neurons. The potential reasons for this incomplete pattern of gene expression are discussed in 
detail and possible approaches to surmount these obstacles are explored. 
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1. The generation of BAC transgenic mice for rtTA/tTA-
dependent gene regulation in cholinergic neurons 
 
1.1. The use of pBelo11 ChAT BAC to achieve cholinergic-specific 
gene expression 
 
At the time these studies were initiated, two attempts had been made to target transgene 
expression to cholinergic neurons in the mouse (Lonnerberg et al., 1995; Naciff et al., 1999). 
In both cases relatively small genomic fragments of 2.3kb and 6.4kb located in the 5’ region 
of the ChAT gene were used. Based on the patterns of transgene expression observed in their 
lines, it appeared that important regulatory elements were not provided by these small 
putative promoter regions. In order to overcome the problems associated with promoters of 
insufficient size, it was thought that the large BAC-based transgenes could provide 
cholinergic transgene expression in the mouse, as this methodology had been used 
successfully to mimic the expression pattern of the zinc finger transcription factor RU49 
(Zipro1) (Yang et al., 1997). 
The first ChAT BAC that was utilized was obtained using a PCR-based screen of a custom 
BAC library at Incyte Genomics. At the time, there was relatively little murine genomic 
sequence available and the associated map of overlapping BAC clones was not generally 
available. Using primers that were located within the VAChT gene, the screen was 
intentionally biased towards the 5’ end of the gene, in order to increase the likelihood that the 
resulting BAC contained sufficient amounts of promoter sequence to provide cholinergic-
specific regulation. The identified BAC, pBelo11ChAT BAC, contained about 96 kb of 
promoter sequence as well as most, but not all of the ChAT gene. It was hoped that this large 
amount of 5’ sequence would be capable of directing rtTA2S-M2 expression to cholinergic 
neurons, as most regulatory elements that are required for proper expression of a gene are 
located in its 5’ region along with intronic enhancers, which are usually located within the 
first intron (Caroni, 1997; Chan et al., 1999; Uveges et al., 2002).  
Homologous recombination in bacteria was used to perform 3 separate manipulations on this 
BAC. First, it was used to insert the rtTA2S-M2 cDNA into the start codon of the ChAT gene, 
next is was used to inactivate the VAChT gene and in the final step it was used to remove a 
loxP site from the pBelo11 vector backbone. Pronuclear injection of circular BAC DNA 
resulted in 13 founder animals, of which 11 were able to transmit the BAC transgene to the 
F1 generation. The use of circular BAC DNA for pronuclear injection was expected to give 
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rise to multiple lines with varying expression patterns, due to random breakage of the BAC 
during integration into the mouse genome. However, none of the lines analyzed by in situ 
hybridization displayed a proper cholinergic expression pattern of rtTA2S-M2. 
It was reasoned that 2 factors may have contributed to the apparent lack of cholinergic 
expression of rtTA2S-M2. First, it was possible that for stochastic reasons the analyzed 
ChAT-BAC transgenics did not display a proper cholinergic expression of rtTA2S-M2 due to 
an insufficient number of founder animals analyzed. Secondly, it was conceivable that 
regulatory elements that are required for faithful cholinergic transgene expression were not 
contained on the BAC. It was speculated that the missing regulatory elements were located 3’ 
to the ChAT gene, as no 3’ flanking sequence was contained on pBelo11 ChAT BAC. Thus, it 
appeared likely that the use of an alternative BAC, that contained 3’ flanking sequence to the 
ChAT gene would be better suited to direct transgene expression to cholinergic neurons. In 
addition to the decision to use a new BAC for the generation of transgenic animals, a switch 
from rtTA to the use of tTA2S was selected for reasons that will be discussed in detail below.  
 
1.2. Cholinergic expression of tTA2S through the use of the RP24-70D4 
BAC 
 
Advances in BAC end nucleotide sequence annotation in the public ENSEMBL database 
allowed for the selection of a new BAC, RP24-70D4, that harbored the complete ChAT gene 
as well as roughly equal amounts of 5’ and 3’ flanking sequence to the ChAT gene. This BAC 
was engineered by homologous recombination in bacteria using manipulations analogous to 
those used with the pBelo11 ChAT BAC. For the subsequent generation of BAC transgenic 
animals both, circular and linear BAC DNA was used. 
Two ChATtTApA mouse lines, ChATtTApA #44 and #73, which were generated with linear 
and circular BAC DNA, displayed apparent cholinergic expression of tTA based on X-Gal 
staining of GFPG:ChATtTApA doubly transgenic animals. The cholinergic expression of 
tTA2S in these lines was confirmed by in situ hybridization and immuno-histological co-
localization of ChAT and transgene-derived EGFP. Next, BAC copy number was determined 
for both lines by Southern blotting, which revealed that line #44 had 3 copies of the BAC 
integrated into its genome, while line #73 harbored 5 copies. It remains to be shown whether 
the higher BAC copy number in line #73 is correlated with a stronger transgene expression 
from the tTA-responsive Ptet promoter in the GFPG3 or Ptet-bi NRG1 lines. Both lines differ, 
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however, in their expression of tTA in cells that appear to be Bergmann glia in the 
cerebellum: While line ChATtTApA#44 tTA expression can be found in this cell type, line 
#73 lacks tTA expression in these cells. The fact that a subset of Bergmann glia appears to be 
cholinergic is a novel finding. Immuno-histochemical co-localization of ChAT and transgene-
derived EGFP was used to verify the cholinergic nature of these cells to exclude ectopic 
expression of the ChAT-BAC transgene in line ChATtTApA#44. The number of cholinergic 
Bergmann glia as well as the extent of tTA expression in these cells will be determined in 
future studies. The functional consequences of this difference between the 2 mouse lines for 
the study of NRG1 function remains to be evaluated.  
 
2. Generation of inducible Ptet-bi NRG1 transgenic mice 
 
The generation of inducible NRG1-expressing mice was the second set of transgenes that was 
needed to study the potential ARIA- and GGF-like properties of NRG1 type I and type III, 
respectively. For the generation of the tTA/rtTA-responsive expression constructs that would 
allow for the inducible overexpression of these NRG1 isoforms, the parental pGFPlacZ 
plasmid, which had been successfully used for the generation of the GFPG3 mouse line, was 
chosen (Krestel et al., 2001). As conventionally-sized transgene constructs are often 
influenced by positional effects upon integration into the mouse genome, the resulting Ptet-bi 
NRG1 founder animals had to be analyzed with regard to these issues. Positional effects can 
have a profound influence on the activation of the Ptet promoter by tTA as well as on the 
expression pattern of the transgene. Therefore, the well characterized α-CaMKII-tTA mouse 
line was used to assess tTA-mediated induction of transgene expression in the resulting 
founder animals and to exclude that positional effects spatially restrict the expression of the 
transgene in brain. Although this assessment is biased towards the functionality of the Ptet-Bi 
transgene in predominantly principal neurons of the forebrain, it appeared to be a reasonable 
approach to address transgene functionality. 
The screen of 9 founder animals identified one Ptet-bi NRG1 type I line, IgbetaBi#24, which 
displayed a stringent tTA-dependent expression of the transgene based on RT-PCR analysis 
and whose expression pattern was not influenced by positional effects. This line was 
subsequently mated to mice of the ChATtTApA#44 line to address its functionality in 
cholinergic neurons of the CNS. It was determined that with succeeding backcrosses of the 
IgbetaBi#24 line to C57Bl6 mice, fewer cholinergic cells were found to express transgene-
Discussion 
 
 55
derived lacZ. In some cases, no lacZ expression was detected in the brains and spinal cords of 
doubly-transgenic animals, indicative of a functional limitations of either the ChATtTApA 
mouse line or the IgbetaBi#24 mouse line. This phenomenon was also observed in 
ChATtTApA:GFPG3 doubly transgenic animals and will be discussed below. 
The generation and identification of a Ptet-bi NRG1 type III line that was characterized by a 
stringent control of transgene expression through dox administration, proved to be less 
efficient. Out of 8 lines analyzed, one line, SMDFBi#26, displayed a α-CaMKII-tTA-like 
expression pattern. However, doxycycline-dependent repression of transgene expression was 
incomplete in this mouse line, despite the high concentrations of doxycycline (6mg dox/g 
food) used. Interestingly, the continuous administration of dox throughout embryogenesis into 
adulthood lead to a complete repression of transgene expression in this line. Considering the 
fact that the lacZ expression pattern appears to be α-CaMKII-tTA-like, transactivation of Ptet-
bi by nearby enhancers does not seem to be the underlying cause for the observed incomplete 
repression. When line SMDFBi#26 was crossed to ChATtTApA#44 animals, the lacZ 
expression pattern in doubly-transgenic animals (Fig. 22D), suggested that this line was also, 
like IgbetaBi#24, characterized by a lack of lacZ-positive cells. 
 
3. Expression analysis of ChATtTApA animals using the GFPG3 
mouse line 
 
The use of the GFPG3 reporter line to analyze tTA2S or rtTA2S-M2 expression in ChAT-
BAC transgenic animals was thought to be an efficient way to assess transgene expression. 
This reporter mouse line expresses both EGFP and lacZ upon transcriptional activation by 
tTA2S or rtTA2S-M2 and can thus be used for an initial characterization of transgene 
expression by X-Gal visualization and also for co-localization studies with EGFP and ChAT-
specific antibodies. 
However, the characterization of ChATtTApA:GFPG3 doubly transgenic animals from both 
ChATtTApA lines revealed a discrepancy between the number of tTA-positive cholinergic 
cells seen by in situ hybridization and the number of cells seen by X-Gal-based detection. 
This discrepancy appeared to increase with each backcross of the ChATtTApA animals to the 
C57Bl6 background resulting in an almost complete loss of lacZ-positive cells in some 
animals. There are a number of mechanisms that could account for the apparent lack of lacZ-
positive cells in ChATtTApA:GFPG3 doubly transgenic animals: First, it was conceivable 
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that the GFP3 reporter mouse line was not competent to monitor tTA expression in 
cholinergic neurons and as a result functional β-galactosidase was not being made by that 
specific neuronal subset. This hypothesis is based on the fact that the GFPG3 reporter mouse 
line was characterized through the use of the α-CaMKII-tTA mouse. The α-CaMKII-tTA 
transgene, however, is not expressed in cholinergic neurons so that the functionality of the 
GFPG3 line in cholinergic neurons could not be assessed. Another possibility is that the 
ChAT promoter could not direct the production of a sufficient number of tTA transcripts and 
molecules of tTA protein to obtain reliable reporter expression. Thus, the ChAT promoter 
could be viewed as being “weaker” than promoters such as that for the α-CaMKII gene used 
for the generation of the α-CaMKII-tTA mouse line. However, the analysis of 
ChATtTApA#73:GFPG3 doubly transgenic animals by tTA- and lacZ-specific ISH revealed 
that tTA transcripts could be readily detected, but lacZ transcripts were only found in few 
cells (Fig. 19). In light of this finding, a third possibility is that lacZ expression may be absent 
or reduced due to events leading to the epigenetic silencing of its expression. A number of 
studies have suggested that methylation of CpG dinucleotides within the lacZ reporter gene 
might be responsible for the observed ‘silencing’ effect (Chevalier-Mariette et al., 2003). 
Methylation of a CpG dinucleotide occurs at position C5 of the cytosine (5meCpG) and is the 
only known epigenetic modification in mammals. The DNA methylation machinery in 
mammals is comprised of two components, the DNA methyltransferases (DNMTs) and 
methyl-CpG binding proteins (MDBs). DNA methylation is catalyzed by three DNMTs: 
DNMT1 and DNMT3b, which are essential for embryonic development, and DNMT3a. Mice 
lacking DNMT3a die within a few weeks of birth (Robertson, 2005). De novo methylation 
can occur at foci from which the methylation spreads to neighboring regions. 5meCpGs are 
bound by MDBs, which are associated with histone deacetylases (HDACs). Histone 
deacetylation in turn leads to chromatin remodeling processes, which result in transcriptional 
silencing of the affected region.  
Experiments by Chevalier-Mariette et al. elegantly demonstrate that the expression of a YAC-
lacZ transgene is strongly correlated with the CpG content of the lacZ gene (Chevalier-
Mariette et al., 2003). Bacterial derived lacZ, which was also used for the generation of the 
GFPG3 mouse line, contains 291 CpGs per 3076bp corresponding to a relative frequency of 
9.24%. The use of synthetic lacZ genes, in which the occurrence of CpG dinucleotides was 
decreased to 1.6% and 0.06% inversely correlated with the expression levels of the gene. It is 
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certainly possible that these epigenetic modifications are contributing to the observed 
silencing of lacZ expression in ChATtTApA:GFPG3 doubly transgenic animals.  
In a related finding by Sutherland et al. varying lacZ expression was oberserved within the 
same litter of globin-lacZ transgenic animals ranging from strong (high-expressors) to no 
detectable lacZ activity (‘non-expressors’) (Sutherland et al., 2000). Interestingly, lacZ 
expression could be reestablished in non-expressors by crossing the mice into a different 
mouse strain. The finding by Sutherland et al. could potentially explain the functional lacZ 
expression in ChATtTApA#44:GFPG3 and ChATtTApA#73:GFPG3 doubly transgenic 
animals during the initial characterization: Both founder animals had not been backcrossed 
onto the C57Bl/6J background and were still CByB6F1 hybrids. Backcrossing the founder 
animals to C57Bl/6J animals for 5 generations and thereby reducing the CByB6F1 
background to ~3% could explain a reversion to a silenced lacZ gene, which was observed 
during later stages of the characterization of both lines. It has been suggested that the ssm1 
locus (strain-specific modifier 1), could be the underlying cause leading to a transgene 
methylation and subsequent silencing in C57Bl6 mice (Padjen et al., 2005). Ssm1 has been 
mapped to the distal arm of chromosome 4 in the mouse genome and its activity has been 
linked to enhanced transgene methylation. The gene or genes encoded by the ssm1 locus have 
not been identified yet, but it is believed that ssm1 does not encode DNMTs, but rather 
‘monitors’ evoked chromatin changes that are induced by the presences of repetitive elements 
or bacterial DNA (Padjen et al., 2005). In the case examined ssm1 activity lead to a strong 
methylation of a transgene, which resulted, through the recruitment of MDBs and HDACs, in 
its silencing. However, if the same transgene was crossed into a different strain of mice, 
transgene methylation was minimal, resulting in functional expression. It is therefore 
conceivable that ssm1 activity influences the expression of the Ptet-bi NRG1 lines as well as 
the expression of the GFPG3 transgene in cholinergic neurons. As mentioned earlier, 
promoter strength might be an important determinant for transgene function and it is possible 
that the use of a strong promoter, like the α-CaMKII promoter, prevents ssm1 from directing 
methylation to the transgene. The use of alternative mouse strains, such as the CBA/Ca strain, 
for the maintenance of the GFPG3 reporter line, will help to provide further insight into the 
strain-specific influence of C57Bl6 mice on reporter gene expression. CBA/Ca mice have 
been reported to result in lower transgene methylation levels and may thus be better suited for 
the characterization of transgenic lines with weaker promoters, such as, presumably, the 
ChAT promoter (Sutherland et al., 2000). 
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Immuno-histological detection of transgene-derived EGFP in ChATtTApA:GFPG3 doubly 
transgenic animals suggested that the expression of EGFP was not affected by this potential 
silencing effect so that despite the lack of lacZ expression, doubly transgenic animals could 
still be used for co-localization of ChAT and EGFP. It cannot be excluded, however, that in 
succeeding generations of backcrosses to C57Bl6 mice EGFP expression will also be 
affected. 
It is very well possible that due to the potential reasons mentioned above, the use of the 
GFPG3 reporter line in C57Bl6 mice is limited to the use of strong promoters driving the 
expression of tTA and that for the characterization of transgenic mouse lines in which the 
expression of tTA is under transcriptional control of a weaker promoter, GFPG3 mice have to 
be maintained in a mouse strain other than C57Bl6. 
It is also possible that the ChATrtTA2S-M2:GFPG3 doubly transgenic animals were also 
affected by these silencing effects, which could explain the absence of lacZ-positive cells in 
the slice culture experiment (Fig. 6). 
Despite the factors that influence lacZ expression in ChATtTApA:GFPG3 doubly transgenic 
animals, a subset of the doubly transgenic embryos allowed for the visualization cholinergic 
neurons in whole mount X-Gal stainings. According to database searches this is a novel 
approach to visualize cholinergic neurons in the developing mouse embryo, without the need 
for subsequent immuno-histochemical procedures or microscopy to visualize cholinergic 
cells.  
 
3.1. The use of circular versus linear BAC DNA for transgenesis 
 
For these studies both circular and linear BAC DNA was used for the generation of transgenic 
animals. The use of linear or circular BAC DNA is associated with a distinct set of technical 
problems that arise during purification and subsequent handling of the DNA as well as during 
the integration process into the genome. 
Circular BAC DNA is easily purified through standard DNA purification procedures and due 
to the fact that intact BAC DNA is supercoiled, subsequent handling of the DNA by pipetting 
does not lead to significant shearing of the DNA. The major problem associated with the use 
of circular BAC DNA arises during its integration into the genome. Random breakage of the 
BAC DNA during integration into the genome can result in linear BAC DNA fragments in 
which regulatory elements from the 3’ end of the gene are placed 5’ to the gene and vice 
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versa. The resulting circular permutation can have profound influence on transgene 
expression. During the characterization of the ChATtTApA-BAC transgenics that were 
generated with circular BAC DNA, circular permutation, that was cuased by random 
breakage of the BAC during the integration into the genome, lead to varying expression 
patterns of tTA. In one animal tTA expression was detected in basket cells of the cingulate 
cortex, while in others incomplete cholinergic expression of tTA was observed.  
The use of linear BAC DNA does not lead to circular permutation, but the purification and 
handling of linearized DNA results in DNA damage through shearing. This is evident on the 
PFG presented in Fig.8: Based on DNA concentration as determined by OD260, 300ng of 
BAC DNA were loaded per gel lane, but relative to the linearized λ-DNA, which was used as 
a standard, it is evident that only ~75ng of full length linear BAC DNA are present. Most of 
the DNA appears to be sheared and is visible as a ‘smear’ of lower molecular weight.  
The presence of sheared BAC DNA can impose problems on the production of BAC 
transgenic animals, if its concentration is considerably high. The sheared DNA will contribute 
to the production of transgenic animals in the same way as full length DNA and thus can 
increase the number of founder animals that need to be screened to achieve faithful transgene 
expression. Based on the results obtained in this thesis, the use of both circular and linear 
BAC DNA appears to be equally well suited for the generation of transgenic animals through 
pronuclear injection. It is not possible to favor one of the two topological isomers as in both 
cases the frequency with which ChAT tTA2S BAC transgenic animals were generated was 
about the same (1:8 for linearized BAC DNA and 1:6 for circular BAC DNA).  
 
3.2. Functional consequences of the blood brain barrier for 
doxycycline-dependent regulation of transgene expression 
 
Despite the ectopic expression of rtTA in ChATrtTA BAC transgenics, transcriptional 
activation of the bi-directional tTA/rtTA-responsive promoter Ptet-bi should be possible in the 
presence of dox. However, none of the lines examined displayed lacZ-positive cells in the 
brain or spinal cord, even though high doses of dox were simultaneously administered to 
ChATrtTA2S-M2:GFPG3 doubly transgenic animals in both food and drinking water (6mg 
dox/g food and 2mg dox/ml drinking water). This was an unexpected finding as previous 
work had demonstrated that through the use of rtTA inducible transgene expression in the 
brain could be achieved in dox-dependent fashion (Mansuy et al., 1998). The published 
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mouse line was claimed to be able to induce transgene expression in doubly transgenic 
animals upon administration of 6mg dox/g food for 6 days. The rtTA used for the generation 
of this mouse line was the first generation rtTA, which requires about 10-fold higher dox 
concentrations than rtTA2S-M2 and it is thus even more surprising that no lacZ-positive cells 
could be detected in ChATrtTA2S-M2:GFPG3 doubly-transgenic animals, even after 
administration of dox in food and drinking water for 2 weeks. 
Work form Prof. Bujard’s laboratory (ZMBH, Heidelberg) indicated that the underlying cause 
for of rtTA’s inability to activate transgene expression in the CNS was most likely not due to 
an insufficient number of founder animals analyzed, but rather attributable to insufficient 
amounts of dox within the CNS caused by the blood brain barrier (Dr. S. Berger, personal 
communication and Berger, 2003). Measurements conducted with luciferase reporter:α-
CaMKII-rtTA2S-M2 doubly-transgenic animals, which were fed 2mg dox/g food, revealed 
that the effective dox concentration in the brain reaches ~0.5ng/ml, a concentration at which 
the transcriptional transactivation potential of rtTA2S-M2 is less than 0.1% of its maximum. 
The measurements also indicated that a theoretical 10-fold increase of the dox concentration 
in the brain would only result in induction levels of <1% for rtTA2S-M2.  
In light of these findings, tTA appears to be the transactivator of choice to achieve 
doxycycline-dependent transgene expression in the CNS. Both tTA and tTA2S are 
characterized by a roughly 10-fold greater sensitivity towards dox than rtTA and rtTA2S-M2. 
Therefore, dox-dependent transcriptional repression is much more effective for tTA2S than 
transcriptional induction through rtTA2S-M2. Whereas 0.5ng/ml dox only induce a 
transcriptional activation of <0.1% by rtTA2S-M2, transcription is repressed to roughly 16% 
at this concentration by tTA2S. It appears likely that the transcriptional repression can be 
further enhanced through the use of higher dox concentrations, as an increase in the effective 
dox concentration in the brain to 1ng/ml would reduce tTA2S-mediated transcription to 
roughly 5%. However, higher dox concentrations can have adverse effects on embryonic 
development and re-induction of transgene expression. Recent work has shown that dox 
administration in the food at concentration >2.5mg dox/g food can result in placental 
abnormalities and that these abnormalities increase with increasing dox concentrations in the 
food (Moutier et al., 2003). The placental defects can become very severe at dox 
concentrations of 10mg/g food leading to early embryonic death. It has been suggested that 
the toxic effects of dox are most likely to an inhibition of proinflammatory cytokines and 
matrix metalloproteinases (Moutier et al., 2003). The adverse effects were not observed, when 
dox was administered in the drinking water in a range of 1-5mg/ml. 
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In addition to the effects on placental development, prolonged administration of dox, that is 
needed to study the effects of regulated transgene expression in adult mice, can lead to 
accumulation of dox in white matter. The stored dox is released upon dox withdrawal, which 
results in a slower re-induction of the transgene in brain regions of high myelin content. This 
can potentially lead to a non-uniform re-induction of the transgene.  
 
3.3. Outlook 
 
3.4. Future experiments 
 
3.5. Generation of additional Ptet-bi NRG1 lines  
 
Future experiments will be focused on the generation of additional Ptet-bi NRG1 type III 
transgenic mouse lines as well as on the further characterization of mouse line IgbetaBi#24. 
NRG1 type I expression in this mouse line will be assessed by immuno-histochemical 
analyses and Western blotting with NRG1-specific antisera. Ptet-bi NRG1 type II mouse lines 
will be generated to further to help evaluate the potential involvement of this isoform in the 
pathogenesis of Schizophrenia. Linkage studies in an Icelandic and Scottish population 
mapped certain haplotypes surrounding the genomic region of the type II-specific exon to an 
increased risk of contracting Schizophrenia. Regulated overexpression of NRG1 type II and 
other NRG1 isoforms during various time points in development or in the mature animal may 
help to generate a mouse model that mimics certain aspects of Schizophrenia. In addition, this 
line will also be useful to establish, whether it is the NRG1 type I or type II isoform that 
serves an “ARIA”-like function in vivo.  
Furthermore, by generating homozygous ChATtTApA transgenic animals, the effects of 
ChATtTApA BAC copy number on transgene expression will be addressed. An increase of 
tTA expression could potentially overcome the incomplete lacZ expression observed in 
GFPG3 mice as well as in Ptet-bi NRG1 lines. In parallel, new transgene constructs for the 
inducible overexpression of NRG1 type I and type III will be generated, that no longer harbor 
the bacterial lacZ gene, but a synthetic CpG-free lacZ reporter gene. This will increase the 
likelihood for the Ptet-bi NRG1 lines not to be influenced by epigenetic phenomena, such as 
CpG methylation. Furthermore, alternative mouse strains, such as CBA/Ca, will be used for 
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the maintenance of the GFPG3 reporter mouse line to address the influence of ssm1 on 
transgene methylation. If ssm1 activity in C57Bl6 mice is indeed the underlying cause for the 
observed discrepancy in the number of tTA-expressing cells versus lacZ-positive cells 
observed, then the use of CBA/Ca mice should result in a re-activation of the GFPG3 
transgene in GFPG3:ChATtTApA doubly transgenic animals.  
In an attempt to minimize the number of Ptet-bi NRG1 founder animals that are needed to be 
screened to identify transgenics that are characterized by a stringent tTA-dependent transgene 
expression, the recently identified “LC1” locus will be utilized (Schonig et al., 2002). This 
locus was identified during the generation of a Ptet-Cre mouse line that displayed a tight 
transcriptional control of Cre recombinase expression by tTA (Schonig et al., 2002). A 
corresponding BAC that harbors the genomic LC1 locus was identified by Dr. Bujard’s 
laboratory. The BAC as well as a targeting construct for homologous recombination in 
bacteria for the LC1 locus were obtained from Dr. Bujard and may facilitate the generation of 
inducible NRG1 transgenic mouse lines that are characterized by a stringent doxycycline-
dependent induction of NRG1 expression.  
 
4. Alternative uses of ChATtTApA mice 
 
Next to the use of the ChATtTApA mouse lines in helping to understand NRG1 function in 
the adult animal, the mice will be a useful tool in neuroscience research. Mouse line 
ChATtTApA#44 is used in a collaborative effort by Dr. D. Isbrandt (ZMNH, Hamburg) to 
study the role of KCNQ2/KCNQ3 (M-channel) potassium channels in the pathogenesis of a 
disease known as benign familial neonatal convulsions (BFNC). BFNC is characterized by 
seizures that start in the first postnatal week, but spontaneously disappear after several weeks. 
It has been reported though that the disease progression resulted in a poor prognosis for 10-
16% of the patients where it persisted into adulthood with reoccurring seizures. 
Thus far, M-channel function has been studied through the regulated overexpression of 
dominant-negative M-channel pore mutants for which a prion protein promoter-tTA 
transgenic mous line was used (Prnp-tTA) (Tremblay et al., 1998; Peters et al., 2005). 
However, KCNQ2/KCNQ3 appear to be predominantly expressed in cholingeric neurons of 
the CNS, so that a cholinergic-specific overexpression of the M-channel mutants is thought to 
provide a better understanding of their involvement in BFNC (Cooper et al., 2001). 
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The ChATtTApA mouse lines might also be a valuable tool for studying the neuropathology 
of Alzheimer’s disease, as cholinergic neurons of the basal forebrain are severely affected in 
Alzheimer’s patients. Current mouse models, that mimick neuropathologic hallmarks of the 
disease were generated through the expression of mutant human amyloid precursor (hAPP) 
driven by the platelet-derived growth factor-β promoter or through CMV promoter driven 
expression of α-NGF antibodies (Games et al., 1995; Capsoni et al., 2000). The use of 
ChATtTApA mouse lines for a regulated and cholinergic overexpression of mutant hAPP or 
α-NGF antibodies might facilitate the understanding of the pathology in Alzheimer’s disease.  
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V. Materials 
 
 
1. Chemicals and laboratory supplies 
 
All chemicals and laboratory equipment and supplies used were purchased from Fisher 
Scientific, VWR or Sigma-Aldrich, unless specified otherwise: 
 
1.1. Laboratory equipment 
 
CCD B/W camera “Orca ER”   Hamamatsu, Bridgewater, NY 
Coffee maker      Krupps, Medford, MA 
Computer software: 
 Adobe Photoshop 7.0    Adobe, San Jose, CA 
Acrobat Reader 6.0    Adobe, San Jose, CA 
 Canvas 8     Deneba Systems, Inc., Miami, FL 
 DNAStrider 1.3    CEA, France 
 DNAStar 5.5     DNAStar, Inc., Madison, WI 
 Endnote 6.0     Thomson ResearchSoft, 
Carlsbad, CA  
 Firefox web browser    Mozilla Foundation, 
Mountain View, CA 
 iTunes 4     Apple, Cupertino, CA 
Keynote     Apple, Cupertino, CA 
Microsoft Office X    Microsoft, Redmond, WA 
 Openlab 3.1.7     Improvision, Lexington, MA 
RasMol v2.7     www.openrasmol.org 
Safari web browser 1.2.4   Apple, Cupertino, CA 
X11      Apple, Cupertino, CA 
Computer hardware: 
 Apple iPOD 20GB    Apple Cupertino, CA 
Apple PowerBook G4   Apple, Cupertino, CA 
 Apple G4, 800Mhz    Apple, Cupertino, CA 
 Apple G4, dual 1Ghz    Apple, Cupertino, CA 
 HP Color LaserJet 4600   Hewlett-Packard, Palo Alto, CA 
Digital camera, Nikon CoolPix 4200  Nikon Corp. 
Electrophoresis chambers    JM Specialty Parts, San Diego, CA 
Eppendorf Mastercycler Gradient PCR machine Eppendorf, Westbury, NY 
Eppendorf Thermomixer compact   Eppendorf, Westbury, NY 
GenePulserII      BioRad, Hercules, CA 
Gilson Pipetman P10, P20, P200, P1000  Gilson Inc., Middleton, WI 
Microscope Olympus BC-50    Olympus, Melville, NY 
Microwave oven     Samsung 
Multichannel pippettor 1-10µl, 10-100µl  Eppendorf, Westbury, NY 
Photospectrometer Beckman DU 7400  Beckman Coulter Inc., Fullerton, CA 
Polytron      GlennMills, Clifton, NJ 
Scintillation counter Beckman LS6500  Beckman Coulter Inc., Fullerton, CA 
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Video imaging System “EagleEye”   Stratagene, La Jolla, CA 
X-ray film developer KODAK XOMAT  Kodak, Rochester, NY 
 
1.2. Laboratory supplies 
 
Cryo-vials      Nalgene, Rochester, NY 
DNeasy Tissue kit     Qiagen, Inc., Valencia, CA 
Filter units 0.22µm, 500ml    Nalgene, Rochester, NY 
MinElute Gel Extraction kit    Qiagen, Inc., Valencia, CA 
Nucleobond AX-500 colums    BD Biosciences, San Jose, CA 
Nucleobond buffer set    BD Biosciences, San Jose, CA 
Nylon membrane “HyBond”    Amersham-Pharmacia, 
Piscataway, NJ 
PVDF membrane “Immobilon P”   Millipore, Billerica, MA 
Qiaquick Gel Extraction kit    Qiagen, Inc., Valencia, CA 
Qiagen Plasmid Purification kits   Qiagen, Inc., Valencia, CA 
Rapid DNA Ligation Kit    Roche, Indianapolis, IN 
RNALater, RNA stabilization reagent  Ambion, Austin, TX 
RNeasy Mini, Midi kits    Qiagen Inc.,Valencia, CA 
rNTPs       Promega Corp., Madison, WI 
Sequencing gel mix “Long Ranger”   BioWhittaker, Walkersville, MD 
Syringe filters, 0.22µm    Nalgene, Rochester, NY 
VECTASTAIN ABC Kit    VectorLabs, Burlingame, CA 
VECTASHIELD HardSet Mounting Medium VectorLabs, Burlingame, CA 
Water, molecular biology grade   Eppendorf, Westbury, NY 
Zeocin       Invivogen, San Diego, CA 
 
1.3. Enzymes 
 
Alkaline phosphatase, CIP    New England Biolabs, Beverly, 
MA 
HotStartTaq MasterMix    Qiagen, Inc., Valencia, CA 
ProofStart Taq polymerase    Qiagen, Inc., Valencia, CA 
Restriction enzymes     New England Biolabs, Beverly, MA 
Roche, Indianapolis, IN 
RNAseH      New England Biolabs, Beverly, 
MA 
RNAsin, RNAse inhibitor    Promega Corp., Madison, WI 
RQ1 DNAse, RNAse-free    Promega Corp., Madison, WI 
SuperScriptII, III     Invitrogen, Carlsbad, CA 
Sp6, T3, T7 RNA polymerases   Promega Corp., Madison, WI 
T4 DNA ligase     Promega Corp., Madison, WI 
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1.4. Antibodies 
 
 
Goat α-ChAT IgG (polyclonal)  Chemicon International, Temecula, CA 
Rabbit α-EGFP IgG (polyclonal)  BD Biosciences, San Jose, CA 
Donkey-α-goatIgG biotin-SP-conjugated, JacksonImmuno, West Grove, PA 
AffiniPure 
Alexa Fluor® 594 donkey anti-rabbit IgG Molecular Probes, Eugene, OR 
α-HA, rat monoclonal (3F10) IgG1  Roche Diagnostics, Penzberg Germany 
α-Nrg1, rabbit polyclonal IgG, sc-348 Santa Cruz Biotechnolgy, Santa Cruz,  
CA 
 
1.5. Mouse lines 
 
GFPG3 (Krestel et al., 2001) Dr. R. Sprengel, MPI for Medical Research, 
Heidelberg 
α-CaMKII-tTA (Mayford et al., 1996) Dr. M. Mayford, The Scripps Research Institute, 
La Jolla, CA 
 
1.6. Bacterial strains 
 
E.coli XL-1 blue    Stratagene, La Jolla, CA 
E.coli DH10B     Invitrogen, Carlsbad, CA 
EL250, EL350     Dr. N. Copeland, NCI Frederick, MD  
 
1.7. Oligonucleotides 
 
Oligonucleotides used for genotyping: 
 
Standard primers: 2285: 5’-ATGAAGCTTCCCAGTCCAAATGAC 
   2286: 5’-CCTATTGGAGTCAATTCTTGTTCTGGAT 
rtTA:   3019: 5’-AGGCGAGTCATGGCAAGACTTTCTG 
2259: 5’-GGCAGGTTCGGCTCCCTGCCGGTC 
htTA:   2321: 5'-CCGGGATGGTGCCAAAGTTCAC 
   2322: 5’-CAGCAGTGGTGGCATGGAGTCAGT 
tTA:   2413: 5'-CATCAAGTCGCTAAAGAAGAAAGGGAAACA 
   2414: 5'-CCGCGGGGAGAAAGGACAGG 
GFPG3:  2008: 5’-GCGGAGAGGGTGAAGGTGATGC 
   2009: 5’-CAGGGCCGTCGCCGATTGG 
lacZ   2384: 5'-TGGCAGGCGTTTCGTCAGTATCC 
   2385: 5'-GCGGTAGTTCAGGCAGTTCAATCAA 
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Oligonucleotides used for homologous recombination: 
 
BAC library screening primers (Incyte Genomics, Inc.): 
 
1723: 5’-GGCGTCATGTTCGCCTCCACAGTCATG (s) 
1724: 5’-ACGCCTAACACGTGTGGCACGAAAGCC (as) 
 
rtTA homologous recombination, inner primer (s): 
 
3069:5’-CCAGGTCGGCAGCTCTGCTACTCTGGATTAAGAATCGCTAGGATGTCT 
AGACTGGACAA 
 
rtTA homologous recombination, outer primer (s): 
 
3070:5’-GCTGAGTCTCCTCTGTTCCCAGGTCGGCAGCTCTG 
 
rtTA homologous recombination inner primer (as): 
 
3071:5’-CAGCTAGAAGCTTGTACAGGCATCTTTGGGGGGACCTTTTCCCCA 
AGCTACTCGCGACC 
 
rtTA homologous recombination outer primer (as): 
 
3072:5’-AAGTCCAGCACCTCCTCACAGCTAGAAGCTTGTAC 
 
∆VAChT inner primer (s): 
 
3076:5’-GGAAGAGCAGCGGGTAGGGGCATGGAACCCACCTAGTGACTACT 
TCACTAACAACCGG 
 
∆VAChT outer primer (s): 
 
3075:5’-CCGGTGGAGGCATCTTAGGAAGAGCAGCGGGTAGG 
 
∆VAChT inner primer (as): 
 
3078:5’-GGCCGCCGCCCGGGCCTGACCGGTTGGCGCGGTAGTGCCAAGCTA 
CTCGCGAC 
 
∆VAChT outer primer (as): 
 
3077:5’-GCTTCCGACAGCTTGGTGGCCGCCGCCCGGGCCTG 
 
∆VAChT screening primer: 
 
3079:5’-CTGGAGCATCTAAGAGCAGCGGCACC 
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htTA homologous recombination inner primer (s) 
 
2302:5’-CCAGGTCGGCAGCTCTGCTACTCTGGATTAAGAATCGCTAGGATG 
TCCAGACTGGACAAG 
 
ChATtTA homologous recombination screening primers: 
 
3066:5’-CTCACGTGCCCTCTACTCTATACCTGA (s) 
 
3068:5’-AGGTGTTGCATGCACTGAAGGTAGGT (as) 
 
Neo/Kan anti-sense screening primer: 
 
3045:5’-CGCGGATCCGGCGTCGCTTGGTCGGTCA (as) 
 
Oligonucleotides used for molecular cloning of Neuregulin-1 typeI and typeIII: 
 
2001: 5’-CTGGTAGAGCTCCTCCGCTTCCAT (as) 
2002: 5’-CCAATAGCCGGCGGGCCAAAAG (s) 
2003: 5’-ATAGGTACCGTCGACTAGGTTTTATACAGCAATAGG (as) 
2010: 5'-GAAGCGGAGGAGCTCTACCAG (s) 
2011: 5'-ATATCTCGAGGTCGACGCCACCATGTCTGAGCGCAAAGAAG (s) 
2012: 5'-CTTCTGGTAGAGCTCCTCCGC (as) 
2014: 5'-ATACTCGAGGTCGACGCCACCATGGAGATTTATCCCCCAG (s) 
2064: 5'-ATATATGTCGACTTATACAGCAATAGGGTCTTGG (as) 
 
Oligonucleotides used for RT-PCR: 
 
2420: 5'-GGCTGATCAGCGAGCTCTAGCATTTC (as) 
2347: 5'-GGATCTGCCTTTTCTCAGTCATGAAAGTTG (s) 
2348: 5'-GCCTCCAGCCCTGCTTGGTGTGG (s) 
2419: 5'-ACCCGCGGCCGCGCCACC (s) 
2059: 5'-CCAGAGTCAGCCAGGGACGC (as) 
2421: 5'-CTACATGGTCTACATGTTCCAGTA(s) 
2422: 5'-TGATGGCATGGACTGTGGTCAT (as) 
2450: 5'-GCGAGCACAGCTTCTTTGCAGC (s) 
2451: 5'-CCACACGCAGCTCATTGTAGAAGG (as) 
 
Oligonucleotides used for sequencing: 
 
2058: 5'-GAGCCTTAGAGACAGGTGAAG (as) 
2059: 5'-CCAGAGTCAGCCAGGGACGC (as) 
2061: 5'-GTCCTCGTGGGCCCCCAGCTGG (as) 
2104: 5'-GACGCAAATGGGCGGTAGGCG (s) 
2105: 5'-TTCAGGGGGAGGTGTGGGAGG (as) 
2378 5’-GTGAGGGCCATTCGCTATGTTCAC (as) 
 
Additionally, standard sequencing primers Sp6, T3 and T7 were used. 
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2. Buffers and solutions 
 
 
Acetylation buffer: 
 
625µl acetic anhydride 
250ml 0.1M tetraethyl ammonium  
 
BAC-TE: 
 
10mM Tris pH7.5 
0.1mM EDTA pH8 
 
β-gal staining buffer: 
 
X-Gal (20 mg/ml in N,N-DMF)  600µl (f.c. 1.2 mg/ml) 
K-Ferricyanid (500 mM in PBS)  100 µl (f.c. 5 mM) 
K-Ferrocyanid (500 mM in PBS)  100 µl (f.c. 5 mM) 
MgCl2 (2 M)     10 µl (f.c. 2mM) 
Add 1xPBS to 10ml. 
 
Blocking buffer for Western blotting: 
 
5g  non-fat dry milk 
 
add TBS-T to 100ml. 
 
Blocking buffer for immunohistochemistry: 
 
5%  donkey serum (heat inactivated) 
0.3%  tween-20 
 
in TBS. Filter blocking buffer prior to use.  
 
Denaturing buffer (Southern): 
 
1.5M NaCl 
0.5M NaOH 
 
50xDenhardt’s: 
 
1% (w/v) Ficoll 400 
1% (w/v) polyvinylpyrrolidone 
1% (w/v) bovine serum albumin (fraction V) 
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DNA loading dye II: 
 
Bromophenol blue     0.25% 
Xylene cyanol      0.25% 
Ficoll (type 400)     15% 
dH20 to 10ml, store in 1ml aliquots at –20°C.  
 
High SDS hybridization buffer: 
 
2.1.1. 1mM  EDTA, pH8 
0.25M  NaH2PO4, pH7.2 
7% SDS 
2.1.2. Pre-heat to 65°C prior to use.  
 
Hybridization buffer (ISH): 
 
25ml formamide 
10ml 50% dextran sulfate 
3ml 5M NaCl 
1ml 50X Denhardts’ 
2.4 ml 1.2M phosphate buffer 
0.1 ml 0.5 M EDTA 
2.5 ml 10 mg/ml tRNA 
1.0ml depc dH2O 
 
Injection buffer, conventional transgene constructs: 
 
10mM  Tris pH 7.5 
0.1mM EDTA pH 8.0 
 
Use molecular biology-grade water to make the buffer, sterile filter buffer through a 0.2µm 
filter. 
 
Injection buffer, BAC constructs: 
 
10mM  Tris pH 7.5 
0.1mM EDTA pH 8.0 
100mM NaCl 
 
Use molecular biology-grade water to make the buffer, sterile filter buffer through a 0.2µm 
filter. 
 
ISH perfusion mix, 500ml: 
 
20g PFA 
38.14g NaBH4 
2g NaOH  
 
dH2O to 500ml, pH 9.5 
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Hydrolysis buffer: 
 
80mM NaHCO3 
120mM Na2CO3 
10mM DTT 
 
2x KCM buffer: 
 
1.0M  KCl 
0.30M  CaCl2 
0.50M  MgCl2 
 
sterile filter, store at RT.  
 
0.02M KPBS: 
 
2.91g K2HPO4 
0.45g KH2PO4 
18.0g NaCl 
dH2O to l000ml 
 
LB-Medium: 
 
Bacto Trypton     10g 
Bacto Hefeextrakt    5g 
NaCl      10g 
 
Dissolve in 1000ml dH2O, adjust pH to 7.5 with 10M NaOH, autoclave.  
 
For selective LB media the following antibiotics were used: 
 
Ampicillin, f.c. 100µg/ml 
Chloramphenicol, f.c. 20µg/ml 
Kanamycin, f.c. 50µg/ml 
Tetracycline, f.c. 12.5µg/ml 
Zeocin, f.c. 25µg/ml 
 
LB plates: 
 
LB-medium 
1.2% Bacto-agar 
 
Autoclave, cool to ~55°C in a waterbath, add desired antibiotic. Store plates at 4°C. 
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LDS sample buffer: 
 
106mM Tris HCl 
141mM  Tris base 
2%   lithium dodecyl sufate (LDS) 
10%  glycerol 
0.51mM  EDTA, pH8.0 
0.22mM  Serva Blue G250 
0.175mM  phenol red 
 
10x modified Gitschier buffer (MGB): 
 
6.7ml  1M Tris pH 8.8 
1.66ml  1M (NH4)2SO4 
650µl  1M MgCl2 
 
add PCR-grade dH20 to 10 ml 
 
For 10ml of 1xMGB combine: 
 
 1ml 10xMGB 
 100µl β-mercaptoethanol 
 500µl 10% Triton X-100 
 8.4ml PCR-grade dH2O 
 
0.9% NaCl solution: 
 
9g  NaCl 
 
add dH2O to 1000ml, filter solution.  
 
Neutralization Solution (ISH): 
 
200mM sodium acetate 
170mM glacial acetic acid 
10mM DTT 
 
Neutralization Solution (Southern): 
 
1.5M NaCl 
1M  Tris, pH7.5 
 
20x NuPAGE MES SDS running buffer: 
 
97.6g  MES 
60.6g  Tris base 
10g  SDS 
3.0g  EDTA 
 
Dissolve in 500ml dH2O, store at 4°C. 
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20x NuPAGE transfer buffer: 
 
81.6g  Bicine 
104.6g  Tris base 
6g  EDTA 
 
Dissolve in 1000ml dH2O, store at 4°C. 
 
1x NUPAGE transfer buffer: 
 
50ml  20xNUPAGE transfer buffer 
100ml  100% methanol 
 
Add dH2O to 1000ml. 
 
Mowiol 4-88: 
 
2.4g  Mowiol 4-88 
6.0g  glycerol 
6.0ml  dH2O 
12.0ml  0.2M Tris, pH8.5 
Mix glycerol and Mowiol 4-88 thoroughly. Add dH2O and incubate for 2 hours at RT, add 
Tris and incubate at 55°C until the Mowiol 4-88 has dissolved. Clear solution by 
centrifugation (20 minutes, 5000g). Aliquot into 1ml samples, store at –20°C.  
 
Buffer P1: 
 
50mM Tris-HCl, pH8.0 
10mM EDTA 
100µg/ml RNAseA 
 
Buffer P2: 
 
200mM NaOH 
1% SDS 
 
Buffer P3: 
 
3.0M potassium acetate, pH5.5 
 
10x PBS: 
 
NaCl     100g  
KCl     2.5g  
Na2HPO4 x 2H2O   7.2g  
KH2PO4    2.5g  
dH2O to 1000ml, dilute 1:10 for 1xPBS 
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1.2M Phosphate buffer: 
 
0.6M  NaH2PO4 
0.6M  Na2HPO4 
 
Mix in a 1:1 ratio, sterile filter. 
 
Phosphate buffer, according to Soerensen: 
 
Solution A: 
27.6g NaH2PO4*H2O, dH2O to 1l 
 
Solution B: 
57.2g Na2HPO4, dH2O to 1l 
 
Combine 115ml solution A, 385ml solution B for 500ml of a 0.2M buffer solution. 
 
4%PFA, phosphate buffered, pH7.4: 
 
Disolve 20g PFA in 230ml dH2O and add 1g NaOH pellets. Heat carefully in microwave to 
65˚C. Add dH2O to 250ml. Add 57.5ml solution A and 192.5ml solution B. 
 
Proteinase K buffer: 
 
25ml 1M Tris, pH 8.0 
250µl proteinase K (10mg/ml, f.c. 10µg/ml) 
25ml 0.5M EDTA, pH 8.0 
to 250ml dH2O 
 
SOC-Medium: 
 
NaCl      10mM 
KCl      2.5mM 
MgSO4     10mM 
Bacto Pepton     2% 
Bacto yeast extract    0.5% 
Glucose     20mM 
 
Autoclave and store at –20°C in 50ml aliquots. 
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Slice culture medium: 
 
For 100ml: 
 
10ml   10x Gibco#79-01012 
25ml   horse serum 
25ml   Hank’s  
3.5ml   glucose (@ 200mg/ml, f.c. 6.5mg/ml) 
1ml  glutamax 
1ml   PenStrep 
34.75ml dH2O (sterile) 
 
sterile filter and store at 4°C. 
 
20x SSC: 
 
0.3M  sodium citrate 
3M  NaCl 
 
dissolve in 800ml dH2O, adjust pH to 7.0, bring to 1000ml. Autoclave. 
 
50x TAE: 
 
Tris-Base    242g 
Gliacil acetic acid   57.1ml 
EDTA (0.5 M, pH 8)   100ml 
dH2O to 1000ml 
 
10x TBE: 
 
Tris-Base    108g 
Boric acid    55g 
EDTA (0.5 M, pH 8)   40ml 
dH2O to 1000ml, filter solution  
 
20x TBS: 
 
Tris-Base   1M 
NaCl  3M 
Dissolve in 700ml dH2O, adjust pH to 7.4 with HCl, add dH2O to 1000ml. 
 
TBS-T: 
 
1xTBS supplemented with Tween20, f.c. 0.02% 
 
TE: 
 
10mM Tris pH7.5 
1mM EDTA pH8 
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TENS buffer: 
 
50mM Tris HCl pH8.0 
0.1M EDTA 
0.1M NaCl 
1%SDS 
 
TSB: 
 
LB    73.5ml 
50% PEG (MW 3350)  20ml, f.c. 10% 
100% DMSO   5ml, f.c. 5% 
2M MgCl2   500µl, f.c. 10mM 
1M MgSO4   1ml, f.c. 10mM 
 
sterile filter, store at 4°C. 
  
WB stripping buffer: 
 
100mM  2-mercaptoethanol 
50mM  Tris-HCl, pH 6.8 
2%  SDS 
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VI. Methods: 
1. DNA transfer into E.coli 
 
1.1. Generation of competent E.coli  
 
1.1.1. Generation of electro-competent cells 
  
An overnight culture of the desired bacterial strain (DH10B, XL-1 blue, EL250, EL350) was 
inoculated from a single colony or directly from a glycerol stock into 4ml of LB or LB-tet 
(10µg/ml) medium (for Xl-1 blue). Typically, 50ml of LB medium were inoculated with 
500µl of the ON culture. Cells were then grown at 37ºC (or 32ºC for EL250, EL350) to an 
OD600~0.5. The cells were then spun down at 5000g for 10min at 2-4ºC. The supernatant was 
then carefully removed and the cells were then re-suspended on ice in 50ml of ice-cold 10% 
glycerol/dH2O. The wash was repeated 2 more times and after the final wash the cells were 
re-suspended in 100-150µl of 10% glycerol/dH2O and snap-frozen in liquid nitrogen. The 
electro-competent cells were stored at -70ºC. The competence of the cells was tested by 
transformation of super-coiled pUC18 plasmid DNA and usually resulted in 5x107 – 8x108 
transformants/µg pUC18 DNA. 
 
1.1.2. Generation of electro-competent and recombination-competent EL250, 
EL350 
 
To obtain recombination-competent EL250 or EL350, 50ml cultures were grown in LB 
medium (see 1.1.1) to an OD600~0.5. At this point the bacteria were heat-shocked in a water 
bath at 42C for 15min under slight agitation to obtain a uniform heat-shock. The cells were 
then chilled on ice for 15min, washed and frozen as described (see 1.1.1). The competence of 
EL250, EL350 cells was usually comparable to electro-competent DH10B. As a control, a 
second 50ml culture of EL250/350 was grown and processed in parallel, but was not heat-
shocked. 
 
1.1.3. Generation of chemically-competent E.coli Xl-1 blue 
 
A 4ml ON culture of E.coli XL-1 blue was grown in LB-tet medium (10µg/ml) and a 200ml 
culture was inoculated with the ON culture (1:100). The cells were then grown to OD600~0.4 
and spun down in a GSA rotor at 5000g. The supernatant was discarded and the cells were re-
suspended in 1/15th of the volume in TSB and incubated on ice for 10 minutes. The cells were 
then snap frozen in 300µl aliquots and stored at –70ºC. For the transformation of the cells, the 
bacteria were incubated with the DNA in 1xKCM buffer on ice for 20 minutes and then 
shifted to room temperature for 10 minutes. 800µl of LB were added and the cells were 
incubated at 37°C for 30-45 minutes in a shaker. 100-150µl of the bacteria were then plated 
on the appropriate selective LB agar plates and incubated at 37°C for 16-18 hours. 
The competence of these cells was usually lower than for the electro-competent cells (4x107 – 
1x108 /µg pUC18 DNA), but sufficient for standard cloning procedures. 
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1.1.4. Electroporation of E.coli 
 
Electrocompetent E.coli were thawed on ice and 40µl were given into a pre-cooled 
electroporation cuvette (gap size: 1mm) along with the DNA to be transformed. The bacteria 
and DNA were mixed in the cuvette, followed by a 15 minute incubation on ice. The cells 
were then placed into the shocking chamber of a “GenePulserII” (BioRad) and electroporated 
with the following settings: Voltage: 1.75kV, resistance: 200Ω, capacitance:25µF. The cells 
were then resuspended in 800µl – 1ml LB or SOC medium, transferred into a Falcon 2059 
tube and incubated for 30-45 minutes at 37°C in an orbital shaker. The cells were then plated 
on LB plates containing the appropriate antibiotic. EL250/350 were incubated for 90 minutes 
at 32°C before being plated. 
High salt concentration and PEG interfere with electroporations and have to be removed by 
ethanol precipitation of the DNA and several washes with 80% ethanol. 
 
1.2. DNA isolation and purification 
 
1.2.1. Standard DNA isolation 
 
1.2.1.1. Small scale DNA purification, “DNA mini preps” 
 
Small scale DNA preparations were carried out using Qiagen’s “Plasmid Mini” kits following 
the manufacturer’s instructions. The basic principle is a modified alkaline lysis protocol 
(Birnboim and Doly, 1979) followed by binding of the DNA to an anion-exchange resin 
under appropriate pH and salt conditions and subsequent wash and elution steps. In brief, 4ml 
ON cultures of a clone were grown in LB medium with the appropriate antibiotic. 2 x 1.5ml 
of each culture were then spun down into the same tube and the supernatant was discarded. 
The bacterial pellet was re-suspended in 250µl P1, lysed by adding 250µl P2 and neutralized 
by adding 350µl of P3. The preps were then spun at maximum speed in an Eppendorf table-
top centrifuge for 10min to pellet cellular debris and chromosomal DNA. The supernatant 
was then transferred onto a Qiagen mini column and centrifuged at ~8000g for 1min. The 
flow-through was discarded and 750µl of buffer PE were added followed by another 
centrifugation step. The flow-through was discarded and the column was dried by a spin at 
maximum speed for 2min. The purified plasmid DNA was eluted into 50µl of dH2O.  
 
1.2.1.2. Large scale DNA preparations, “maxi preps” 
 
Preparative purification of plasmid DNA was carried out using Qiagen’s “Plasmid maxi kit”, 
which is based on an alkaline lysis procedure (Birnboim and Doly, 1979) coupled to anion-
exchange resin purification under appropriate low-salt and pH conditions. In this procedure 
contaminating RNAs and low-molecular weight impurities are removed by medium salt 
washes. The plasmid DNA is then eluted from the resin by a high-salt buffer and precipitated 
with isopropanol followed by several washes to remove residual salt from the elution buffer. 
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1.2.1.3. BAC DNA preparation 
 
Small scale preparation of bacterial artificial chromosomal DNA, “BAC minis” 
 
For the purification of small amounts of BAC DNA for BAC fingerprinting a modified 
alkaline lysis procedure was used (Birnboim and Doly, 1979). In brief, 4ml of LB medium 
with the appropriate antibiotic were inoculated from a single BAC clone or glycerol stock and 
grown ON at 37ºC or 32ºC (for bacterial strains EL250, EL350). 2x1.5ml of ON culture were 
then spun down into the same tube, the supernatant was discarded and the pellet was re-
suspended in 400µl of buffer P1. The cells were lysed by adding 400µl of buffer P2 and 
proteins and bacterial chromosomal DNA were precipitated by adding 400µl of chilled buffer 
P3. The cellular debris was removed by centrifugation and the supernatant was transferred 
into a new tube. BAC DNA was then precipitated by adding 450µl ice-cold isopropanol 
followed by an incubation at –20ºC for 1h. The BAC DNA was pelleted by centrifugation 
(13.000g, 10 minutes) in a table-top centrifuge. The supernatant was discarded and the DNA 
was washed once with 1ml of 80% ethanol, air dried and re-suspended in 40µl of BAC-TE. 
 
1.2.1.4. Large scale purification of bacterial artificial chromosomal DNA, “BAC 
maxis” 
 
Larger amounts of BAC DNA were obtained by an alkaline lysis procedure (see 2.2) followed 
by anion-exchange resin chromatography (NucleoBond kit, Clontech). 250ml of selective LB 
medium were inoculated with 2.5ml of an BAC ON culture and grown for 18 hours at the 
appropriate temperature. Cells were spun down and either frozen away or directly processed.  
Cells were re-suspended in 12ml of chilled buffer S1, lysed by adding 12ml of buffer S2. Due 
to the large amount of cells, the lysis time was extended to 5 minutes. 12ml of chilled buffer 
S3 were added and the lysate was cleared by filtration through a pre-wetted filter. The lysate 
was then passed onto a AX-500 tip, which was pre-equilibrated with 5ml of buffer N2 
followed by 2 x 12ml washes with buffer N3. The BAC DNA was eluted from the column by 
two 3ml elution steps with buffer N5 heated to 55ºC. The DNA was precipitated by adding 
8.4ml of isopropanol and pelleted by centrifugation at 12.000g for 25 minutes. The BAC-
DNA pellet was then washed with 2x4ml of 80% ethanol, air dried and re-suspended in 200-
300µl of BAC-TE. 
 
1.2.2. Preparation of genomic DNA for Southern blotting 
 
For the preparation of mouse genomic DNA for Southern blotting, ~200mg of tissue (liver or 
tail) were digested in 700µl TENS buffer supplemented with proteinase K (f.c. of 0.5µg/µl) 
ON at 55°C. The debris was pelleted by centrifugation (5min, 10.000g) and the supernatant 
was transferred to a new Eppendorf tube. An equal volume of phenol:chloroform:isoamyl 
alcohol (49:49:2), pH8, was added and incubated under constant agitation for 20-30 minutes. 
The aqueous phase was separated by centrifugation (10min, 10.000g) and transferred into a 
new tube. An equal volume of isopropanol was carefully pipetted onto the sample and the 
genomic DNA was spooled onto glas rods by stirring and twisting. The DNA was washed 
twice by stirring it in 70% ethanol, followed by a wash in absolute ethanol to facilitate drying. 
The tip of the glas rod was broken into a new tube and the DNA resuspended in 200µl TE. 
This method usually yielded 150-200µg of genomic DNA.  
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1.2.3. Extraction of DNA from agarose gels 
 
DNA fragments between 200bp-12kb were extracted from agarose gels using Qiagen’s 
“Qiaquick Gel Extraction kit” following the manufacturer’s instructions. The Qiaquick kit is 
based on the ability of DNA to bind to silica-membranes under high-salt conditions at a pH 
≤7.5. In brief, the desired DNA fragment was cut out of the agarose gel on a UV screen and 
placed into an Eppendorf tube. For each 100mg of agarose, 100µl of buffer QG were added 
and the sample was placed in a heat block at 50ºC until the agarose was dissolved. For DNA 
fragments larger than 4kb the appropriate amount of isopropanol was added to the mix prior 
to loading it onto the spin column. The sample was then centrifuged at 3000g in a table-top 
centrifuge and washed with 750µl of buffer PE. The flow-through was discarded and the 
column was spun dry for 1 minute at 10,000g. The DNA was then eluted by adding either 
dH2O or buffer EB onto the column followed by a 1 minute incubation prior to centrifugation. 
Depending on the amount of DNA present in the agarose the elution volume was typically 
between 25-40µl. To facilitate the elution process for DNA fragments ≥4kb the dH2O was 
pre-heated to 50ºC. 
For the extraction of small amounts of DNA from agarose gels Qiagen’s MinElute Gel 
Extraction Kit was used, which allows for the elution of the adsorbed DNA into a volume of 
10µl dH2O. 
 
 
1.2.4. Purification of DNA fragments and oligonucleotides by spin column 
chromatography (gel filtration chromatography) 
 
For de-salting or simple clean-up procedures after restriction digests with endonucleases or 
kinasing reactions, Amersham-Pharmacia S-200, S-300 or S-400 spin columns were used. 
These columns contain sepharose beads with a defined pore size and allow for the purification 
of DNA fragments of different sizes. Prior to use, the buffer was removed from the columns 
by centrifugation at 1,500g for 1min in a table-top centrifuge. 
For the purification the sample volume was adjusted to at least 50µl and loaded onto the 
column bed followed by a centrifugation at 1,500g for 1min.  
 
1.2.5. Purification of nucleic acids by phenol-chloroform extraction 
 
To quantitatively remove proteins form nucleic acid solutions, an equal sample volume of 
phenol (buffered to pH8):chloroform:isoamyl alcohol (49:49:2) was added to the sample. For 
smaller DNA fragments or RNA the sample was vortexed for 30 seconds – 1 minute and then 
centrifuged at 15,000g in a table-top centrifuge. For the purification of genomic DNA, the 
sample was carefully mixed by inversion for several minutes using a rotating tube holder and 
subsequently centrifuged at 15,000g for 10 minutes in a table-top centrifuge. The aqueous 
phase was then carefully transferred into a new tube, precipitated and re-suspended in dH2O 
or TE. 
 
1.2.6. Preparation of mouse genomic DNA for genotyping 
 
For the preparation of genomic mouse DNA for genotyping either two ear punches or 2-3mm 
of mouse tail were placed in a 96 well plate and 90µl of 1xMGB were added to each well and 
the wells were sealed with cap strips. The 96 well plate was then heated to 95ºC for 5 minutes 
in a PCR machine. The plate was removed from the PCR machine and allowed to cool for 
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several minutes prior to the addition of 10µl of proteinase K per well. The 96 well plate was 
then placed back into the PCR machine and incubated at 55ºC for 2 hours followed by a 5 
minute heat kill at 95ºC. The plate was placed on a vortex for several seconds and then 
centrifuged at 2500g for 10 minutes. For PCR 1-2µl of this prep were used. 
 
 
1.2.7. Concentration of nucleic acids by precipitation 
 
A standard procedure for concentrating nucleic acids is ethanol precipitation. In this method, 
1/10 of the sample volume of 3M sodium acetate (pH 5) is added and 2 to 2.5 sample volumes 
of absolute ethanol are added. The sample is mixed by pipetting and the nucleic acids are 
precipitated by an incubation at –20ºC for 1 hour. The nucleic acids are then pelleted by 
centrifugation in a table-top centrifuge (10 minutes, 15,000g), the supernatant is discarded. 
The pellet is washed twice with 80% ethanol, air dried and re-suspended in dH2O or TE. In 
the case that the concentration of the nucleic acids was <100ng/ml, carrier substances such as 
tRNA or glycogen were added to the sample to enhance precipitation and to help visualize the 
resulting pellet. 
 
1.2.8. Purification of DNA for pronuclear injection 
 
1.2.8.1. Purification of DNA for pronuclear injection of conventional transgenes 
 
For the generation of DNA suited for pronuclear injection, the desired construct was 
linearized with the appropriate restriction endonucleases and gel purified using Qiagen’s 
“Qiaquick Gel Exctraction kit”. The bound DNA was washed twice with 750µl of wash 
buffer PE. The column was dried by centrifugation (2 minutes at 15,000g in a table-top 
centrifuge). The DNA was then eluted with injection buffer and the integrity was checked by 
running a fraction of the eluate on a gel. The DNA concentration was determined 
photometrically and subsequently diluted to a concentration of 8ng/µl. 
This purification protocol was used for transgene constructs for up to 12kb in size. 
 
1.2.8.1. Linearization and purification of RPCI23, -24 BAC DNA for pronuclear 
injection 
 
For the generation of linearized, full-length RPCI-23- or RPCI-24-derived BAC DNA for 
pronuclear injection, roughly 40µg of BAC DNA (‘maxi prep’ grade) were digested with the 
homing endonuclease PI-SceI in a 100µl reaction volume at 37°C for 12-16 hours. The 
enzyme was then heat-killed by an incubation at 70°C for 15 minutes. The sample volume 
was increased to 195µl and 5µl of a 0.25% bromphenol blue solution were added.  
Using a Pasteur pipet the sample was carefully loaded onto a 4CL-B sepharose column (bed 
volume ≈ 5ml), which was pre-equilibrated with 4 column volumes of BAC injection buffer. 
The sample was allowed to enter the column bed and 1 column volume of injection buffer 
was loaded onto the column. One column volume in 200µl fractions was collected until the 
brome-phenol blue had migrated out of the sepharose matrix. The DNA concentration in each 
fraction was determined photometrically and the fractions with the highest DNA 
concentration were run on a PFGE gel next to λ-DNA standards. The fraction with the highest 
DNA concentration and the highest ratio of full-length BAC DNA to sheared DNA was 
chosen for transgenesis and diluted to 1ng/µl in BAC injection buffer. 
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1.3. Preparation of RNA 
 
1.3.1. Small scale RNA purification, Qiagen “RNeasy mini prep” 
 
Small scale RNeasy mini preps were used to purify up to 100µg of total RNA from tissues or 
tissue samples. The kit is based on a selective binding of RNAs >200 bases to a silica-gel-
based membrane under high-salt conditions, which excludes 5S, 5.8S and tRNAs from the 
prep. RNAs were purified following the manufacturer’s instructions. In brief, cultured cells 
were washed on ice with chilled PBS to remove residual culture medium. The PBS was 
removed and the cells were lysed by the addition of buffer RLT and scraped off the culture 
dish with a cell scraper and the lysate was transferred to an Eppendorf tube. The appropriate 
amount of RNA-grade 70% ethanol was added and mixed by pipetting. The sample was then 
transferred onto the RNeasy column and centrifuged at 8,500g for 1 minute. The flow-through 
was discarded, the column was washed with 700µl RW1, followed by two washes with 500µl 
of buffer RPE. The column was dried by centrifugation. The RNA was eluted from the 
column by adding 30-50µl of RNase-free dH2O. RNA quality was assessed by gel 
electrophoresis or by analysis on an Agilent 2100 Bioanalyzer. For the isolation of total RNA 
form mouse tissues, the tissue was homogenized with an Ultra-Turrax in buffer RLT and 
purified as described above.  
 
1.3.1. Lare Scale RNA purification, Qiagen “RNeasy midi prep” 
 
Larger amounts of total RNA (up to 1mg) were purified using Qiagen’s “RNeasy midi prep” 
kit. The kit is based on the same principle as the “RNeasy mini kit” and was primarily used to 
obtain RNAs from mouse tissues according to Qiagen’s instructions.  
Mouse tissues that were not processed immediately were stored in the RNA stabilization 
agent “RNAlater” at 4ºC for up to 10 days prior to RNA isolation. 
 
1.4. Determination of nucleic acid concentration 
 
1.4.1. Photometric determination of nucleic acid concentration 
 
According to the Lambert-Beer law the absorption of an aqueous solution of a substance is 
directly proportional to its concentration, 
A=εcl , 
where ε is the molar extinction coefficient (unit: M-1cm-1), c the concentration (unit: M) and l 
is the path length of the light through the sample (unit: cm). The extinction coefficients for 
nucleic acids are (at λ=260nm): 
 
guanine  : ε=12010 M-1cm-1 
cytosine  : ε=7050 M-1cm-1 
adenine  : ε=15200 M-1cm-1 
thymine/uracil : ε=8400 M-1cm-1 (8111 M-1cm-1 for uracil ) 
 
The absorption was measured at 260nm and 280nm, which represent the absorption maxima 
for nucleic acids and proteins, respectively. The measured absorption is the sum of the 
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absorptions of all the bases in the solution. For working purposes the following OD260 – 
concentration relations were used: 
 
1 OD260 for dsDNA    : 50mg/ml 
1 OD260 for RNA   : 40mg/ml 
1 OD260 for ss-oligonucleotides : 33mg/ml 
 
The purity of a given sample was assessed by the ratio OD260:OD280. For clean preparations of 
nucleic acids, the ration should be between 1.7-2.0, lower ratios usually indicate a protein 
contamination. 
Depending on the expected concentration of a sample it was diluted 1:50 to 1:1000 prior to 
measuring.  
 
1.4.1. Estimation of BAC DNA concentration on PFGE gels 
 
To estimate the concentration of linearized full-length BAC DNA, several dilutions of the 
BAC DNA were run on a PFGE gel next to defined amounts of linearized λ-DNA as a 
standard. The gel was then stained with ethidium bromide and placed on a UV screen to 
estimate the concentration and subsequently photographed.  
 
1.5. Analysis of nucleic acids 
 
1.5.1. Gel electrophoretic analysis of nucleic acids 
 
 
1.5.1.1. Separation of DNA and its topological isomers in agarose gels 
 
Due to the constant mass-to-charge ratio of nucleic acids, their migration velocity in a 
constant electrical field depends on the properties of the matrix (gel), the molecular weight 
and the topology of the nucleic acid. Since the side chains of the nucleic acids have the same 
same pKS value, it is not their charge that determines the migration velocity in the gel (unlike 
for proteins), but their diffusion coefficient. The migration velocity is inversely proportional 
to the decimal logarithm of the molecular weight. 
Two different gel systems can be used depending on size and nature of the nucleic acid: The 
para-crystalline meshwork of agarose gels allows for the separation of DNA ranging from 
100bp to several Mb. The polymerization-based and covalently coupled matrix of 
polyacrylamide gels allow for the separation of smaller nucleic acids (up to only a few kb). 
The separation properties of the polyacrylamide gels not only depends on the gel 
concentration, but also on the degree to which they are cross-linked. 
 
A detailed description of the different gel systems, their handling and generation is described 
in Sambrook “Molecular Cloning – A Laboratory Manual”, CSHL Press, 2001. 
 
1.5.1.2. Separation of DNA fragments by “conventional” gel electrophoresis 
 
For the separation of DNA fragments between 100bp and 14kb agarose gels ranging from 
0.8% to 2.5% were used.  
For the generation of agarose gels, the appropriate amount of agarose was dissolved in 
1xTAE buffer by heating the suspension in a microwave until the agarose had completely 
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dissolved. After  the agarose had cooled to approx. 60ºC, ethidium bromide was added (f.c. 
1µg/ml) and the agarose was poured into a sealed horizontal gel tray, combs were placed in 
the setup and the agarose was allowed to solidify. The gel was then placed in a gel chamber 
filled with 1xTAE buffer so that the gel was submerged by 2-3mm in the buffer. One 10th of 
the sample volume was added as “loading dye II” to each sample prior to loading it on the gel. 
The gels were run at 4-6Vcm-1 until the desired separation was achieved. DNA fragments 
were visualized by placing the gel on an UV screen (wavelength 260nm) and photographed.  
 
1.5.1.3. Separation of DNA fragments by pulsed-field gel electrophoresis (PFGE) 
 
PFGE allows for the separation of linear DNA fragments up to 10Mb and was first described 
by Schwartz and Cantor (Schwartz and Cantor, 1984). Unlike conventional electrophoresis, 
PFGE requires DNA molecules to periodically change their direction of migration. 
Several types of PFGE have been described, all of which utilize the basic principle of 
applying an electric field alternating in two orientations. The difference lies in the manner in 
which the alternating electrical fields are generated. The method described by Schwartz and 
Cantor and orthogonal field-alternation gel electrophoresis (OFAGE) utilizes arrays of point 
electrodes that yield non-homogenous electrical fields and non-linear lanes in the final 
migration pattern. In transverse alternating field electrophoresis (TAFE) the distortion of 
DNA migration, as seen in OFAGE, is eliminated by running the gel vertically and applying 
the electrical field at an angle to the face of the gel plates (see: (Gardiner et al., 1986; 
Gardiner et al., 1988)). In another version of PFGE, the field inversion gel electrophoresis 
(FIGE; (Carle et al., 1986)) involves a periodic inversion of the electrical field. Forward 
movement of the DNA molecules is obtained by either a shorter pulse time or a lower field 
strength for the reverse direction. This results in a linear migration of the molecules, although 
DNA migration is not always monotonic with size for molecules >2Mb. 
For this thesis a fourth variant of PFGE was used, contour-clamped homogenous electric field 
electrophoresis (CHEF). This method was first described by (Chu et al., 1986) and uses 
multiple electrodes arranged along a closed contour, which are clamped to predetermined 
electrical potentials equal to those calculated to be generated by two parallel, infinitely long 
electrodes. With this arrangement of electrodes, the distortion of DNA migration is overcome, 
which is observed in non-homogenous electrical fields. The system used here (BioRad CHEF 
DRII system) generates a homogenous electrical field that alternates between two orientations 
that are 120º apart. The CHEF system was further advanced by using a hexagonal array of 24 
electrodes which could be independently controlled (programmable autonomously controlled 
electrode gel electrophoresis (PACE)). 
As for conventional gel electrophoresis, a number of factors are known to influence the 
resolution of linear DNA fragments: the topology of DNA, the time interval between 
reorientation of the electrical field (the pulse time), the angle at which the alternating 
electrical field is applied, field strength, the gel concentration and the temperature at which 
the gel is run. Linear and circular DNA molecules of the same size migrate differently in 
PFGE. Open circular DNA molecules do not enter the gel matrix, thus BACs have to be 
linearized by restriction endonucleases prior to analysis by PFGE.  
The pulse time has a major effect on the migration of the DNA and it therefore depends on 
the size of the DNA molecules that need to be resolved. Generally speaking, the larger the 
DNA molecule the longer is the pulse time required for resolution. At any given pulse time, 
DNA molecules greater than an upper limit do not have enough time to re-orient in the 
alternating electrical field. Consequently, they migrate along the direction of the average 
electrical field and cannot be resolved. Conversely, DNA molecules smaller than the lower 
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limit become completely re-oriented and thus move as in conventional gel electrophoresis. 
These molecules usually migrate off the gel. 
The mobility of DNA increases with increasing temperature of the electrophoresis, thus 
permitting shorter run times. However, the resolution of the fragments is decreased at higher 
temperatures. Since these effects are more pronounced in PFGE than in conventional gel 
electrophoresis, PFGE gel buffers are kept at a constant temperature, usually 14ºC.  
Increasing the gel concentration decreases the mobility of all sizes of DNA molecules, thus 
improving resolution. Although smaller sized fragments may appear sharper, the resolution of 
larger DNA fragments will decrease. 
For this thesis 1% agarose gels made with 0.5XTBE were used which allowed for the 
resolution of DNA fragments between 3kb – 280kb. The gels were run in a CHEF DRII 
system with 0.5XTBE buffer chilled to 14ºC and programmed to the following settings: 
 
Run time : 16 hours 
1st switch : 5 seconds 
final switch : 15 seconds 
field strength : 6 Vcm-1 
 
After the gel run was finished, the gels were placed in a tray filled with 0.5XTBE that 
contained 1µg/ml ethidium bromide for 20 minutes and then photographed.  
As a standard linear, multimerized λ-DNA that was contained in agarose was used 
(MidRange PFGE marker I or II, NEB). For electrophoresis a thin slice of the marker was cut 
and placed in a well, which was then sealed with agarose.  
 
1.5.1.4. Separation of RNA by denaturing polyacrylamid gel electrophoresis 
 
For the electrophoretic separation of RNAs, it is necessary to include denaturing agents into 
the gel system to resolve intra-molecular secondary structures of the RNAs, which would 
influence their migration behavior in the gel matrix. Usually urea or formamide are used for 
this purpose. As a consequence of the low ionic strength of the gel system, the electric 
resistance is high leading to a heating of the gel system. This thermal energy in turn 
additionally improves the resolution of the gel by ‘melting’ secondary structures that might 
still exist. 
For the analysis of in vitro transcribed RNAs and the analysis of hydrolyzed ISH probes PAA 
gels were prepared as follows: 
 
  35ml 10M urea (f.c. 8M) 
   6ml 50% PAA (BioWhitttaker Long Ranger sequencing gel mix) 
   5ml 10XTBE  
   4ml dH2O 
 
The polymerization was started by adding 250µl of 10%APS and 25µl of TEMED. A 3µl 
sample + 22µl loading dye were loaded per well, and the samples were run at 260V, 25mA in 
1XTBE running buffer. 
The electrophoretic separation was allowed to proceed until the bromophenol blue dye, which 
corresponding to a fragment size of 29 nts, migrated out of the gel. The gel was then exposed 
to a Kodak Biomax MR film for 6- 24h. 
 
Methods 
 86
1.6. Fragmentation of DNA with endonucleases  
 
1.6.1. Fragmentation of DNA with restriction endonucleases (“DNA 
digests”) 
 
Restriction endonucleases are enzymes that recognize specific sequences within dsDNA and 
cut both DNA strands. There are 3 groups of restriction endonucleases: 
Type I and type III restriction enzymes each carry both the endonuclease and methylase 
activity on a single protein. Type I enzymes cleave the DNA at a possibly random site located 
at least 1000bp from the recognition sequence, whereas type III enzymes do so 24-26bp 
distant from the recognition sequence. Type II restriction enzymes, which were discovered 
and characterized by Smith and Nathans (Nathans and Smith, 1975), are separate entities from 
their corresponding modification methylases. They cleave at specific sites within their 
recognition sequence. The recognition sequence of type II restriction enzymes usually ranges 
from 4-8bp in length and is in most cases palindromic.  The hydrolysis of both dsDNA 
strands can generate 5’-protruding, 3’-protruding or blunt ends. The 5’ ends are always 
phosphorylated and the 3’ ends always carry a hydroxyl group. These characteristics make 
them a useful tool in molecular biology for sequence specific fragmentation of DNA. 
Each restriction enzyme has its own reaction conditions, which are specified by the supplier. 
Important parameters are reaction temperature and the components of the restriction buffer, 
which specify the pH of the reaction mix and ionic strength of a restriction digest. If two 
enzymes require the same reaction conditions, both can be used within the same reaction. In 
the case that the reaction conditions are incompatible, the DNA has to be cut with one of the 
enzymes first, then precipitated and subsequently cut with the second enzyme. Alternatively, 
the DNA can be cut with the enzyme that requires the lower salt concentrations first, then the 
reaction conditions are adjusted for the second enzyme in a volume of 60-80µl. 
For analytical DNA digests, usually 500ng-1µg of DNA were used and digested with 1-20 
units of the corresponding enzyme. A unit is defined as the amount of enzyme required to cut 
1µg of λ-DNA in 1 hour at 37°C. Commercially available enzymes are usually supplied in 
50% glycerol, and glycerol concentrations of >10% in the restriction digest can lead to “star 
activity” of the enzyme (George et al., 1980). This limits the amount of enzyme that can be 
used in a given reaction volume to avoid unspecific cleavage of the DNA. Usually, a 
restriction digest was allowed to proceed for 45 minutes to 2 hours at 37°C and was setup as 
follows: 
 
 x µl DNA (500ng - 2µg) 
 4 µl 10X reaction buffer 
 1 µl enzyme 1 
 1 µl enzyme 2 
 dH2O to 40µl. 
  
Restriction enzymes can be inactivated by a heat-kill at 65°C for 20 minutes (for heat 
sensitive enzymes), or the enzymes can be removed  either by phenol-cholorform extraction 
or by purifying the DNA fragment after electrophoretic separation in an agarose gel using a 
Qiagen “QiaQuick gel extraction” kit.  
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1.6.1. DNA fragmentation with homing endonucleases 
 
Homing endonucleases are dsDNAses that have large, asymmetric recognition sites of 12-
40bp in size. Their coding sequences are usually embedded in either introns or inteins. 
Homing endonucleases are named using conventions similar to those used for restriction 
endonucleases: Intron-encoded endonucleases begin with “I-“ and intein-encoded 
endonucleases begin with “PI-“. 
The recognition sequences for homing endonucleases are extremely rare; for example, an 
18bp recognition sequence will occur only every 7x1010 bases. However, homing 
endonucleases tolerate some sequence degeneracy within their recognition sequence resulting 
in an effective recognition sequences of 10-12bp.  
The extremely rare cutting frequency makes homing endonucleases a valuable tool in BAC-
based genome analysis, eg. in linearizing BACs for the production of transgenic animals. For 
the linearization of BACs digests were setup as follows: 
 
 
    x µl BAC-DNA (~40 µg, maxi prep grade) 
  10 µl 10x PI-SceI buffer 
    8 µl PI-SceI (5U/µl) 
  dH2O to 100µl 
 
The reaction was allowed to proceed ON at 37°C followed by a heat-inactivation of the 
enzyme (10minutes, 70°C). 
 
1.7. DNA sequencing 
 
 
Custom DNA sequencing was carried out by Retrogen, Inc. San Diego, CA using a modified 
enzymatic DNA sequencing procedure, the dideoxy-chain termination method, that was first 
described by Sanger (Sanger et al., 1977).This method is based upon an in vitro replication of 
DNA with a modified taq polymerase (‘Sequenase’). The sequencing reactions were analyzed 
using an “Applied Biosystems 3730 DNA-Analyzer” and the proprietary “BigDye Terminator 
v3.1” chemistry. 
 
1.8. Sequence analysis 
 
Data obtained through DNA sequencing was analyzed using DNAStar’s “Lasergene” 
software package version 5.5 as well as applications available at the “National Center for 
Biotechnology Information” (NCBI, http://www.ncbi.nlm.nih.gov) and ENSEMBL 
(http://www.ensembl.org). 
For the analysis of protein and amino acid sequences, the “Lasergene” software package as 
well as the resources at NCBI, ExPASy (http://www.expasy.org/) and the Wellcome Trust 
Sanger Institute (http://www.sanger.ac.uk/) were used. 
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2. Modification of DNA 
 
2.1. In vitro modification of DNA 
 
2.1.1. Synthesis of oligonucleotides 
 
Custom oligonucleotides were obtained through the following companies: Proligo, Inc., 
Operon, Inc and Eurogentec, Inc. The oligonucleotides were synthesized using a 
phosphoramidite-based chemistry (Caruthers et al., 1983). Oligonucleotides >50bp were also 
HPLC purified to eliminate aberrant synthesis products. 
 
2.1.2. Covalent ligation of DNA fragments with T4 DNA ligase 
 
The bacteriophage T4-encoded enzyme DNA ligase catalyses the formation of phosphodiester 
bonds between neighboring 3’-hydroyl- and 5’-phosphoryl-termini. The enzyme requires 
Mg2+-ions and ATP as co-factors. The enzymatic activity is measured in Weiss units. 1 Weiss 
unit is the amount of enzyme required to catalyze the exchange of 1nmol of 32P from 
pyrophosphate to ATP in 20 minutes at 37°C. Another commonly used unit definition is the 
‘cohesive end ligation unit’, and it is defined as the amount of enzyme required to give a 50% 
ligation of HindIII digested λ-DNA in 30 minutes at 16°C in 16µl at a 5’ termini 
concentration of 0.12µM. One Weiss unit corresponds to 67 cohesive-end-ligation units. 
The efficacy of a ligation reaction is influenced by several factors, e.g. incubation 
temperature, reaction volume and the concentration of DNA termini. Commercially available 
“rapid ligation kits” also use inert polyethylene glycol in their ligation buffer to enhance the 
ligation efficacy, which in turn reduces the incubation time.  
For a typical ligation reaction 0.08 to 0.15 pmol of vector DNA and the 3-5 molar excess of 
insert was used. When a commercial kit was used for the ligation of ‘sticky’ ends, the ligation 
reaction was allowed to proceed at room temperature for several hours. “Blunt” end ligations 
were carried out at 16°C for >12 hours. 
 
2.1.3. Phosphorylation of 5’ hydroxyl ends using polynucleotide kinase (PNK) 
 
Polynucleotid kinase catalyzes the transfer and exchange of a γ-Pi from ATP to the 5’-OH end 
of dsDNA, RNA and single-stranded oligonucleotides. For the quantitative phosphorylation 
of double-stranded oligonucleotides, ATP was added to the reaction at a final concentration of 
1mM to strongly favor the transfer of γ-Pi onto the 5’-OH ends of the double-stranded 
oligonucleotides. Typically, a kinasing reaction was setup as follows: 
 
   xµl ds-oligonucleotide (~50pmol) 
   4µl 10xPNK buffer 
   4µl dATP (f.c. 1mM) 
   1µl PNK (10 units) 
   dH2O to 40µl.  
 
The reaction was allowed to proceed for 30 minutes at 37°C and it was stopped by a heat kill 
of PNK at 70°C for 15min. The oligonucleotides were allowed to re-anneal and were purified 
using a S-400 sepharose column. 
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2.1.4. Dephosphorylation of 5’-ends of DNA fragments 
 
Terminal 5’-phosphoryl groups can be removed enzymatically by treating the dsDNA with 
the enzyme calf intestinal phosphatase (CIP). The enzymatic treatment of vector DNA with 
CIP prevents unwanted re-ligation. The CIP used was compatible with the NEB (NEB) and 
SURE cut (Roche) restriction buffer systems and for the removal of 5’phosphoryl groups, 1-2 
U of CIP were added to a completed restriction digest and incubated for 30 minutes at 37°C. 
Since CIP cannot be heat inactivated, the treated DNA was subsequently gel purified using 
the “Qiaquick gel extraction kit”. One unit of CIP is defined as the amount of enzyme 
required to hydrolyze 1µM p-nitrophenolphosphate to nitrophenol in 1 minute at 37°C. 
 
2.1.5. Amplification of DNA fragments in vitro using polymerase chain reaction 
(PCR) 
 
The polymerase chain reaction allows the in vitro amplification of a specific DNA sequence 
(Mullis et al., 1986). The DNA synthesis is started at two primers that are flanking the 
sequence to be amplified. One of the primers anneals to the sense and the other one to the 
anti-sense strand of the amplicon. The synthesis reaction is catalyzed by the DNA polymerase 
of the thermophilic bacterium Thermus aquaticus (taq polymerase). The enzyme is stable at 
95°C and catalyzes the synthesis of DNA at a temperature of 72°C. DNA synthesis therefore 
can be achieved in a thermocycler shifting temperatures between 95°C, the specific annealing 
temperature of the primers and 72°C for DNA synthesis in the presence of a DNA template, 
primers and dNTPs and corresponding salt and pH conditions for taq polymerase.  
Usually, 24 – 40 cycles are necessary to obtain sufficient quantities of the PCR product for 
subsequent steps. For this thesis Qiagen’s “HotStar taq PCR Master Mix” was used, which 
contains a taq polymerase that is inactive at ambient temperatures to avoid misprimed PCR 
products. The “Master Mix” also contains dNTPs and a proprietary buffer. The enzyme can 
be activated by an initial denaturing step at 95°C for 15 minutes.  
Standard PCR reactions were setup as follows: 
 
 10µl HotStar PCR MasterMix 
   1µl primer1 (@ 15pmol/µl) 
   1µl primers (@ 15pmol/µl) 
   1µl DNA template (100pg – 25ng) 
   7µl PCR-grade dH2O 
 20µl 
 
For so called “multiplex” PCRs in which several PCR products are amplified in the same 
PCR reaction using multiple primers, up to 3 primer pairs were used in a total reaction 
volume of 20µl. Multiplex PCRs were exclusively used for genotyping transgenic mice.  
PCR was also used to introduce new restriction sites into the amplified product. The new 
restrictions sites to be added were contained within the PCR primers used.  
Taq polymerase does not possess a 3’-5’ exonuclease activity (“proofreading”), which on 
average leads to the introduction of a mutation every 1.3x105 nucleotides. For high-fidelity 
amplifications, the DNA polymerase of pyrococcus furiosus (pfu polymerase) was used, 
which has a proofreading activity that results in a >10-fold reduced mutation rate. 
PCR products were ran on an agarose gel for either visualization or purification followed by 
gel extraction. Alternatively, DNA fragments were purified using a S-200 spin column. 
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2.2. Homologous recombination in bacteria 
 
2.2.1. Bacterial artificial chromosomes 
 
Bacterial artificial chromosomes (BACs) are F-factor based plasmids, which are capable of 
harboring large pieces of DNA of up to 1Mb (Shizuya et al., 1992).They are maintained at a 
low copy number of 1-2 copies per bacterial cell, which reduces the likelihood of unwanted 
recombination between BACs.  
The first BAC backbone vector described was based on the mini F-factor pMBO131 and 
contained, next to the required regulatory sequences oriS, repE, parA and parB, a multiple 
cloning site which was flanked by Sp6 and T7 promoters respectively (Shizuya et al., 1992). 
Furthermore, the vector contained a cosN and a loxP site 5’ to the T7 promoter, which can be 
used for linearization.  
Large pieces of genomic DNA of up to 300kb can be generated through partial digests with 
restriction endonucleases. The genomic DNA fragments can then be used to create BAC 
libraries by ligating them into the BAC backbone vectors. 
Improvements have been made to the first generation BAC backbone vectors, and they now 
also contain a recognition sequence for the homing endonuclease PI-SceI, which can be used 
to linearize a given BAC. 
For this thesis pBelo11- and RPCI-24-based BAC clones were used. The pBelo11 BAC 
clones were obtained from Incyte Genomics, Inc. (now part of Research Genetics, Inc). The 
RPCI-24 based clones were obtained through “BAC/PAC Resources”, Oakland, CA 
(http://www.chori.org/bacpac). The DNA used to construct the RPCI-24 library was 
generated by a partial MboI digest of spleen and brain genomic DNA of a male C57Bl/6J 
mouse, which was then cloned into pTARBAC1 (Zeng, C et al., 2001). The DNA used for the 
construction of the pBelo11-based library was derived from SV129 ES cells.  
The “pBelo11-ChAT-BAC” was identified through a BAC library screen at Incyte Genomics 
using a ChAT promoter-specific probe. With the advances of the ENSEMBL database 
(http://www.ensembl.org), a suitable “cholinergic” BAC (RPCI-24-70D4) was identified 
through the use of the implemented “Cytoview” option. 
 
2.2.2. Homologous recombination in bacteria 
 
The use of restriction endonucleases is a standard procedure to modify a given piece of DNA. 
It is limited by the frequency with which an enzyme cuts the target DNA and the presence of 
restriction sites in a given piece of DNA. In recent years recombination systems have been 
developed that utilize phage-derived factors that enable a site-specific recombination without 
the restriction-ligation-based methodology (Zhang et al., 1998; Lee et al., 2001). This new 
technique makes it possible to modify virtually any target DNA independent of its size to 
generate complex targeting vectors for ‘knock-out’ or transgene constructs. This methodology 
is also referred to as ‘recombineering’. 
Several publications have described this and related systems and their properties in great 
detail (Zhang et al., 1998; Muyrers et al., 2000; Yu et al., 2000; Liu et al., 2003), therefore, 
only a brief overview of the technique shall be given here: 
Efficient homologous recombination in E. coli is made possible by the use of λ-phage 
encoded Red genes. Copeland and colleagues (Lee et al., 2001) constructed several bacterial 
strains that carry a defective λ-prophage encoding the Red proteins exo, bet and gam, which 
have been placed under the transcriptional control of a temperature-sensitive λ-repressor. Exo 
encodes a 5’-3’ exonuclease that acts on 5’ends of linear dsDNA fragments to produce 3’ 
ssDNA overhangs; bet encodes a pairing protein that binds to 3’ overhangs produced by exo 
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and promotes their annealing to the complimentary strands on the target DNA. The gam 
protein inhibits the RecBCD exonuclease activity of E. coli thereby protecting the linear 
dsDNA targeting DNA from degradation. By shifting the growth temperature from 32°C to 
42°C for 10 – 15 minutes the temperature-sensitive λ-repressor is no longer able to bind to the 
PL promoter allowing the transcription of exo, bet and gam at high levels. This system works 
very efficiently so that homology arms of 50-70bp are already sufficient for homologous 
recombination. For this thesis homology arms were routinely added to targeting constructs by 
PCR followed by sequence verification. 
The bacterial strains EL250 and EL350 also carry inducible cre and flpe site-specific 
recombinases under the transcriptional control of the PBAD promoter. This way their 
expression can be controlled by adding L-arabinose (0.5% w/v) to the LB medium. The 
recombinases were used to excise selectable markers, such as the zeocin resistance or 
kanamycin resistance, which were either flanked by loxP or FRT sites.  
For the excision of a selectable marker an ON culture of the desired clone was grown at 32°C. 
A 2ml LB-only culture was then inoculated with 20µl of the ON culture and grown to an 
OD600 of ~0.5. At this point 50µl of a 20% w/v L-arabinose solution  (f.c. 0.5%) were added 
and the cells were allowed to grow for an additional hour. From this culture a new 2ml culture 
was inoculated (1:50) and the cells were grown for another hour. 5-10µl of this culture were 
then plated on LB-Cm plates and grown ON at 32°C. 
The next day clones were picked into 3ml of LB-Cm and grown ON. 1µl of each culture was 
used in a PCR screen to verify the excision of the selectable marker.  
 
3. In situ hybridization 
 
3.1. Synthesis of RNA by in vitro transcription 
 
RNA polymerases of the bacteriophages T3, T7 and Sp6 have a high affinity to their own 
promoters and can thus be used for the in vitro synthesis of RNA. The polymerases only 
require a DNA-template, Mg2+-ions and rNTPs as co-factors. A polymerase unit is defined as 
the amount of enzyme required to catalyze the incorporation of 5nmol CTP into acid-
insoluble product in 60 minutes at 37°C in a total volume of 100µl.  
For the generation of radioactive in situ hybridization probes 33P-labelled rUTP 
(111TBq/mmol) can be used. The probes were generated according to the following protocol: 
 
- 2µg of the plasmid harboring the in situ probe fragment was linearized with the appropriate 
enzyme, gel purified and eluted into RNase-free Eppendorf tubes with 40µl dep dH2O.  
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The in vitro transcription was setup as follows for each probe: 
 
3.0   µl 5X transcription buffer 
1.5   µl 100mM DTT 
0.25 µl Rnasin (40u/µl) 
0.75 µl  rATP (10mM) 
0.75 µl rCTP (10mM) 
0.75 µl rGTP (10mM) 
0.75 µl 33P-rUTP (10mM) 
5.25 µl dep dH2O 
1.0   µl linearized DNA template 
1.0 µl DNA polymerase 
15    µl 
 
The reaction was incubated at 37°C for 1 hour, then 0.8µl of RNase-free DNAse were added 
followed by a 15 minute incubation at 37°C. 
3µl of tRNA (10mg/ml) were added and a 1µl aliquot was analyzed on a 6% PAA gel, the rest 
of the probe was stored at –70°C. 
 
3.2. In situ hybridization of 33P-labelled RNAs on murine tissues 
 
In situ hybridization (ISH) is a very sensitive method to detect RNAs in morphologically 
preserved animal tissues or cells. The technique was first described by Gall and Pardue (Gall 
and Pardue, 1969) and by John (John et al., 1969). ISH procedures have been improved to not 
only work with radioactively-labeled probes but also with digoxigenin and fluorescein-
labeled RNA probes allowing a chromogenic detection of RNAs (Schaeren-Wiemers and 
Gerfin-Moser, 1993). 
For this thesis ISH was carried out on tissue section of 20-30µm thickness mounted on 
Fisherbrand Superfrosted microscope slides, or poly-L-lysine/gelatine coated microscope 
slides which were dried ON in a dessicator at RT. 
The radioactively labeled RNA probes were hydrolyzed to achieve a greater tissue 
penetration: 
25µl of hydrolysis solution were added to each probe and incubated for 15 mintes at 58°- 
60°C. The samples were then cooled on ice and 25µl of neutralization solution were added. 
The probes were then purified using a S-200 spin column pre-equilibrated with 50µ of a 
SDS/tRNA/EDTA solution (40µ 10% SDS, 16µ 10mg/ml tRNA, 40µl 0.5M EDTA, 
280µl dep-H2O).  
3µl (+23µl formamide-based loading dye) of the probe were run on a denaturing PAA gel 
next to 1µl of the non-hydrolyzed probe to assess the quality of the generated probes. A 
BioMAX-MR x-ray film was then placed on the gel and exposed for 8-16 hours. In addition, 
1µl of the final probes was diluted 1:10 and 1µl of the dilutions was added to 14ml of 
Scintiverse fluid in scintillation vails, and counts were measured in a Beckman  LS6500 
scintillation counter. Probes were stored for up to a week at –70°C. 
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3.2.1. Pre-hybridization treatment of mounted tissue sections 
 
The sections were removed from the dessicator and placed in 10% phosphate-buffered 
formalin for 30 minutes followed by 4x 5 minute washes in 0.02M KPBS. The samples were 
then treated in 0.001% proteinase K for 10 minutes in a waterbath at 37°C and gently rinsed 
with depc dH2O. The slides were then equilibrated in 0.1M triethanolamine (TEA), pH 8.0 for 
2-3 minutes, followed by a 10 minute acetylation step in acetylation buffer.  
The samples were then rinsed 2x in 2xSSC (RNA grade) for 2 minutes followed by 
dehydration in ascending concentrations of fresh ethanol: 
 
50% EtOH, 3 minutes 
70% EtOH, 3 minutes 
95% EtOH, 3 minutes 
100% EtOH, 3 minutes 
100% EtOH, 3 minutes 
 
The slides were then drained on a paper towel and air-dried and placed in the dessicator for at 
least 1 hour prior to applying the 33P-labeled probe. 
 
3.2.2. Hybridization 
 
The probes were thawed on ice and spun briefly to collect all liquid. For hybridizations 
~2x107 cpm/ml in hybridization buffer were used: 
 
900 µl hybridization buffer 
 µl probe 
10 µl tRNA (10mg/ml) 
add depc dH2O to 1ml 
 
The probe hybridization mix was heated to 70°C for 5 minutes, placed on ice and centrifuged 
briefly. 100µl of the solution were applied to a cover glass and inverted onto the slide. The 
hybridization was allowed to proceed ON at 55°-60°C in a humidified “slidemoat” chamber. 
 
3.2.3. Post hybridization treatment of samples 
 
The slides were removed from the “slidemoat” chamber and placed in a clean staining rack 
filled with 4xSSC and were incubated for 30 minutes allowing the cover glass to slide off 
followed by 4 additional 5 minute rinses with 4xSSC. The samples were then RNAseA 
treated for 35 minutes at 37°C in RNAse buffer and subsequently washed and desalted as 
follows: 
 
2X SSC for 5 minutes 
2X SSC for 5 minutes 
1X SSC for 5 minutes 
0.5X SSC for 5 minutes 
0.1X SSC for 30 minutes at 65°C. 
0.1X SSC for 2 minutes at RT 
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The tissue was dehydrated in ethanol again: 
 
50% EtOH + 1 ml 20X SSC for 3 minutes 
70% EtOH + 1 ml 20X SSC for 3 minutes 
95% EtOH for 3 minutes 
100% EtOH, 3 changes of 3 minutes each 
 
The microscope slides were then drained on paper towels and placed in a dessicator until they 
were completely dried. 
For preliminary ISH results, the slides were mounted on cardboard with scotch tape, placed in 
a film cassette and exposed to BioMAX-MR film for 24 hours and in a second exposure for 3 
days.  
Prior to autoradiography the tissue was treated with xylenes, 2 changes of 10 minutes and 1 
hour, to remove all residual fats from the slides. 
 
3.2.4. Autoradiography 
 
The slides were dipped in Kodak NBT-2 emulsion mixed 1:1 with dH2O in a darkroom and 
allowed to dry in a humidified box at RT. They were then placed in a box with dessicant and 
kept in a refrigerator for 5 days to 4 weeks depending on the signal intensity expected.  
Developing of the slides: 
 
The slides were allowed to warm to RT and developed as follows: 
 
1. 4 minutes in Kodak D-19 at 15°C 
2. 30 second wash in dH2O at 15°C 
3. 6 minutes in Kodak Polymax-T fix at 15°C (diluted 1:4 with dH2O) 
4. Slides were washed in running tap water for 30 minutes. 
 
The slides were then dehydrated again in ethanol and coversliped with DPX.  
 
 
4. Generation, handling and analysis of transgenic mice 
 
 
All animals used for this thesis were kept and treated in the mouse facilities of The Scripps 
Research Institute in accordance with the guidelines for animal welfare established by the 
National Institutes of Health (NIH) and TSRI. 
 
4.1. Generation of transgenic mice 
 
The generation of transgenic mice by pronuclear injection was carried out at the transgenic 
core facility of TSRI. A detailed description of this complex technique can be found in 
“Manipulating the mouse embryo: A laboratory manual” A. Nagy (ed.), CSHL Press, 2002.  
In brief, super-ovulated mice are mated to a male and sacrificed 24 hours later and the 
fertilized oocytes are removed from the ovaries. At this stage the male and female pronuclei 
have not fused and DNA can be injected into the male pronucleus, which is larger in size than 
the female pronucleus. Hybrid strains such as B6D2F1 or FVB/N are usually used for this 
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purpose, since their pronuclei are exceptionally large and they tolerate the manipulations 
better than oocytes derived from C57Bl/6J mice. The injected oocytes are then implanted into 
the ovaries of a pseudo-pregnant foster mouse. After the resulting pups have been weaned, a 
piece of tail is cut and the genomic DNA is extracted. Potential founders are identified by 
PCR using transgene-specific primers. Depending on the transgene construct, founders were 
either mated to reporter mice or to wild-type C57Bl/6J mice. 
 
4.2. Analysis of transgenic mice 
 
4.2.1. Transgene-specific genotyping PCRs 
 
For the identification of transgenic animals, either at founder level or for regular breeding, 
genomic tail DNA was isolated and transgene-specific primers were used for PCR (see: 
Materials). The PCRs were setup as multiplex PCRs and contained next to the transgene-
specific primers a primer pair (2285, 2286) that amplified a 157bp fragment from exon1  the 
erbB4 gene. PCRs were setup as follows: 
 
10µl HotStar PCR MasterMix 
   1µl primer 1(sense) 
   1µl primer 1(as)  
   1µl primer 2(sense) 
   1µl primer 2(as) 
   1µl primer 2285 
   1µl primer 2286 
   1µl genomic DNA 
  3µl PCR-grade dH2O 
  
20µl 
 
The PCR parameters for the amplification were:  
 
(1) 15min @ 95°C 
(2) 45s @ 95°C 
(3) 30s @ 60°C 
(4) 30s @ 72°C 
(5) go to (2) 37x  
(6) 5min @ 72°C 
 
The PCR products were resolved on a 2.5% agarose gel. 
 
 
4.2.2. Generation of cDNA from total RNA extracts from cells or tissues 
 
The conversion of RNA into DNA is catalyzed by the enzyme reverse transcriptase, a RNA-
directed DNA polymerase. The enzyme synthesizes DNA in the 5’ to 3’ direction and 
requires short RNA:DNA hybrids as primers. Commercially available enzymes have been 
improved through point mutations yielding enzymes with a higher processivity due to the 
removal of the endogenous RNAseH activity and an improved thermal stability enabling 1st 
strand cDNA synthesis at temperatures of up to 55°C. 
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Different priming methods can be used for cDNA synthesis with the 2 most commonly used 
being oligo-dT priming and random-priming. Oligo-dT priming initiates cDNA at the polyA 
tail of eukaryotic mRNAs and thereby introduces a 3’ bias into the generated cDNAs. For this 
thesis cDNAs were generated with random-priming, which initiates the reverse transcription 
at multiple, unspecified positions on the target RNA.  
The protocol used was adapted from the ATLAS-array cDNA-synthesis protocol from 
Clontech, Inc. and carried out in 500µl Eppendorf PCR tubes in a thermocycler: 
 
  µl total RNA (~500ng) 
  up to 11.5µl RNA-grade dH2O 
  1µl random nonamers @ 20µM 
- incubate RNA-primer mix for 2 minutes at 70°C 
- quickly place tube on ice, then the following components were added: 
4 µl 5x reaction buffer 
1 µl 0.1M DTT 
1 µl dNTPs (10mM each) 
0.5 µl RNAsin (40U/µl) 
1 µl Superscript II or Superscript III (200U/µl) 
20 µl 
- mix the reaction by pipetting 
- incubate the reverse transcription reaction at 50 – 55°C for 1 hour 
- heat kill the reverse transcriptase by a 5 minute incubation at 94°C 
 
For the removal of the RNAs from the 1st strand cDNAs, the reaction was RNAseH treated, 
which specifically degrades RNA in RNA:DNA hybrids: 
 
20µl cDNA synthesis reaction 
+4µl 10x RNAseH buffer 
+16µl dH2O 
40µl 
 
The reaction was incubated for 30 minutes at 37°C, followed by a 5 minute incubation at 
94°C to inactivate the enzyme. 40µl dH2O were added to a final volume of 80µl. 1-2 µl of the 
cDNA were then used for PCR. 
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4.2.3. Southern blotting 
 
Southern blotting was introduced by Ed Southern in 1975 (Southern, 1975) and is used for the 
detection of specific DNA fragments in complex mixtures of DNA fragments separated by gel 
electrophoresis. The DNA fragments are transferred onto a nylon membrane by capillary 
transfer and cross-linked by baking the membrane for 1h at 80°C or by exposing it to UV 
light.  
For this thesis mouse genomic DNA or BAC DNA was digested ON with the desired 
restriction enzymes and separated by gel electrophoresis on a 1% agarose gel. As a standard 
for subsequent analysis, a ruler was placed next to the gel and the gel was photographed. For 
a more efficient transfer of larger DNA fragments, the DNA was partially depurinated by 
incubating the gel for 15 minutes in 0.25M HCl. The gel was then briefly rinsed with dH2O 
and incubated for 30 minutes in denaturing buffer. The gel was rinsed in dH2O and 
transferred into neutralizing buffer for 15 minutes after which the buffer was replaced by 
fresh buffer and the gel was incubated for an additional 15 minutes. The gel was equilibrated 
in 10xSSC for 10 minutes prior to placing it in the blotting setup. A piece of nylon membrane 
was cut to the appropriate size and equilibrated in 10xSSC for several minutes. The capillary 
transfer was then assembled as follows:  
 
 
 
The transfer was allowed to proceed for 12 hours, after which the blot was disassembled and 
the membrane was rinsed in 10xSSC to remove unwanted pieces of agarose from the 
membrane. The membrane was allowed to air-dry for several minutes after which it was 
placed into a StrataLinker (Stratagene) to cross-link the DNA to the membrane. The 
membrane was stored at –20°C until use. 
 
 
4.2.3.1. Preparation of 32P-labeled probes for Southern blotting 
 
For the generation of a 32P-labeled probe, ~20ng of DNA were labeled with the “random 
prime-it kit II” (Stratagene). The kit was used according to the instructions provided by the 
manufacturer. In brief, the reaction was setup as follows: 
 
 25ng of DNA 
 10µl random oligonucleotide primers 
 dH2O to 34µl 
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The mix was then boiled for 5 minutes in a water bath, briefly centrifuged and placed on ice. 
The following components were then added: 
 
 10µl 5xdCTP buffer 
  5µl [α-32P]-dCTP (3000 Ci/mmol) 
  1µl exo(-) Klenow 
 
The labeling reaction was incubated for 10 minutes at 37°C, after which the reaction was 
stopped by adding 2µl “stop mix”. Unincorporated radionucleotides were removed by column 
purification using a S-300 column (Amersham). 
 
4.2.3.2. Hybridization of 32P-labeled probes 
 
Southern membranes were pre-hybridized with 20ml of high-SDS hybridization buffer for 30 
minutes at 65°C prior to adding the 32P-labeled probe. For hybridization, the 32P-labeled probe 
was denatured by boiling it for 5 minutes in a water bath after which it was placed on ice. The 
pre-hybridization buffer was removed, 10ml of pre-heated high-SDS hybridization buffer 
were added to the hybridization bottle and the denatured probe was pipetted into the 
hybridization bottle. The hybridization was allowed to proceed for 18 hours at 65°C under 
constant agitation.  
The hybridization solution was then discarded and the membrane was subjected to 2 –3 low 
stringency washes at 68°C in 2xSSC/0.1%SDS in a water bath under constant agitation. A 
final high stringency wash was carried out in 0.2xSSC/0.1%SDS for 5-10 minutes. Membrane 
background was monitored with a hand-held β-counter between washes. 
Following the washes, the membrane was wrapped in saran wrap and exposed to a 
FUJIFILM BAS-5000 screen for 2 hours at RT or to a KODAK BioMAX MS film 
with enhancer screen for 12-48 hours at –70°C. 
 
4.2.4. Doxycycline administration 
 
Doxycycline was administered to mice either via the food or through the drinking water.  
Doxycycline-containing food (DOX-food) (6mg/g food) was purchased from BioServ, 
Frenchtown, NJ. The food contained green food coloring to more readily identify animals on 
DOX-food. DOX-food was used for up to 180 days after its mill date, after which it was 
autoclaved and discarded. 
Several factors have to be taken into account when administering DOX in the drinking water. 
Ca2+ and Mg2+ ions efficiently chelate doxycycline and therefore destilled water should be 
used to avoid unwanted precipitation of doxycycline. The drinking water should also be 
supplemented with 5% sucrose, since doxycycline is bitter tasting. Furthermore, doxycycline 
is light sensitive, and the drinking bottles should therefore be wrapped with aluminum foil. 
For this thesis the drinking water was supplemented with 2mg/ml doxycycline and 5% 
sucrose and was replaced every 2 days. 
 
4.2.5. Transcardial perfusion of mice 
 
Animals were kept and treated in accordance to the guidelines for animal welfare in the 
mouse facilities of The Scripps Research Institute. 
Mice were deeply anesthetized by injection with sodium-pentobarbitol (0.25mg/g body 
weight). The thorax was opened and a 25G needle was inserted into the left ventricle, 
followed by a cut into the right atrium. The mouse was then perfused with 0.9% NaCl 
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solution, pre-warmed to 37°C. The flow rate of the perfusion pump was set to 1-3ml/minute 
and the perfusion was allowed to proceed until all blood was replaced by NaCl solution. 
Depending on the intended use of the mouse, it was then perfused with either cold phosphate-
buffered 4%-PFA, pH7.4 for 10-15 minutes for subsequent immuno-histochemical analysis or 
with 4%PFA-borate for ISH analysis. 
Organs were removed and post fixed for 2 – 24 hours in the same solution used for perfusion.  
 
4.2.6. Histochemical and Immuno-histochemical procedures 
 
4.2.6.1. Detection of β-galactosidase in tissue sections, ‘X-Gal’ staining 
 
The bacterial enzyme β-galactosidase catalyzes the cleavage of the O1 bond of the sugar β-D-
galactose to a substituent. Due to a broad substrate specificity the enzyme can also be used to 
cleave organic compounds such as 5-bromo4-chloro-3-indolyl-β-D-galactoside (X-Gal) 
giving rise to a colorful indigo-colored precipitate (5-bromo-4-chloro-3-hydroxyindole) under 
oxidizing buffer conditions. Furthermore, the enzyme can be expressed in mammalian cells, 
when placed under the appropriate regulatory elements and is usually well tolerated. This 
property of the enzyme allows the use of β-galactosidase in transgenic mice as a reporter for 
the detection of transgene activity or for the detection of promoter activity of an endogenous 
gene in ‘knock-in’ approaches (Goring et al., 1987; Sanes, 1994). 
For the detection of β-galactosidase activity in transgenic mice, PFA-fixed tissues were cut on 
a Leica VT-1000S vibratome (50-75µm sections). The tissue was then placed in ‘β-gal 
staining buffer’ for 3-24 hours at 37°C in the dark. The reaction was stopped by washing the 
samples 3x15 minutes in PBS. Sections were then mounted on FisherBrand ‘superfrosted’ 
slides, air-dried and cover-slipped with Mowiol-488. The mounting medium was allowed to 
solidify and the cover slips were then sealed with clear nail polish. Tissue sections were 
stored for up to 6 months at 4°C in the dark without any detectable loss of tissue integrity or 
diffusion of the indigo-colored precipitates. 
 
4.2.6.2. Whole mount β-glactosidase staining of mouse embryos 
 
For the detection of β-galactosidase activity in transgenic embryos (E13-E16), time-pregnant 
mice were sacrificed and the embryos were removed. A piece of tail was cut for genotyping 
and the embryos were fixed in cold phosphate-buffered 4%PFA for 4 hours. Embryos of the 
desired genotype were incubated ON in ‘β-gal staining buffer’ at 37°C in the dark followed 
by 3x20 minute washes in PBS. The embryos were then dehydrated in ascending 
concentrations of methanol (50%, 70%, 90%, 100%) at 4°C. The embryos were cleared in a 
benzyl benzoate-benzyl alcohol (2:1) mix for 20 minutes to 1 hour and photographed. 
 
4.2.7. Western blotting 
 
Western blotting allows the immunological detection of proteins in biological samples and 
was first introduced by Towbin and colleagues (Towbin et al., 1979). In this thesis the 
technique was used to detect endogenous and transgene-derived protein in tissue lysates from 
transgenic mice. 
Proteins from tissue lysates were subjected to denaturing gel electrophoresis (SDS-PAGE) to 
detect HA-tagged neuregulin-1 a-tail protein by immunoblotting. For the detection of the HA-
tagged protein, a rat monoclonal IgG α-HA antibody was used. 
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4.2.7.1. Generation of protein lysates for Western blotting 
 
Mouse tissues were removed from sacrificed animals, frozen on dry ice and stored at –70°C 
until processing. For tissue lysis 1ml of ‘WB lysis buffer’ was used per 100mg of tissue, 
which was disrupted in an Ultrathurrax homogenizer. The cellular debris was removed by 
centrifugation and the supernatant was transferred into a new tube and snap-frozen in liquid 
nitrogen and stored at –70°C.  
 
4.2.7.2. Protein concentration determination according to Bradford 
 
This assay was first introduced by Bradford and is a quick and reliable means of determining 
the protein concentration of a given solution (Bradford, 1976).  
Basic amino acid side chains of proteins form complexes with Coomassie Brilliant Blue G-
250 in solution that appear blue with an absorption maximum at λ=595nm. The absorption is 
proportional to the amount of protein in solution. Through comparison with a calibration 
curve the protein concentration in a sample can be determined photometrically by measuring 
its OD595. Calibration curves have to be generated for each assay with defined protein 
concentrations. The interactions of Coomassie Brilliant Blue G-250 and the amino acid side 
chains are detergent sensitive; thus detergent concentrations of >1% in the assay should be 
avoided. 
Usually, a Bradford assay was setup as follows: 
 
  1-10µl protein lysate 
  dH2O to 40µl 
  +160µl Bradford reagent 
 
The mix was incubated for 20 minutes at RT prior to measuring OD595. If the OD595 was >1, 
the sample was diluted further and the assay was repeated.  
 
4.2.7.3. Separation of proteins through discontinous denaturing PAA gel 
electrophoresis (SDS-PAGE) 
 
Unlike DNA, proteins do not have a constant mass-charge ratio due to their differing amino 
acid sequence. Through heat-denaturing of the protein in the presence of the detergent sodium 
dodecylsulfate (SDS), the detergent is able to form a ‘micelle’ with the unfolded protein as its 
core. The length of this structure is proportional to the polypeptide chain length and therefore 
to its molecular weight. In addition to SDS, a reducing agent like β-mercaptoethanol or DTT 
is added to reduce any disulfide bonds. 
The gel electrophoresis is carried out in a 2 step gel system consisting of a stacking gel and a 
running gel (Laemlli, 1970). The stacking gel consists of a low-percentage PAA gel (usually 
3%, pH6.7) and the running gel of a higher-percentage PAA gel at a basic pH (8-12% PAA, 
pH8.9). The focusing of proteins in the stacking gel relies on the fact that the mobility of 
glycine is made to be less than the mobility of the chloride ion. The amino proton of glycine 
is only feebly dissociated below pH 9 so that most of the glycine in the stacking buffer exists 
in an electrically neutral zwitterion form resulting in a low mobility. When voltage is applied, 
the chloride ions begin to move faster than the glycine. Any tendency for a “gap” to appear in 
the ion concentration will lead to a drop in conductivity in the boundary region. Since the 
current has to be the same at every point in the gel, the voltage gradient will increase across 
this boundary and slower ions will be accelerated so as to keep up. When the boundary passes 
from the stacking gel into the running gel, 2 important changes occur. First, the higher pH in 
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the running gel favors the formation of glycine- ions resulting in a greater mobility of the 
glycine. Second, the higher gel concentration in the running gel impedes on the proteins. As a 
consequence, glycine overpasses the proteins and a glycine-chloride boundary moves ahead. 
The proteins are now electrophoresing in a uniform glycine buffer and are being separated by 
the molecular sieving effect of the running gel. During the course of this work, pre-cast gels 
were used (Novex and Invitrogen) as well as NuPAGE pre-cast gels. NuPAGE gels differ 
from the the SDS-PAGE system described by Laemmli in that their running gel has a pH of 7, 
reducing running artifacts like band distortion and loss of resolution caused by the basic pH: 
12µl sample were mixed with 4µl of 4x LDS sample buffer, heated to 75°C for 10 minutes 
followed by a brief centrifugation prior to loading them onto the gel. The gels were run at 
6Vcm-1 until the desired separation was achieved.  
 
4.2.7.4. Immunoblot for the identification of recombinant proteins 
 
The transfer of proteins resolved with SDS-PAGE onto a PVDF membrane was carried out in 
a “XCellSureLock” wet blotting chamber (Invitrogen, Carlsbad, CA). The blot was setup as 
follows: 
 
 
 
 
 
Before setting up the blot, the PVDF membrane was wetted in methanol for 30s and then 
washed with transfer buffer. 
When an electric current is applied to the XCell blotting module, the negatively charged 
proteins migrate from the cathode to the anode and are retained on the PVDF membrane by 
electrostatic and hydrophobic interactions. For the transfer the blotting chamber was placed in 
a bucket with ice to avoid heating of the setup, which was carried out at 150mA and a 
maximum of 25V for 2-3 hours. The blot was then disassembled and the membrane was 
placed in blocking buffer for 1 hour at RT or ON at 4°C. The primary antibody was diluted 
into blocking buffer and incubated with the membrane for 2-3 hours at RT followed by 
4x15m minute washes in TBS-T. The secondary HRP-coupled antibody, diluted into blocking 
buffer, was then applied to the membrane and incubated for 1-2 hours at room temperature 
followed by 4x15 minute washes in TBS-T.  
ECL solution was given onto the membrane for 1 minute (Amersham-Pharmacia) according 
to the manufacturer’s recommendations. The membrane was then covered with Saran wrap 
and an ECL hyperfilm (Amersham) was exposed to the membrane. The exposition times 
varied depending on the signal intensity. The films were then developed in a KODAK X-O-
MAT developer.  
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For re-probing of the membrane with a second antibody, the membrane was placed into ‘WB 
stripping buffer’ at 60°C for 1-2 hours in a water bath followed by 3x15 minute washes with 
TBS-T. 
 
4.2.8. Immunohistochemistry 
 
This standard procedure allows for the detection of proteins with mono- or polyclonal 
antibodies. The technique has been described in great detail in (Harlow and Lane, 1988)  and 
thus will only be outlined briefly. 
For the detection of transgene-derived EGFP, a polyclonal peptide antibody (rabbit-α-EGFP, 
BD Biosciences) was used 1:100. As a secondary antibody, α-rabbit-IgG-AlexaFluor568 was 
used, 1:5000 – 1:8000. For the detection of ChAT protein, a tyramide-based amplification 
protocol was used (Winsky-Sommerer et al., 2000). This protocol was also used to detect 
EGFP and ChAT on the same specimen. “A” and “B” refer to components of the “VectaStain 
ABC kit” (Vectorlabs): 
 
- Block sections for ~ 2h @ 4°C in blocking buffer 
- Incubate tissue ON @ 4°C with primary antibodies (anti-CHAT: 1:1000, anti-EGFP: 
1:100) in incubation buffer 
- Wash 3x 15min @ RT in TBS-T  
- Incubate with 2° antibody (Biotin SP-donkey α-goatIgG, 1:300, 45min –1h @ RT) in 
incubation buffer 
 
in the meantime:  mix  5ml PBS 
    + 1 drop “A” 
    + 1 drop “B”  
-> vortex 
->incubate 30-45min @ RT (ABC/PBS solution) 
  Tubes “A” and “B” were vortexed prior to use. 
 
- Wash 3x with TBS-T 
- Incubate 45min in ABC/PBS solution 
- Wash 3x 5min in TBS 
- Incubate 10min in TSA amplification buffer (dilute TSA in dilution buffer [TSA kit] 
1:100) 
- Wash 3x 5min in TBS 
- Incubate with 2nd 2° antibody (α-rabbitIgG-Alexa568, 1:5000 – 1:8000) for 45min @ 
RT in blocking buffer (use goat serum for blocking) 
- Wash 3x 10min with TBS-T  
- Mount sections with VectaShield HardSet Mounting medium (VectorLabs, 
Burlingame, CA) 
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4.3. Tissue culture 
 
4.3.1. Culturing of mammalian cells 
 
For this thesis the following cell lines were cultured according to well established protocols: 
cos7 (Gluzman, 1981) and PC12 (Greene and Tischler, 1976). In brief, cos7 cells were 
maintained in DMEM supplemented with 10%FBS and 1xPenStrep in a humidified incubator 
in a 5%CO2 atmosphere. Cells were grown on 15cm dishes and split 1:10 upon reaching 90% 
confluence. 
PC12 cells were grown on PLL-coated 15cm dishes in DMEM supplemented with 10%FBS, 
5%HS and 1xPenStrep. The cells were split upon reaching 80% confluence, the number of 
passages was marked on the culture dish and cells were discarded after 35 passages. The 
PC12 cells were triturated prior to plating to obtain a single cell suspension. PC12 cells were 
usually split 1:10. 
For passaging, both cell lines were detached from their culture dishes by mild treatment with 
trypsin/PBS for 5 minutes after which the cells were washed off the culture dish with culture 
media, transferred into 15ml canonical tubes and centrifuged for 3 minutes at 900g. The 
supernatant was discarded and the cells were re-suspended in the desired volume of culture 
medium and plated.  
 
4.3.2. Slice cultures of mouse brains 
 
This method was adapted from (Schwab et al., 2000). In brief, P5 animals were sacrificed by 
decapitation and their brains were removed. The brains were then transferred into cold slice 
culture medium and the meninges were removed. The prepared brains were placed in a slicer 
and 400µm sections were cut and collected into cold slice culture medium. Brain slices were 
then transferred onto TC inserts (0.4mm pore size, Greiner, cat#657641), which had been 
placed into 6 well plates containing slice culture medium. In case of GFPG3:rtTAS2-M2 
doubly transgenic brain slices, doxycycline was added toa f.c.of 1µg/ml. 
The slices were cultured for 3 days in a humidified 5% CO2 atmosphere, after which they 
were fixed with 4%PFA and assessed by lacZ histo-chemistry. 
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VII. Abbreviations 
 
aa   amino acid  
α-CaMKII  Ca2+/calmodulin-dependent protein kinase II-α 
AChR   acetylcholine receptor 
Amp   ampicillin 
APS   ammoniumpersulfate 
ARIA   acetylcholine receptor-inducing activity 
BAC   bacterial artificial chromosome 
BBB   blood brain barrier 
BDNF   brain-derived neurotrophic factor 
BGHpA  bovine growth hormone polyadenylation site 
bla   beta-lactamase 
bp   base pair 
ChAT   choline acetyltransferase 
CIP   calf intestinal phosphatase 
CMV   cytomegalovirus 
CNS   central nervous system 
CpG   deoxy(cytidylyl-guanosine) dimer 
depc   diethyl-pyrocarbonate 
DIV   days in vitro 
DNAse  deoxyribonuclease 
dNTPs   deoxyribonucleic acid tri-phosphate 
DMSO  dimethyl sulfoxide 
dox   doxycycline 
DRG   dorsal root ganglion 
dsDNA  double stranded DNA 
E   embryonic day (mouse development) 
EDTA   Ethylene Diamine Tetra Acetic Acid 
EGF   epidermal growth factor 
EST   expressed sequence tag 
EtOH   ethanol 
f.c.   final concentration 
floxed   flanked by loxP sites 
flped   flanked by FRT sites 
GABA   gamma-aminobutyric acid 
GAPDH  glyceraldehyde-3-phosphate dehydrogenase 
Ggl.   ganglion 
GGF   glial growth factor 
HRG   heregulin 
kb    kilo base pairs 
l   liter 
lacZ   β-galactosidase 
LB   Luria broth 
KanR   kanamycin resistance 
m.   musculus 
Mb   mega bases 
ml   milliliter 
MMP   matrix metallo-proteinase 
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NMDA  N-methyl-D-aspartate 
NRG1   neuregulin-1 
OD   optical density 
ON   over night 
ORF   open reading frame 
ori   origin of replication 
P   postnatal day (mouse development) 
Ptet-bi   bi-directional tTA/rtTA responsive promoter (Baron et al., 1995) 
pA   polyadenylation signal 
PAC   P1 artificial chromosomes 
PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PFA   para-formaldehyde 
PFG   pulsed-field gel 
PFGE   pulsed-field gel electrophoresis 
PH   pleckstrin homology 
pH   pH=-lg[H+] 
PNS   peripheral nervous system 
PVDF   polyvinylidene fluoride 
RNAse  ribonuclease 
RNAsIn  recombinant RNAse inhibitor 
RT   room temperature 
SDS   sodium dodecyl sulfate  
ssDNA  single stranded DNA 
TAE   Tris-Acetate-EDTA 
TE   Tris-EDTA solution 
TEA   Triethanolamine 
TEMED  N,N,N',N'-Tetramethyl-1-,2-diaminomethane 
Tris   Tris(hydroxymethyl)aminomethane 
UV   ultra violet 
VAChT  vesicular acetylcholine transporter 
WB   Western blot 
wt   wild type 
@   at 
X-Gal   5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside 
zeoR   zeocin resistance 
 
 
 
References 
 
 106
VIII. References 
 
Anton ES, Ghashghaei HT, Weber JL, McCann C, Fischer TM, Cheung ID, Gassmann M, Messing A, Klein R, 
Schwab MH, Lloyd KC, Lai C (2004) Receptor tyrosine kinase ErbB4 modulates neuroblast migration 
and placement in the adult forebrain. Nat Neurosci 7:1319-1328. 
Bao J, Wolpowitz D, Role LW, Talmage DA (2003) Back signaling by the Nrg-1 intracellular domain. J Cell 
Biol 161:1133-1141. 
Bao J, Lin H, Ouyang Y, Lei D, Osman A, Kim TW, Mei L, Dai P, Ohlemiller KK, Ambron RT (2004) 
Activity-dependent transcription regulation of PSD-95 by neuregulin-1 and Eos. Nat Neurosci 7:1250-
1258. 
Baron U, Gossen M, Bujard H (1997) Tetracycline-controlled transcription in eukaryotes: novel transactivators 
with graded transactivation potential. Nucleic Acids Res 25:2723-2729. 
Baron U, Freundlieb S, Gossen M, Bujard H (1995) Co-regulation of two gene activities by tetracycline via a 
bidirectional promoter. Nucleic Acids Res 23:3605-3606. 
Ben-Baruch N, Yarden Y (1994) Neu differentiation factors: a family of alternatively spliced neuronal and 
mesenchymal factors. Proc Soc Exp Biol Med 206:221-227. 
Benes FM, Berretta S (2001) GABAergic interneurons: implications for understanding schizophrenia and bipolar 
disorder. Neuropsychopharmacology 25:1-27. 
Berger S (2003) Untersuchungen zur nichtinvasiven Tetrazyklin-abhängigen Kontrolle von Genaktivitäten in 
vivo, Ph.D. thesis. In: Zentrum fuer Molekulare Biologie: Universität Heidelberg. 
Berrard S, Varoqui H, Cervini R, Israel M, Mallet J, Diebler MF (1995) Coregulation of two embedded gene 
products, choline acetyltransferase and the vesicular acetylcholine transporter. J Neurochem 65:939-
942. 
Berse B, Blusztajn JK (1995) Coordinated up-regulation of choline acetyltransferase and vesicular acetylcholine 
transporter gene expression by the retinoic acid receptor alpha, cAMP, and leukemia inhibitory 
factor/ciliary neurotrophic factor signaling pathways in a murine septal cell line. J Biol Chem 
270:22101-22104. 
Birnboim HC, Doly J (1979) A rapid alkaline extraction procedure for screening recombinant plasmid DNA. 
Nucleic Acids Res 7:1513-1523. 
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein 
utilizing the principle of protein-dye binding. Anal Biochem 72:248-254. 
Brockes JP, Lemke GE, Balzer DR, Jr. (1980) Purification and preliminary characterization of a glial growth 
factor from the bovine pituitary. J Biol Chem 255:8374-8377. 
Buonanno A, Fischbach GD (2001) Neuregulin and ErbB receptor signaling pathways in the nervous system. 
Curr Opin Neurobiol 11:287-296. 
Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward 
CW, Yokoyama S (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB 
receptors. Mol Cell 12:541-552. 
Burgess TL, Ross SL, Qian YX, Brankow D, Hu S (1995) Biosynthetic processing of neu differentiation factor. 
Glycosylation trafficking, and regulated cleavage from the cell surface. J Biol Chem 270:19188-19196. 
Busfield SJ, Michnick DA, Chickering TW, Revett TL, Ma J, Woolf EA, Comrack CA, Dussault BJ, Woolf J, 
Goodearl AD, Gearing DP (1997) Characterization of a neuregulin-related gene, Don-1, that is highly 
expressed in restricted regions of the cerebellum and hippocampus. Mol Cell Biol 17:4007-4014. 
Cabedo H, Carteron C, Ferrer-Montiel A (2004) Oligomerization of the sensory and motor neuron-derived factor 
prevents protein O-glycosylation. J Biol Chem 279:33623-33629. 
Cabedo H, Luna C, Fernandez AM, Gallar J, Ferrer-Montiel A (2002) Molecular determinants of the sensory 
and motor neuron-derived factor insertion into plasma membrane. J Biol Chem 277:19905-19912. 
Capsoni S, Ugolini G, Comparini A, Ruberti F, Berardi N, Cattaneo A (2000) Alzheimer-like neurodegeneration 
in aged antinerve growth factor transgenic mice. Proc Natl Acad Sci U S A 97:6826-6831. 
Carle GF, Frank M, Olson MV (1986) Electrophoretic separations of large DNA molecules by periodic inversion 
of the electric field. Science 232:65-68. 
Caroni P (1997) Overexpression of growth-associated proteins in the neurons of adult transgenic mice. J 
Neurosci Methods 71:3-9. 
Carpenter G (2003) ErbB-4: mechanism of action and biology. Exp Cell Res 284:66-77. 
Carraway KL, 3rd, Cantley LC (1994) A neu acquaintance for erbB3 and erbB4: a role for receptor 
heterodimerization in growth signaling. Cell 78:5-8. 
Carraway KL, 3rd, Weber JL, Unger MJ, Ledesma J, Yu N, Gassmann M, Lai C (1997) Neuregulin-2, a new 
ligand of ErbB3/ErbB4-receptor tyrosine kinases. Nature 387:512-516. 
References 
 
 107
Caruthers MH, Beaucage SL, Becker C, Efcavitch JW, Fisher EF, Galluppi G, Goldman R, deHaseth P, 
Matteucci M, McBride L, et al. (1983) Deoxyoligonucleotide synthesis via the phosphoramidite 
method. Gene Amplif Anal 3:1-26. 
Chalifour LE, Gomes ML, Wang NS, Mes-Masson AM (1990) Polyomavirus large T-antigen expression in heart 
of transgenic mice causes cardiomyopathy. Oncogene 5:1719-1726. 
Chan RY, Boudreau-Lariviere C, Angus LM, Mankal FA, Jasmin BJ (1999) An intronic enhancer containing an 
N-box motif is required for synapse- and tissue-specific expression of the acetylcholinesterase gene in 
skeletal muscle fibers. Proc Natl Acad Sci U S A 96:4627-4632. 
Chen MS, Bermingham-McDonogh O, Danehy FT, Jr., Nolan C, Scherer SS, Lucas J, Gwynne D, Marchionni 
MA (1994) Expression of multiple neuregulin transcripts in postnatal rat brains. J Comp Neurol 
349:389-400. 
Chevalier-Mariette C, Henry I, Montfort L, Capgras S, Forlani S, Muschler J, Nicolas JF (2003) CpG content 
affects gene silencing in mice: evidence from novel transgenes. Genome Biol 4:R53. 
Chu G, Vollrath D, Davis RW (1986) Separation of large DNA molecules by contour-clamped homogeneous 
electric fields. Science 234:1582-1585. 
Citri A, Skaria KB, Yarden Y (2003) The deaf and the dumb: the biology of ErbB-2 and ErbB-3. Exp Cell Res 
284:54-65. 
Colognato H, Baron W, Avellana-Adalid V, Relvas JB, Baron-Van Evercooren A, Georges-Labouesse E, 
ffrench-Constant C (2002) CNS integrins switch growth factor signalling to promote target-dependent 
survival. Nat Cell Biol 4:833-841. 
Cooper EC, Harrington E, Jan YN, Jan LY (2001) M channel KCNQ2 subunits are localized to key sites for 
control of neuronal network oscillations and synchronization in mouse brain. J Neurosci 21:9529-9540. 
Corfas G, Falls DL, Fischbach GD (1993) ARIA, a protein that stimulates acetylcholine receptor synthesis, also 
induces tyrosine phosphorylation of a 185-kDa muscle transmembrane protein. Proc Natl Acad Sci U S 
A 90:1624-1628. 
Corfas G, Roy K, Buxbaum JD (2004) Neuregulin 1-erbB signaling and the molecular/cellular basis of 
schizophrenia. Nat Neurosci 7:575-580. 
Corfas G, Rosen KM, Aratake H, Krauss R, Fischbach GD (1995) Differential expression of ARIA isoforms in 
the rat brain. Neuron 14:103-115. 
Cosgaya JM, Chan JR, Shooter EM (2002) The neurotrophin receptor p75NTR as a positive modulator of 
myelination. Science 298:1245-1248. 
Cronin CA, Gluba W, Scrable H (2001) The lac operator-repressor system is functional in the mouse. Genes Dev 
15:1506-1517. 
Dai X, Lercher LD, Clinton PM, Du Y, Livingston DL, Vieira C, Yang L, Shen MM, Dreyfus CF (2003) The 
trophic role of oligodendrocytes in the basal forebrain. J Neurosci 23:5846-5853. 
Doetschman T, Gregg RG, Maeda N, Hooper ML, Melton DW, Thompson S, Smithies O (1987) Targetted 
correction of a mutant HPRT gene in mouse embryonic stem cells. Nature 330:576-578. 
Elder GA, Friedrich VL, Jr., Lazzarini RA (2001) Schwann cells and oligodendrocytes read distinct signals in 
establishing myelin sheath thickness. J Neurosci Res 65:493-499. 
Falls DL (2003) Neuregulins: functions, forms, and signaling strategies. Exp Cell Res 284:14-30. 
Falls DL, Rosen KM, Corfas G, Lane WS, Fischbach GD (1993) ARIA, a protein that stimulates acetylcholine 
receptor synthesis, is a member of the neu ligand family. Cell 72:801-815. 
Fischbach GD, Rosen KM (1997) ARIA: a neuromuscular junction neuregulin. Annu Rev Neurosci 20:429-458. 
Flames N, Long JE, Garratt AN, Fischer TM, Gassmann M, Birchmeier C, Lai C, Rubenstein JL, Marin O 
(2004) Short- and long-range attraction of cortical GABAergic interneurons by neuregulin-1. Neuron 
44:251-261. 
Friede RL (1972) Control of myelin formation by axon caliber (with a model of the control mechanism). J Comp 
Neurol 144:233-252. 
Friede RL, Bischhausen R (1982) How are sheath dimensions affected by axon caliber and internode length? 
Brain Res 235:335-350. 
Gall JG, Pardue ML (1969) Formation and detection of RNA-DNA hybrid molecules in cytological 
preparations. Proc Natl Acad Sci U S A 63:378-383. 
Games D, Adams D, Alessandrini R, Barbour R, Berthelette P, Blackwell C, Carr T, Clemens J, Donaldson T, 
Gillespie F, et al. (1995) Alzheimer-type neuropathology in transgenic mice overexpressing V717F 
beta-amyloid precursor protein. Nature 373:523-527. 
Garcia RA, Vasudevan K, Buonanno A (2000) The neuregulin receptor ErbB-4 interacts with PDZ-containing 
proteins at neuronal synapses. Proc Natl Acad Sci U S A 97:3596-3601. 
Gardiner K, Laas W, Patterson D (1986) Fractionation of large mammalian DNA restriction fragments using 
vertical pulsed-field gradient gel electrophoresis. Somat Cell Mol Genet 12:185-195. 
References 
 
 108
Gardiner K, Watkins P, Munke M, Drabkin H, Jones C, Patterson D (1988) Partial physical map of human 
chromosome 21. Somat Cell Mol Genet 14:623-637. 
Garratt AN, Voiculescu O, Topilko P, Charnay P, Birchmeier C (2000) A dual role of erbB2 in myelination and 
in expansion of the schwann cell precursor pool. J Cell Biol 148:1035-1046. 
Gassmann M, Casagranda F, Orioli D, Simon H, Lai C, Klein R, Lemke G (1995) Aberrant neural and cardiac 
development in mice lacking the ErbB4 neuregulin receptor [see comments]. Nature 378:390-394. 
George J, Blakesley RW, Chirikjian JG (1980) Sequence-specific endonuclease Bam HI. Effect of hydrophobic 
reagents on sequence recognition and catalysis. J Biol Chem 255:6521-6524. 
Gill G, Ptashne M (1988) Negative effect of the transcriptional activator GAL4. Nature 334:721-724. 
Gluzman Y (1981) SV40-transformed simian cells support the replication of early SV40 mutants. Cell 23:175-
182. 
Gong S, Zheng C, Doughty ML, Losos K, Didkovsky N, Schambra UB, Nowak NJ, Joyner A, Leblanc G, 
Hatten ME, Heintz N (2003) A gene expression atlas of the central nervous system based on bacterial 
artificial chromosomes. Nature 425:917-925. 
Gordon JW, Scangos GA, Plotkin DJ, Barbosa JA, Ruddle FH (1980) Genetic transformation of mouse embryos 
by microinjection of purified DNA. Proc Natl Acad Sci U S A 77:7380-7384. 
Goring DR, Rossant J, Clapoff S, Breitman ML, Tsui LC (1987) In situ detection of beta-galactosidase in lenses 
of transgenic mice with a gamma-crystallin/lacZ gene. Science 235:456-458. 
Gossen M, Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline- responsive 
promoters. Proc Natl Acad Sci U S A 89:5547-5551. 
Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H (1995) Transcriptional activation by 
tetracyclines in mammalian cells. Science 268:1766-1769. 
Greene LA, Tischler AS (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma 
cells which respond to nerve growth factor. Proc Natl Acad Sci U S A 73:2424-2428. 
Gu H, Marth JD, Orban PC, Mossmann H, Rajewsky K (1994) Deletion of a DNA polymerase beta gene 
segment in T cells using cell type-specific gene targeting. Science 265:103-106. 
Gu Z, Jiang Q, Fu AK, Ip NY, Yan Z (2005) Regulation of NMDA receptors by neuregulin signaling in 
prefrontal cortex. J Neurosci 25:4974-4984. 
Guan ZZ, Zhang X, Blennow K, Nordberg A (1999) Decreased protein level of nicotinic receptor alpha7 subunit 
in the frontal cortex from schizophrenic brain. Neuroreport 10:1779-1782. 
Guy PM, Platko JV, Cantley LC, Cerione RA, Carraway KL, 3rd (1994) Insect cell-expressed p180erbB3 
possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci U S A 91:8132-8136. 
Harari D, Tzahar E, Romano J, Shelly M, Pierce JH, Andrews GC, Yarden Y (1999) Neuregulin-4: a novel 
growth factor that acts through the ErbB-4 receptor tyrosine kinase. Oncogene 18:2681-2689. 
Harlow E, Lane D (1988) Antibodies : a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor 
Laboratory. 
Higashiyama S, Horikawa M, Yamada K, Ichino N, Nakano N, Nakagawa T, Miyagawa J, Matsushita N, 
Nagatsu T, Taniguchi N, Ishiguro H (1997) A novel brain-derived member of the epidermal growth 
factor family that interacts with ErbB3 and ErbB4. J Biochem (Tokyo) 122:675-680. 
Hillen W, Berens C (1994) Mechanisms underlying expression of Tn10 encoded tetracycline resistance. Annu 
Rev Microbiol 48:345-369. 
Hippenmeyer S, Shneider NA, Birchmeier C, Burden SJ, Jessell TM, Arber S (2002) A role for neuregulin1 
signaling in muscle spindle differentiation. Neuron 36:1035-1049. 
Ho WH, Armanini MP, Nuijens A, Phillips HS, Osheroff PL (1995) Sensory and motor neuron-derived factor. A 
novel heregulin variant highly expressed in sensory and motor neurons. J Biol Chem 270:26722. 
Huang YZ, Won S, Ali DW, Wang Q, Tanowitz M, Du QS, Pelkey KA, Yang DJ, Xiong WC, Salter MW, Mei 
L (2000) Regulation of neuregulin signaling by PSD-95 interacting with ErbB4 at CNS synapses. 
Neuron 26:443-455. 
Ishii K, Oda Y, Ichikawa T, Deguchi T (1990) Complementary DNAs for choline acetyltransferase from spinal 
cords of rat and mouse: nucleotide sequences, expression in mammalian cells, and in situ hybridization. 
Brain Res Mol Brain Res 7:151-159. 
Jacobson C, Duggan D, Fischbach G (2004) Neuregulin induces the expression of transcription factors and 
myosin heavy chains typical of muscle spindles in cultured human muscle. Proc Natl Acad Sci U S A 
101:12218-12223. 
Jessell TM, Siegel RE, Fischbach GD (1979) Induction of acetylcholine receptors on cultured skeletal muscle by 
a factor extracted from brain and spinal cord. Proc Natl Acad Sci U S A 76:5397-5401. 
John HA, Birnstiel ML, Jones KW (1969) RNA-DNA hybrids at the cytological level. Nature 223:582-587. 
Jones JT, Akita RW, Sliwkowski MX (1999) Binding specificities and affinities of egf domains for ErbB 
receptors. FEBS Lett 447:227-231. 
References 
 
 109
Kim UJ, Birren BW, Slepak T, Mancino V, Boysen C, Kang HL, Simon MI, Shizuya H (1996) Construction and 
characterization of a human bacterial artificial chromosome library. Genomics 34:213-218. 
Kramer R, Bucay N, Kane DJ, Martin LE, Tarpley JE, Theill LE (1996) Neuregulins with an Ig-like domain are 
essential for mouse myocardial and neuronal development. Proc Natl Acad Sci U S A 93:4833-4838. 
Krestel HE, Mayford M, Seeburg PH, Sprengel R (2001) A GFP-equipped bidirectional expression module well 
suited for monitoring tetracycline-regulated gene expression in mouse. Nucleic Acids Res 29:E39. 
Lai C, Feng L (2004) Implication of gamma-secretase in neuregulin-induced maturation of oligodendrocytes. 
Biochem Biophys Res Commun 314:535-542. 
Lax I, Bellot F, Honegger AM, Schmidt A, Ullrich A, Givol D, Schlessinger J (1990) Domain deletion in the 
extracellular portion of the EGF-receptor reduces ligand binding and impairs cell surface expression. 
Cell Regul 1:173-188. 
Lee EC, Yu D, Martinez de Velasco J, Tessarollo L, Swing DA, Court DL, Jenkins NA, Copeland NG (2001) A 
highly efficient Escherichia coli-based chromosome engineering system adapted for recombinogenic 
targeting and subcloning of BAC DNA. Genomics 73:56-65. 
Lee KF, Simon H, Chen H, Bates B, Hung MC, Hauser C (1995) Requirement for neuregulin receptor erbB2 in 
neural and cardiac development [see comments]. Nature 378:394-398. 
Lemke G (1996) Neuregulins in development. Mol Cell Neurosci 7:247-262. 
Li L, Cleary S, Mandarano MA, Long W, Birchmeier C, Jones FE (2002) The breast proto-oncogene, HRGalpha 
regulates epithelial proliferation and lobuloalveolar development in the mouse mammary gland. 
Oncogene 21:4900-4907. 
Liu FF, Stone JR, Schuldt AJ, Okoshi K, Okoshi MP, Nakayama M, Ho KK, Manning WJ, Marchionni MA, 
Lorell BH, Morgan JP, Yan X (2005) Heterozygous Knock Out of the Neuregulin-1 Gene in Mice 
Exacerbates Doxorubicin-Induced Heart Failure. Am J Physiol Heart Circ Physiol. 
Liu P, Jenkins NA, Copeland NG (2003) A highly efficient recombineering-based method for generating 
conditional knockout mutations. Genome Res 13:476-484. 
Liu Y, Ford B, Mann MA, Fischbach GD (2001) Neuregulins increase alpha7 nicotinic acetylcholine receptors 
and enhance excitatory synaptic transmission in GABAergic interneurons of the hippocampus. J 
Neurosci 21:5660-5669. 
Loeb JA, Susanto ET, Fischbach GD (1998) The Neuregulin Precursor proARIA Is Processed to ARIA after 
Expression on the Cell Surface by a Protein Kinase C-Enhanced Mechanism. Mol Cell Neurosci 11:77-
91. 
Loeb JA, Khurana TS, Robbins JT, Yee AG, Fischbach GD (1999) Expression patterns of transmembrane and 
released forms of neuregulin during spinal cord and neuromuscular synapse development. Development 
126:781-791. 
Lonnerberg P, Lendahl U, Funakoshi H, Arhlund-Richter L, Persson H, Ibanez CF (1995) Regulatory region in 
choline acetyltransferase gene directs developmental and tissue-specific expression in transgenic mice. 
Proc Natl Acad Sci U S A 92:4046-4050. 
Mansuy IM, Winder DG, Moallem TM, Osman M, Mayford M, Hawkins RD, Kandel ER (1998) Inducible and 
reversible gene expression with the rtTA system for the study of memory. Neuron 21:257-265. 
Marchionni MA, Goodearl AD, Chen MS, Bermingham-McDonogh O, Kirk C, Hendricks M, Danehy F, 
Misumi D, Sudhalter J, Kobayashi K, et al. (1993) Glial growth factors are alternatively spliced erbB2 
ligands expressed in the nervous system. Nature 362:312-318. 
Marmor MD, Skaria KB, Yarden Y (2004) Signal transduction and oncogenesis by ErbB/HER receptors. Int J 
Radiat Oncol Biol Phys 58:903-913. 
Mayford M, Bach ME, Huang YY, Wang L, Hawkins RD, Kandel ER (1996) Control of memory formation 
through regulated expression of a CaMKII transgene. Science 274:1678-1683. 
McKnight GS, Hammer RE, Kuenzel EA, Brinster RL (1983) Expression of the chicken transferrin gene in 
transgenic mice. Cell 34:335-341. 
Meyer D, Birchmeier C (1995) Multiple essential functions of neuregulin in development [see comments] 
[published erratum appears in Nature 1995 Dec 14;378(6558):753]. Nature 378:386-390. 
Meyer D, Yamaai T, Garratt A, Riethmacher-Sonnenberg E, Kane D, Theill LE, Birchmeier C (1997) Isoform-
specific expression and function of neuregulin. Development 124:3575-3586. 
Michailov GV, Sereda MW, Brinkmann BG, Fischer TM, Haug B, Birchmeier C, Role L, Lai C, Schwab MH, 
Nave KA (2004) Axonal neuregulin-1 regulates myelin sheath thickness. Science 304:700-703. 
Misawa H, Takahashi R, Deguchi T (1995) Coordinate expression of vesicular acetylcholine transporter and 
choline acetyltransferase in sympathetic superior cervical neurones. Neuroreport 6:965-968. 
Moberg PJ, Agrin R, Gur RE, Gur RC, Turetsky BI, Doty RL (1999) Olfactory dysfunction in schizophrenia: a 
qualitative and quantitative review. Neuropsychopharmacology 21:325-340. 
References 
 
 110
Morris JK, Lin W, Hauser C, Marchuk Y, Getman D, Lee KF (1999) Rescue of the cardiac defect in ErbB2 
mutant mice reveals essential roles of ErbB2 in peripheral nervous system development [In Process 
Citation]. Neuron 23:273-283. 
Moutier R, Tchang F, Caucheteux SM, Kanellopoulos-Langevin C (2003) Placental anomalies and fetal loss in 
mice, after administration of doxycycline in food for tet-system activation. Transgenic Res 12:369-373. 
Mullis K, Faloona F, Scharf S, Saiki R, Horn G, Erlich H (1986) Specific enzymatic amplification of DNA in 
vitro: the polymerase chain reaction. Cold Spring Harb Symp Quant Biol 51:263-273. 
Muyrers JP, Zhang Y, Buchholz F, Stewart AF (2000) RecE/RecT and Redalpha/Redbeta initiate double-
stranded break repair by specifically interacting with their respective partners. Genes Dev 14:1971-
1982. 
Naciff JM, Behbehani MM, Misawa H, Dedman JR (1999) Identification and transgenic analysis of a murine 
promoter that targets cholinergic neuron expression. J Neurochem 72:17-28. 
Nathans D, Smith HO (1975) Restriction endonucleases in the analysis and restructuring of dna molecules. Annu 
Rev Biochem 44:273-293. 
No D, Yao TP, Evans RM (1996) Ecdysone-inducible gene expression in mammalian cells and transgenic mice. 
Proc Natl Acad Sci U S A 93:3346-3351. 
Oda Y (1999) Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous 
system. Pathol Int 49:921-937. 
Okada M, Corfas G (2004) Neuregulin1 downregulates postsynaptic GABAA receptors at the hippocampal 
inhibitory synapse. Hippocampus 14:337-344. 
Osoegawa K, de Jong PJ (2004) BAC library construction. Methods Mol Biol 255:1-46. 
Osoegawa K, Zhu B, Shu CL, Ren T, Cao Q, Vessere GM, Lutz MM, Jensen-Seaman MI, Zhao S, de Jong PJ 
(2004) BAC resources for the rat genome project. Genome Res 14:780-785. 
Ozaki M, Sasner M, Yano R, Lu HS, Buonanno A (1997) Neuregulin-beta induces expression of an NMDA-
receptor subunit. Nature 390:691-694. 
Ozaki M, Itoh K, Miyakawa Y, Kishida H, Hashikawa T (2004) Protein processing and releases of neuregulin-1 
are regulated in an activity-dependent manner. J Neurochem 91:176-188. 
Padjen K, Ratnam S, Storb U (2005) DNA methylation precedes chromatin modifications under the influence of 
the strain-specific modifier Ssm1. Mol Cell Biol 25:4782-4791. 
Palmiter RD, Brinster RL, Hammer RE, Trumbauer ME, Rosenfeld MG, Birnberg NC, Evans RM (1982) 
Dramatic growth of mice that develop from eggs microinjected with metallothionein-growth hormone 
fusion genes. Nature 300:611-615. 
Pankonin MS, Gallagher JT, Loeb JA (2005) Specific structural features of heparan sulfate proteoglycans 
potentiate neuregulin-1 signaling. J Biol Chem 280:383-388. 
Peles E, Bacus SS, Koski RA, Lu HS, Wen D, Ogden SG, Levy RB, Yarden Y (1992) Isolation of the neu/HER-
2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells. Cell 
69:205-216. 
Peters HC, Hu H, Pongs O, Storm JF, Isbrandt D (2005) Conditional transgenic suppression of M channels in 
mouse brain reveals functions in neuronal excitability, resonance and behavior. Nat Neurosci 8:51-60. 
Phelps PE, Barber RP, Vaughn JE (1991) Embryonic development of choline acetyltransferase in thoracic spinal 
motor neurons: somatic and autonomic neurons may be derived from a common cellular group. J Comp 
Neurol 307:77-86. 
Pinkas-Kramarski R, Shelly M, Guarino BC, Wang LM, Lyass L, Alroy I, Alimandi M, Kuo A, Moyer JD, Lavi 
S, Eisenstein M, Ratzkin BJ, Seger R, Bacus SS, Pierce JH, Andrews GC, Yarden Y, Alamandi M 
(1998) ErbB tyrosine kinases and the two neuregulin families constitute a ligand-receptor network 
[published erratum appears in Mol Cell Biol 1998 Dec;18(12):7602]. Mol Cell Biol 18:6090-6101. 
Raff MC, Abney E, Brockes JP, Hornby-Smith A (1978) Schwann cell growth factors. Cell 15:813-822. 
Rieff HI, Raetzman LT, Sapp DW, Yeh HH, Siegel RE, Corfas G (1999) Neuregulin induces GABA(A) receptor 
subunit expression and neurite outgrowth in cerebellar granule cells. J Neurosci 19:10757-10766. 
Rimer M, Barrett DW, Maldonado MA, Vock VM, Gonzalez-Lima F (2005) Neuregulin-1 immunoglobulin-like 
domain mutant mice: clozapine sensitivity and impaired latent inhibition. Neuroreport 16:271-275. 
Rimer M, Prieto AL, Weber JL, Colasante C, Ponomareva O, Fromm L, Schwab MH, Lai C, Burden SJ (2004) 
Neuregulin-2 is synthesized by motor neurons and terminal Schwann cells and activates acetylcholine 
receptor transcription in muscle cells expressing ErbB4. Mol Cell Neurosci 26:271-281. 
Robertson KD (2005) DNA methylation and human disease. Nat Rev Genet 6:597-610. 
Rosen KM, Sandrock AW, Jr., Goodearl AD, Loeb JA, Fischbach GD (1996) The role of neuregulin (ARIA) at 
the neuromuscular junction. Cold Spring Harb Symp Quant Biol 61:427-434. 
Sandrock AW, Jr., Dryer SE, Rosen KM, Gozani SN, Kramer R, Theill LE, Fischbach GD (1997) Maintenance 
of acetylcholine receptor number by neuregulins at the neuromuscular junction in vivo. Science 
276:599-603. 
References 
 
 111
Sanes JR (1994) Lineage tracing. The laatest in lineaage. Curr Biol 4:1162-1164. 
Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci 
U S A 74:5463-5467. 
Schaeren-Wiemers N, Gerfin-Moser A (1993) A single protocol to detect transcripts of various types and 
expression levels in neural tissue and cultured cells: in situ hybridization using digoxigenin-labelled 
cRNA probes. Histochemistry 100:431-440. 
Schambra UB, Sulik KK, Petrusz P, Lauder JM (1989) Ontogeny of cholinergic neurons in the mouse forebrain. 
J Comp Neurol 288:101-122. 
Schonig K, Schwenk F, Rajewsky K, Bujard H (2002) Stringent doxycycline dependent control of CRE 
recombinase in vivo. Nucleic Acids Res 30:e134. 
Schwab MH, Bartholomae A, Heimrich B, Feldmeyer D, Druffel-Augustin S, Goebbels S, Naya FJ, Zhao S, 
Frotscher M, Tsai MJ, Nave KA (2000) Neuronal basic helix-loop-helix proteins (NEX and 
BETA2/Neuro D) regulate terminal granule cell differentiation in the hippocampus. J Neurosci 
20:3714-3724. 
Schwartz DC, Cantor CR (1984) Separation of yeast chromosome-sized DNAs by pulsed field gradient gel 
electrophoresis. Cell 37:67-75. 
Scrable H, Stambrook PJ (1997) Activation of the lac repressor in the transgenic mouse. Genetics 147:297-304. 
Shirakabe K, Wakatsuki S, Kurisaki T, Fujisawa-Sehara A (2001) Roles of Meltrin beta /ADAM19 in the 
processing of neuregulin. J Biol Chem 276:9352-9358. 
Shizuya H, Birren B, Kim UJ, Mancino V, Slepak T, Tachiiri Y, Simon M (1992) Cloning and stable 
maintenance of 300-kilobase-pair fragments of human DNA in Escherichia coli using an F-factor-based 
vector. Proc Natl Acad Sci U S A 89:8794-8797. 
Smith KJ, Blakemore WF, Murray JA, Patterson RC (1982) Internodal myelin volume and axon surface area. A 
relationship determining myelin thickness? J Neurol Sci 55:231-246. 
Southern EM (1975) Detection of specific sequences among DNA fragments separated by gel electrophoresis. J 
Mol Biol 98:503-517. 
Stefansson H, Sarginson J, Kong A, Yates P, Steinthorsdottir V, Gudfinnsson E, Gunnarsdottir S, Walker N, 
Petursson H, Crombie C, Ingason A, Gulcher JR, Stefansson K, Clair DS (2003) Association of 
neuregulin 1 with schizophrenia confirmed in a Scottish population. Am J Hum Genet 72:83-87. 
Stefansson H, Sigurdsson E, Steinthorsdottir V, Bjornsdottir S, Sigmundsson T, Ghosh S, Brynjolfsson J, 
Gunnarsdottir S, Ivarsson O, Chou TT, Hjaltason O, Birgisdottir B, Jonsson H, Gudnadottir VG, 
Gudmundsdottir E, Bjornsson A, Ingvarsson B, Ingason A, Sigfusson S, Hardardottir H, Harvey RP, 
Lai D, Zhou M, Brunner D, Mutel V, Gonzalo A, Lemke G, Sainz J, Johannesson G, Andresson T, 
Gudbjartsson D, Manolescu A, Frigge ML, Gurney ME, Kong A, Gulcher JR, Petursson H, Stefansson 
K (2002) Neuregulin 1 and susceptibility to schizophrenia. Am J Hum Genet 71:877-892. 
Steinthorsdottir V, Stefansson H, Ghosh S, Birgisdottir B, Bjornsdottir S, Fasquel AC, Olafsson O, Stefansson 
K, Gulcher JR (2004) Multiple novel transcription initiation sites for NRG1. Gene 342:97-105. 
Sutherland HG, Kearns M, Morgan HD, Headley AP, Morris C, Martin DI, Whitelaw E (2000) Reactivation of 
heritably silenced gene expression in mice. Mamm Genome 11:347-355. 
Thomas KR, Capecchi MR (1987) Site-directed mutagenesis by gene targeting in mouse embryo-derived stem 
cells. Cell 51:503-512. 
Tolwani RJ, Cosgaya JM, Varma S, Jacob R, Kuo LE, Shooter EM (2004) BDNF overexpression produces a 
long-term increase in myelin formation in the peripheral nervous system. J Neurosci Res 77:662-669. 
Towbin H, Staehelin T, Gordon J (1979) Electrophoretic transfer of proteins from polyacrylamide gels to 
nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A 76:4350-4354. 
Tremblay P, Meiner Z, Galou M, Heinrich C, Petromilli C, Lisse T, Cayetano J, Torchia M, Mobley W, Bujard 
H, DeArmond SJ, Prusiner SB (1998) Doxycycline control of prion protein transgene expression 
modulates prion disease in mice. Proc Natl Acad Sci U S A 95:12580-12585. 
Tsai G, Coyle JT (2002) Glutamatergic mechanisms in schizophrenia. Annu Rev Pharmacol Toxicol 42:165-
179. 
Tumbar T, Sudlow G, Belmont AS (1999) Large-scale chromatin unfolding and remodeling induced by VP16 
acidic activation domain. J Cell Biol 145:1341-1354. 
Ullian EM, Christopherson KS, Barres BA (2004) Role for glia in synaptogenesis. Glia 47:209-216. 
Urlinger S, Baron U, Thellmann M, Hasan MT, Bujard H, Hillen W (2000) Exploring the sequence space for 
tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. 
Proc Natl Acad Sci U S A 97:7963-7968. 
Uveges TE, Shan Y, Kramer BE, Wight DC, Parysek LM (2002) Intron 1 is required for cell type-specific, but 
not injury-responsive, peripherin gene expression. J Neurosci 22:7959-7967. 
Wang JY, Miller SJ, Falls DL (2000) The N-terminal Region of Neuregulin Isoforms Determines the 
Accumulation of Cell Surface and Released Neuregulin Ectodomain. J Biol Chem. 
References 
 
 112
Wang Y, Schnegelsberg PN, Dausman J, Jaenisch R (1996) Functional redundancy of the muscle-specific 
transcription factors Myf5 and myogenin. Nature 379:823-825. 
Wilkins A, Chandran S, Compston A (2001) A role for oligodendrocyte-derived IGF-1 in trophic support of 
cortical neurons. Glia 36:48-57. 
Winsky-Sommerer R, Benjannet S, Rovere C, Barbero P, Seidah NG, Epelbaum J, Dournaud P (2000) Regional 
and cellular localization of the neuroendocrine prohormone convertases PC1 and PC2 in the rat central 
nervous system. J Comp Neurol 424:439-460. 
Wolpowitz D, Mason TB, Dietrich P, Mendelsohn M, Talmage DA, Role LW (2000) Cysteine-rich domain 
isoforms of the neuregulin-1 gene are required for maintenance of peripheral synapses. Neuron 25:79-
91. 
Yamada K, Ichino N, Nishii K, Sawada H, Higashiyama S, Ishiguro H, Nagatsu T (2000) Characterization of the 
human NTAK gene structure and distribution of the isoforms for rat NTAK mRNA. Gene 255:15-24. 
Yang X, Kuo Y, Devay P, Yu C, Role L (1998) A cysteine-rich isoform of neuregulin controls the level of 
expression of neuronal nicotinic receptor channels during synaptogenesis [published erratum appears in 
Neuron 1998 Apr;20(4):823]. Neuron 20:255-270. 
Yang X, Arber S, William C, Li L, Tanabe Y, Jessell TM, Birchmeier C, Burden SJ (2001) Patterning of muscle 
acetylcholine receptor gene expression in the absence of motor innervation. Neuron 30:399-410. 
Yang XW, Model P, Heintz N (1997) Homologous recombination based modification in Escherichia coli and 
germline transmission in transgenic mice of a bacterial artificial chromosome. Nat Biotechnol 15:859-
865. 
Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137. 
Yu D, Ellis HM, Lee EC, Jenkins NA, Copeland NG, Court DL (2000) An efficient recombination system for 
chromosome engineering in Escherichia coli. Proc Natl Acad Sci U S A 97:5978-5983. 
Zhang D, Sliwkowski MX, Mark M, Frantz G, Akita R, Sun Y, Hillan K, Crowley C, Brush J, Godowski PJ 
(1997) Neuregulin-3 (NRG3): a novel neural tissue-enriched protein that binds and activates ErbB4. 
Proc Natl Acad Sci U S A 94:9562-9567. 
Zhang Y, Buchholz F, Muyrers JP, Stewart AF (1998) A new logic for DNA engineering using recombination in 
Escherichia coli. Nat Genet 20:123-128. 
 
 
Appendix 
 
 113
IX. Appendix 
 
1. Plasmid maps 
 
 
 
 
 
pFRTzeo5’MCSpA-hTTA: This plasmid was used as a PCR template for the generation of 
the homologous recombination fragment to insert tTA2S into the start codon of the ChAT 
gene. Functional elements are: htTA, tTA2S; pA, polyadenylation signal, FRT, FRT site for 
Flp-mediated excision of the zeocin resistance; zeoR, zeocin resistance; pUC ori, pUC18 
origin of replication; AmpR, ampicillin resistance. 
 
HindIII
BamHI
loxP
KanR
loxP
pUC ori
bla
pKaXdelta
7275 bp
 
pKaXdelta: Plasmid used as a PCR template for the generation of targeting constructs for 
homologous recombination in bacteria. The functional elements are: loxP, loxP site for a Cre-
mediated excision of the kanamycin resistance; KanR, kanamycin resistance; pUC ori, pUC 
18 origin of replication; bla, β-lactamse. 
SalI 300
XhoI 1074
AgeI 1316
HindIII 1377
BamHI 2673
htTA
pA
FRT
zeoR
FRT
pUC ori
AmpR
pFRTzeo5'MCSpA-htTA
8539 bp
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AseI
AseI
NotI
NotI SA SD
PtetBi
lacZ
beta globin pA & intronpUC oribla
SV40 pA
NRG1 cDNA
 
 
Ptet-bi NRG1 vector: Expression construct for the tTA-dependent expression of NRG1 
isoforms and β-galactosidase in transgenic mice from the bi-directional Ptet-bi promoter.The 
construct was linearized for pronuclear injection by an AseI digest. Functional elements are: 
NRG1 cDNA. NRG1 cDNA cloned into the vector as a NotI insert; lacZ, β-galactosidase 
gene; bla, β-lactamase gene; SA, splice acceptor site; SD, splice donor site. 
